Protac degraders of MLLT1 and / or MLLT3

Abstract

The invention relates to a compound which is a Proteolysis Targeting Chimera (PROTAC) or a pharmaceutically acceptable salt thereof, wherein the PROTAC has the structure (AA) wherein U is an E3 ubiquitin ligase binding moiety, LINK is a moiety that covalently links M and U, and M is an MLLT1 and / or MLLT3 binder of formula (I) wherein Z1, Z2, Y1, Y2, Y3, R1, R2, R8, X, L and Hy are as defined herein, and either R8 is a bond to LINK, or M is bonded to LINK via a C or N atom within group R8 or ring Hy such that a hydrogen atom on the C or N atom within group R8 or ring Hy is replaced with a bond to LINK. The compounds are useful in the treatment of cancer.

Description

[0001] PROTAC DEGRADERS OF MLLT1 AND / OR MLLT3 Field of the Invention The present invention relates to compounds that find use in the treatment of cancer by inducing selective degradation of MLLT1 and / or MLLT3. The invention also provides such compounds per se, pharmaceutical compositions comprising such compounds, and methods of treating cancer by administering such compounds. Background The processes controlling gene transcription are highly regulated during development and normal homeostasis. Dysregulation of gene transcription is a common driver of cancer with somatic defects in proteins that control gene transcription a frequent occurrence (Cell, 2013, 153, 17; Cell, 2017, 168, 629). Transcriptional elongation is a central step in gene transcription, carried out by the RNA polymerase II (PolII), which itself is kept under tight control by regulatory protein complexes. During development PolII is recruited to sites of the genome proximal to the transcription start site for target genes and is kept in a paused state. Such target genes are often immediate response genes such as heat-shock genes and key developmental genes. Productive elongation is initiated by the coordinated interplay of regulatory protein complexes including the super elongation complex (SEC). The SEC includes multiple proteins with diverse functions including protein phosphorylation, histone reader, histone modification and regulatory activities. Critical to the recruitment of the SEC to target genes are the histone reader proteins MLLT1 (mixed lineage leukaemia translocated to 1, also known as eleven- nineteen leukaemia, ENL) and MLLT3 (mixed lineage leukaemia translocated to 3, also known as AF-9). MLLT1 and 3 contain essential YEATS domains that bind acetylated histones. Mutations in the YEATS domains reduce loading of PolII on to SEC target genes and suppression of gene transcription. (Cell Mol Life Sci 2018, 75, 3931; Nat Rev Mol Cell Biol 2012, 13, 543). Gain-of-function mutations in the MLLT1 Yeats domain have been causally associated with Wilm’s tumor (also known as nephroblastoma) a kidney cancer most commonly observed in children (Nature 2020, 577, 121). Additionally, it has been shown that for certain acute leukaemias MLLT1 represents a critical dependency (Nature 2017, 543, 270). Such leukaemias include mixed-lineage leukaemia (MLL) rearranged leukaemia. MLL rearrangements arise from in frame fusions of the MLL gene with more than 80 different partner genes, many of which are involved in the regulation of transcription elongation including components of the SEC (Front. Pediatr.5:4. doi: 10.3389 / fped.2017.00004). MLL rearrangements are observed in approximately 10% of all acute leukaemias including a high frequency in infantile ALL where it accounts for 70-80% of all cases (Front. Pediatr.5:4. doi: 10.3389 / fped.2017.00004). Notably it is reported that patients with MLL rearranged leukaemias have an especially poor prognosis (New Engl J Med 2016, 374, 2209). Target genes for MLL-SEC complexes include potent oncogenes such as BCL-2, Myc and CDK6 along with many other genes implicated in maintaining cancer cell self-renewal, growth and survival, such as the HOX family genes and MEIS1 (Front. Pediatr.5:4. doi: 10.3389 / fped.2017.00004). Consistent with a role in the regulation of multiple oncogenes, it has been demonstrated that the SEC can play a critical role in the transcriptional addiction of both hematopoietic and solid cancers. For example, data supports potential in non-MLL rearranged leukaemia (Cancer Disc 2022, 12, 2684) and it is reported that with some breast cancer cells, growth and survival is dependent on a SEC mediated transcription of the Myc oncogene (Cell Rep.2021 Feb 16;34(7):108749. doi: 10.1016 / j.celrep.2021.108749. PMID: 33596420; PMCID: PMC8006859). Taken together the evidence supports MLLT1 and / or MLLT3 as an attractive therapeutic target across acute leukaemias and solid cancers. Proteolysis targeting chimeras (PROTACs) have been proposed as a small molecule-based platform technology capable of inducing proteolysis of a target protein in the body. The PROTAC is a bifunctional compound in which a molecule that binds to a disease-related target protein and an E3 ubiquitin ligase binding moiety are linked by a chemical linker. Theoretically, the PROTAC compound is capable of inducing degradation of the target protein by placing the disease-related target protein near the E3 ubiquitin ligase. Drug discovery efforts have resulted in agents that either bind the YEATS domain to block the MLLT1 and / or MLLT3 protein to histone interaction or that result in degradation of the MLLT1 and / or MLLT3 protein (using a PROTAC approach). In all cases however, the reported activity has been weak (ACS Cent Sci 2021, 7, 815; Cancer Disc 2022, 12, 2684; Angew. Chem. Int. Ed.2018, 57, 16302). Accordingly, there remains a high need to identify potent modulators of MLLT cell function. Summary of the Invention The inventors have discovered a series of compounds that induce selective degradation of MLLT1 and / or MLLT3. Accordingly, the invention provides a compound which is a Proteolysis Targeting Chimera (PROTAC) or a pharmaceutically acceptable salt thereof, wherein the PROTAC has the structure: wherein U is an E3 ubiquitin ligase binding moiety, LINK is a moiety that covalently links M and U, and M is an MLLT1 and / or MLLT3 binder of formula (I): wherein: one of Z1and Z3is -N(H)- and the other is N or -C(R4)-, Y1is N, Y2is N or -C(R6)-, and Y3is N or -C(R5)-; Hy is a 4- to 7-membered heterocyclic ring containing X and at least one N atom, wherein: ring Hy is linked to ring A via a C atom within ring Hy, said C atom also being linked to R2; a N atom within ring Hy is substituted by R1; X is a bond, -N(R11)-, O, S, -S(O)2-, -S(O)(NR11)-, or - C(R11)2-; and the rest of ring Hy is unsubstituted or substituted by one or two R3; L is –C(O)N(H)-, wherein the C atom of L is bonded to R8, and the N atom of L is bonded to ring B; R1is H, C1-4cycloalkyl, or C1-4alkyl which is itself unsubstituted or substituted with one C1-4alkoxy or one, two or three halo; R2is H or methyl; each R3is independently selected from C1-4alkyl, C1-4alkoxy, phenyl, a 5- to 6-membered heteroaryl ring and halo, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring; R4and R6are independently selected from H, halo, CN, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R5is selected from H, halo, C1-4alkoxy, C3-5cycloalkyl and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R8is (i) a bond to LINK or (ii) a group selected from a 6-membered aryl ring, a 5- to 6- membered heteroaryl ring, a 5- to 6-membered heterocyclyl ring, and a 5- to 6-membered cycloalkyl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkoxy, R10, -(C1-4alkylene)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two R9; each R9is independently selected from halo and C1-4alkoxy; R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 6-membered heterocyclyl ring, and a phenyl ring, the group R10being unsubstituted or substituted by one or two substituents independently selected from C1-4alkyl, C1-4alkoxy, and halo; and each R11is independently selected from H, C1-4alkyl, and C1-4cycloalkyl; wherein either R8is (i) a bond to LINK, or R8is a group (ii) and M is bonded to LINK via a C or N atom within group R8such that a hydrogen atom on the C or N atom within group R8is replaced with a bond to LINK. In a preferred embodiment, M is of formula (II): wherein: Z1, Z3, Y1, Y2, Y3, R1, R2, R8, X and L are as defined herein; R3aand R3bare independently selected from H, C1-4alkyl, phenyl, a 5- to 6-membered heteroaryl ring and C1-4alkoxy, or R3aand R3bform, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring, R3cand R3dare independently selected from H, C1-4alkyl, halo, phenyl, a 5- to 6-membered heteroaryl ring and C1-4alkoxy, or R3cand R3dform, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring, or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, with the proviso that when X is -N(R11)-, O, S, -S(O)2- or -S(O)(NR11)-, then neither R3cnor R3dare halo; wherein at least two of R3a, R3b, R3cand R3dare H; and wherein either R8is (i) a bond to LINK, or R8is a group (ii) and M is bonded to LINK via a C or N atom within group R8such that a hydrogen atom on the C or N atom within group R8is replaced with a bond to LINK. In a more preferred embodiment, M is of formula (III): wherein: R1is H or C1-4alkyl which is itself unsubstituted or substituted with one C1-4alkoxy or one, two or three halo, preferably with one C1-4alkoxy; R2is H or methyl; R3aand R3bare independently selected from H, C1-4alkyl, and C1-4alkoxy, or R3aand R3bform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, or R3cand R3dform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, with the proviso that when X is -N(Me)- or O, then neither R3cnor R3dare halo; wherein at least two of R3a, R3b, R3cand R3dare H; X is a bond, -N(Me)-, O or -CH2-; R4is selected from H, CN, halo, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R5and R6are independently selected from H, halo, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R8is (i) a bond to LINK or (ii) a group selected from a 6-membered aryl ring, a 5- to 6- membered heteroaryl ring, and a 5- to 6-membered heterocyclyl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkoxy, R10, -(C1-4alkylene)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two R9; each R9is independently selected from halo and C1-4alkoxy; R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 6-membered heterocyclyl ring, and a phenyl ring, the group R10being unsubstituted or substituted by one or two substituents independently selected from C1-4alkyl, C1-4alkoxy, and halo; and wherein either R8is (i) a bond to LINK, or R8is a group (ii) and M is bonded to LINK via a C or N atom within group R8such that a hydrogen atom on the C or N atom within group R8is replaced with a bond to LINK. In a particularly preferred embodiment, M is of formula (IV): wherein R8is (i) a bond to LINK or (ii) a group selected from a 6-membered aryl ring and a 5- to 6-membered heteroaryl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkyl and R10; R10is a 3-membered cycloalkyl ring; wherein either R8is (i) a bond to LINK, or R8is a group (ii) and M is bonded to LINK via a C or N atom within group R8such that a hydrogen atom on the C or N atom within group R8is replaced with a bond to LINK. As discussed elsewhere herein, the stereochemistry of the compounds of the invention at the ring Hy is preferably such that the bond from ring Hy to the core ring A is in the “up” position and the bond from ring Hy to R2is the down position. Thus, formula (IV) preferably has the stereochemistry depicted below:

[0002] The present invention also provides a compound as described herein for use in a method of treating cancer in a subject in need thereof. Also provided is a method for treating cancer in a subject, which method comprises administering to said subject an effective amount of a compound as described herein. Further provided is the use of a compound as described herein in the manufacture of a medicament for use in treating cancer in a subject. Brief Description of the Drawings Figure 1: Graph showing reduction in tumour growth in in vivo mouse model of human AML, following oral administration of the compound of Example 55, following the procedure described in Example 236. Detailed Description of the Invention Definitions As used herein, a C1-4alkyl group is a linear or branched alkyl group containing from 1 to 4 carbon atoms. A C1-4alkyl group is often a C1-3alkyl group. Examples of C1-4alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, and tert-butyl. A C1-3alkyl group is typically a C1-2alkyl group. A C1-2alkyl group is methyl or ethyl, typically methyl. For the avoidance of doubt, where multiple alkyl groups are present, the alkyl groups may be the same or different. As used herein, a C1-4alkoxy group is typically a said C1-4alkyl group which is joined to the rest of the molecule via an oxygen atom. Typically, a C1-4alkoxy group is a C1-3alkoxy group. Examples of C1-4alkoxy groups include methoxy, ethoxy, propoxy and butoxy. Typically, a C1-3alkoxy group is a C1-2alkoxy group such as a methoxy or ethoxy group. For the avoidance of doubt, where two alkoxy groups are present, the alkoxy groups may be the same or different. As used herein, a C1-30alkylene group is a linear or branched divalent alkyl group that contains from 1 to 30 carbon atoms. A C1-30alkylene group is sometimes a C1-20alkylene group, and often a C1-10alkylene group. C1-30alkylene groups, C1-20alkylene groups and C1-10alkylene groups are preferably linear. A C1-30alkylene group is sometimes a C1-6alkylene group, typically a C1-4alkylene group or a C1-3alkylene group. Examples of C1-4alkylene groups include methylene, ethylene, n- propylene, iso-propylene, n-butylene, sec-butylene, and tert-butylene. A C1-3alkylene group is typically a C1-2alkylene group. A C1-2alkylene group is methylene or ethylene, typically methylene. For the avoidance of doubt, where multiple alkylene groups are present, the alkylene groups may be the same or different. As used herein, a C2-6alkenylene group is a linear or branched divalent alkenyl group containing from 2 to 6 carbon atoms and having one or more, e.g. one or two, typically one double bonds. Typically, a C2-6alkenylene group is a C2-4alkenylene group. Examples of C2-4alkenylene groups include divalent ethenylene, propenylene and butenylene. For the avoidance of doubt, where multiple alkenylene groups are present, the alkenylene groups may be the same or different. An alkyl, alkoxy, alkylene or alkenylene group as used herein may be unsubstituted or substituted. Unless otherwise stated, substituted alkyl, alkoxy, alkylene or alkenylene groups typically carry one or more, e.g. one, two or three e.g. one, or two, e.g. one substituent selected from halo, OH, and unsubstituted C1-4alkoxy. Preferred substituents are halo and C1-4alkoxy unless otherwise stated. The substituents on a substituted alkyl, alkoxy, alkylene or alkenylene group are typically themselves unsubstituted. Where more than one substituent is present, these may be the same or different. As used herein, a halo typically refers to chlorine, fluorine, bromine or iodine, preferably chlorine, bromine or fluorine, more preferably chorine or fluorine, most preferably fluorine unless otherwise stated. A C3-8cycloalkyl ring is a cyclic hydrocarbon containing from 3 to 8 carbon atoms. A cycloalkyl ring may be saturated or partially unsaturated, but is typically saturated. A C3-8 cycloalkyl ring is typically a C3-6cycloalkyl ring. A partially unsaturated cycloalkyl ring is a cyclic hydrocarbon containing 1 or 2, e.g.1 double bond. C3-6cycloalkyl and C5-6cycloalkyl rings may also be referred to herein as 3- to 6-membered cycloalkyl rings and 5- to 6-membered cycloalkyl rings respectively. A C3-6cycloalkyl ring may be a saturated C3-6cycloalkyl ring. A C3-6cycloalkyl ring may be a C5-6cycloalkyl ring, in particular a saturated C5-6cycloalkyl ring. Examples of C3-6cycloalkyl rings are cyclopropyl, cyclobutyl cyclopentyl and cyclohexyl groups. A C3-8cycloalkyl ring may be a C7-8cycloalkyl ring, in particular a saturated C7-8cycloalkyl ring. Examples of C7-8cycloalkyl rings are cycloheptanly, cyclooctanyl, bicyclo[2.2.1]heptanyl and bicyclo[2.2.2]octanyl groups. A 4- to 7-membered heterocyclyl ring is a cyclic group containing from 4 to 7 atoms selected from C, O, N and S in the ring, including at least one heteroatom, and typically one or two heteroatoms unless otherwise stated. The heteroatom or heteroatoms are typically selected from O, N, and S, most typically from S and N, especially N. For example, where the heterocyclyl ring is denoted a nitrogen-containing heterocyclyl group, it contains one nitrogen atom and optionally a further heteroatom selected from O, N and S. A heterocyclyl ring may be saturated or partially unsaturated, but is typically saturated. A 4- to 7- membered partially unsaturated heterocyclyl ring is a cyclic group containing from 4 to 7 atoms selected from C, O, N and S in the ring and containing 1 or 2, e.g.1 double bond. Typically, in the compounds described herein, a heterocyclyl ring is saturated unless otherwise specified. A 4- to 7- membered heterocyclyl ring may sometimes be a 5- to 6-membered ring. A 4- to 7- membered heterocyclyl ring is typically a monocyclic ring and may be a monocyclic 5- or 6- membered heterocyclyl ring. In some compounds described herein, a 4- to 7- membered heterocyclyl group is a 4- to 7- membered nitrogen-containing heterocyclyl ring which is unsubstituted or is substituted as described herein. Preferred 4- to 7- membered nitrogen- containing heterocyclyl rings include morpholine, pyrrolidine, piperidine and piperazine. Examples of 5- and 6- membered saturated heterocyclyl rings include piperazine, piperidine, morpholine, diazinane and pyrrolidine. Diazinane is typically 1,4-diazinane. As used herein, a 6- to 10-membered aryl ring is a substituted or unsubstituted, monocyclic or fused polycyclic aromatic group containing from 6 to 10 carbon atoms in the ring portion. Examples include monocyclic groups such as phenyl and fused bicyclic groups such as naphthyl and indenyl. Phenyl (benzene) is preferred. As used herein, a 5- to 10- membered heteroaryl ring is a substituted or unsubstituted monocyclic or fused polycyclic aromatic group containing from 5 to 10 atoms in the ring portion, including at least one heteroatom, for example 1, 2 or 3 heteroatoms, typically selected from O, S and N. A heteroaryl ring is typically a 5- or 6-membered heteroaryl ring or an 8- to 10- membered heteroaryl ring. Preferably, the heteroaryl ring comprises 1, 2 or 3, preferably 1 or 2 nitrogen atoms. Examples of 5- and 6- membered heteroaryl rings include thiazole, pyrazole, pyrimidine, triazole, 1,2,4-oxadiazole and pyrazine. Examples of 8-, 9- and 10- membered heteroaryl rings include indazole, thieno[2,3-c]pyrazole, imidazo[4,5-b]pyridine, pyrazolo[3,4-b]pyridine, furo[2,3-c]pyridine, indole, benzoxazole, benzothiazole, [1,2,4]triazolo[4,3-a]pyridine, thieno[2,3-d]pyrimidine, 1,2,3-benzotriazole, imidazo[1,5-a]pyridine, imidazo[1,2-a]pyrazine, oxazolo[5,4-b]pyridine, quinoline, naphthyridine, isoquinoline, quinazoline, and quinoxaline. 8-, 9- and 10- membered heteroaryl rings as used herein are typically fused bicyclic groups. For the avoidance of doubt, references to a heteroaryl ring also include fused polycyclic ring systems, including for instance fused bicyclic systems in which a heteroaryl ring is fused to an aryl group. When the heteroaryl ring is such a fused heteroaryl group, preferred examples are fused ring systems wherein a 5- to 6-membered heteroaryl group is fused to a phenyl group. Indazole is preferred. As used herein, a fused bicyclic group is a group comprising two cyclic moieties sharing a common bond between two atoms. When R8is selected from a 6-membered aryl ring, a 5- to 6-membered heteroaryl ring, a 5- to 6- membered heterocyclyl ring and a 5- to 6-membered cycloalkyl ring, it is to be understood that R8is a monocyclic ring. A cycloalkyl, heterocyclyl, aryl or heteroaryl ring may be unsubstituted or substituted as described herein unless otherwise stated. For example, a cycloalkyl, heterocyclyl, aryl or heteroaryl ring may be unsubstituted or substituted with 1, 2 or 3, typically 1 or 2 such as e.g.1 substituent. Suitable substituents include halo, C1-4alkoxy, R10, -(C1-4alkylene)-R10, =O, -CN, and C1-4alkyl, wherein R10is as defined herein). The substituents on a substituted cycloalkyl, heterocyclyl, aryl or heteroaryl ring are typically themselves unsubstituted, unless otherwise stated. The compounds described herein comprise at least one heterocyclyl ring comprising at least one nitrogen atom. Said nitrogen atom(s) are independently selected from secondary, tertiary and quaternary nitrogen atom(s). A quaternary nitrogen atom is present when the compound comprises a quaternised derivative of one or more monocyclic groups or fused bicyclic groups. As used herein, a quaternised derivative of a moiety such as a cyclic moiety is formed by bonding an additional alkyl group to a nitrogen atom in the moiety such that the valency of the said nitrogen atom increases from 3 to 4 and the nitrogen atom is positively charged. The compounds described herein comprise a heterocyclyl ring identified as ring Hy, which is a 4- to 7-membered heterocyclyl ring. Ring Hy contains X and at least one N atom in the ring portion, wherein X is a bond, -N(R11)-, O, S, -S(O)2-, -S(O)(NR11)-, or -C(R11)2-, and R11is as defined herein. Ring Hy is linked to ring A (as identified in formula (I) above) via a C atom within ring Hy, said C atom also being linked to R2which is as defined herein. A N atom within ring Hy is substituted by R1which is as defined herein. The rest of ring Hy is unsubstituted or substituted by one or two R3. Each R3is independently selected from C1-4alkyl, C1-4alkoxy and halo, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring, as defined herein. In option (ii), the skilled person would understand that the C atom to which the two R3are attached is a spiro atom (i.e. the common atom that connects the two rings of a spiro compound). As used herein, the terms “monovalent” or “monovalent moiety” are used to describe a chemical group obtainable by removing a hydrogen atom from the corresponding compound. As used herein, the terms “divalent” or “divalent moiety” are used to describe a chemical group obtainable by removing a hydrogen atom from the corresponding monovalent moiety. Thus, as used herein, the terms “divalent” and “divalent moiety” are used to describe a chemical group obtainable by removing two hydrogen atoms from the corresponding compound. It is to be understood that each individual atom present in the formulae depicted herein may be present in the form of any of its naturally occurring isotopes, with the most abundant isotope(s) being preferred. Thus, by way of example, each individual hydrogen atom present in the formulae depicted herein may be present as a 1H, 2H (deuterium) or 3H (tritium) atom, preferably 1H. Similarly, by way of example, each individual carbon atom present in the formulae depicted herein may be present as a 12C, 13C or 14C atom, preferably 12C. In the compounds of the invention, the stereochemistry is not limited. In particular, where moiety M of formula (I) and / or moiety U contains one or more chiral centre, the compounds may be used in enantiomerically or diastereoisomerically pure form, or in the form of a mixture of isomers. Further, for the avoidance of doubt, the compounds of the invention may be used in any tautomeric form. Typically, the agent or substance described herein contains at least 50%, preferably at least 60%, 75%, 90% or 95% of a compound which is enantiomerically or diasteriomerically pure. Thus, the compound is preferably substantially optically pure. The moiety M of formula (I) typically contains at least one chiral centre at the carbon atom of ring Hy which is linked to R2and to ring A. Moiety M may be provided in the form of the R- enantiomer at said carbon atom, in the form of the S-enantiomer at said carbon atom, or in the form of a mixture of the two enantiomers. The substance or agent described herein may contain at least 50%, preferably at least 60, 75%, 90% or 95% of a compound which is enantiomerically or diasteriomerically pure at moiety M. A pure enantiomeric form of either the R- or the S- enantiomer may be preferred. In some embodiments, the R-enantiomer at said carbon atom is preferred, and in particular when R2is H then the R-enantiomer at said carbon atom is preferred. The preferred stereochemistry at said carbon atom is also depicted by the following illustrative structure of formula (I) where the bond from ring Hy to the core ring A is in the “up” position and the bond from ring Hy to R2is the down position: This steroechemsitry at the carbon atom of ring Hy which is linked to R2and to ring A, where the bond from ring Hy to the core ring A is in the “up” position and the bond from ring Hy to R2 is the down position (as depicted above), is also preferred for the moiety M of formulae (II), (III), (IV), and for the compounds of formulae (I’), (II’) and (III’). As discussed further herein, where the compounds of the invention contain a chiral centre, and in particular where moiety M and / or moiety U contains a chiral centre, the individual stereoisomers may be obtained by chiral synthesis, or by separation of stereoisomers. Stereoisomers may be separated, for example, using chiral chromatography. The individual stereoisomers may be identified using the IUPAC labels R and S as appropriate. Alternatively, the individual stereoisomers may be identified by the order in which they elute, for example the first, second, third or fourth stereisomer respectively, as obtained by separation using chiral chromatography. Where two or more stereocentres are present in a compound or moiety, a combination of IUPAC nomenclature for stereocentres where absolute stereochemistry has been defined, and rate of elution, may be used. For example, where two or more individual stereoisomers are unidentified by IUPAC nomenclature, these stereoisomers may be identified as the first- and second-eluting isomers, as obtained by separation using chiral chromatography. Therefore, the stereoisomers at a chiral carbon atom of ring Hy which is linked to R2and to ring A may be defined as the first-eluting and second-eluting stereoisomers, as obtained by separation using chiral chromatography. Chiral chromatography is typically reverse phase HPLC. The compounds of the present invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms. A compound of the present invention can be converted into a pharmaceutically acceptable salt thereof, and a salt can be converted into the free compound, by conventional methods. For instance, a compound of the present invention can be contacted with a pharmaceutically acceptable acid to form a pharmaceutically acceptable salt. A pharmaceutically acceptable salt is a salt with a pharmaceutically acceptable acid or base. Pharmaceutically acceptable acids include both inorganic acids such as hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic or nitric acid and organic acids such as oxalic, citric, fumaric, maleic, malic, ascorbic, succinic, tartaric, benzoic, acetic, methanesulphonic, ethanesulphonic, benzenesulphonic or p-toluenesulphonic acid. Pharmaceutically acceptable bases include alkali metal (e.g. sodium or potassium) and alkali earth metal (e.g. calcium or magnesium) hydroxides and organic bases such as alkyl amines, aralkyl amines and heterocyclic amines. Hydrochloride salts and acetate salts are preferred, in particular hydrochloride salts. Proteolysis Targeting Chimera (PROTAC)s The compounds of the invention comprise a binder of MLLT1 and / or MLLT3 (M) that is covalently attached via a linker moiety (LINK) to an E3 ubiquitin ligase binding moiety (U). The inventors have surpisingly discovered that such compounds may have substantially enhanced efficacy compared with a corresponding MLLT1 and / or MLLT3 inhibitor that is not attached to an E3 ubiquitin ligase binding moiety. For example, the antiproliferative effects of the compounds may be substantially enhanced by covalent attachment to the E3 ubiquitin ligase binding moiety. Such compounds may induce selective degradation of MLLT1 and / or MLLT3. For instance, such compounds may induce selective degradation of MLLT1 and / or MLLT3 without inducing degradation of other proteins, such as FLT3 (fms like tyrosine kinase 3). Such compounds may also not inhibit FLT3. Thus, the invention provides a compound which is a Proteolysis Targeting Chimera (PROTAC) or a pharmaceutically acceptable salt thereof, wherein the PROTAC has the structure: wherein U is an E3 ubiquitin ligase binding moiety, LINK is a moiety that covalently links M and U, and M is an MLLT1 and / or MLLT3 binder of formula (I) as defined herein. In the compounds of the present invention, the MLLT1 and / or MLLT3 binder is covalently attached to the E3 ubiquitin ligase binding moiety via the moiety labelled LINK. LINK is either a single bond or a chemical group that covalently attaches the MLLT1 and / or MLLT3 binder to the E3 ubiquitin ligase binding moiety. The MLLT1 and / or MLLT3 binder is attached to LINK via (i) a single bond at R8, or (ii) a C or N atom within group R8or ring Hy (as described herein) such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. In case (ii), a hydrogen atom on the C or N atom within group R8or ring Hy is replaced by either a direct single bond to the E3 ubiquitin ligase binding moiety or by a chemical group that covalently attaches the MLLT1 and / or MLLT3 binder to the E3 ubiquitin ligase binding moiety. The description herein discusses the substitution of group R8and ring Hy by various chemical groups aside from LINK. For completeness, the skilled person would readily appreciate that where group R8and / or ring Hy are defined as being unsubstituted, this is intended as a reference to the absence of substituents other than a bond to LINK. Therefore, such a definition retains the option that group R8or ring Hy is attached to LINK via a C or N atom within group R8or ring Hy such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. Furthermore, the skilled person would readily appreciate that where group R8and / or ring Hy are defined as being substituted by one or more chemical groups (suitable such chemical groups are defined herein), this is intended as a reference to substituents other than a bond to LINK. Therefore, such a definition includes group R8or ring Hy being attached to LINK via a C or N atom within group R8or ring Hy such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. Therefore, where group R8and / or ring Hy are defined as being unsubstituted or substituted by one or more chemical groups (suitable such chemical groups are defined herein), then one of group R8or ring Hy may also be attached to LINK via a C or N atom within group R8or ring Hy such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. A bond to LINK may optionally be positioned on a carbon atom which carries a further substituent (where chemically possible). Typically, a carbon or nitrogen atom which is bonded to LINK does not carry a further substituent. For the avoidance of doubt, where group R8and / or ring Hy are defined as being substituted by a hydrogen atom (e.g. where R1, R2, R11, R3a, R3b, R3cand R3dare defined as being a hydrogen atom), then a reference herein to a hydrogen atom within group R8or ring Hy being replaced with a bond to LINK, includes the option that said hydrogen atom (e.g. a hydrogen atom at R1, R2, R11, R3a, R3b, R3cand R3d) is replaced with a bond to LINK. Therefore, where R1, R2, R11, R3a, R3b, R3cand R3dare defined as being a hydrogen atom, then said hydrogen atom may be replaced with a bond to LINK. For the avoidance of doubt, where ring Hy or group R8is substituted, a C or N atom which is bonded to LINK may be within the aryl, heteroaryl, heterocyclyl, or cycloalkyl ring of ring Hy or group R8, or it may be a C or N atom of a substituent on ring Hy or group R8. Preferably, a C or N atom which is bonded to LINK is a C or N atom on the heterocyclyl ring of ring Hy (i.e. directly to the ring and not via a substituent), a C or N atom of the heteroaryl ring of group R8, or the heteroaryl, cycloalkyl, heterocyclyl or phenyl ring of R10in the case that a group R10is present as, or as part of, a substituent on R8. As the skilled person would readily appreciate, methods for preparation of compounds (in which two discrete chemical entities contribute discrete biological functions to the overall compound) are very well known in the art. A hugely diverse range of techniques for covalently attaching the respective chemical entities, via a vast number of chemical linker moieties, is well established. Such is the ubiquity of these methodologies, that standard text books devoted entirely to this topic have long been available. One such textbook is “Bioconjugate Techniques” (Greg T. Hermanson, Academic Press Inc., 1996), the content of which is herein incorporated by reference in its entirety. MLLT1 and / or MLLT3 binder group M In the compounds of the invention, the MLLT1 and / or MLLT3 binder M is a monovalent moiety of formula (I) as defined herein. In the description that follows, the skilled person will readily understand that M is a monovalent moiety that is bonded to LINK via (i) a single bond at R8, or (ii) a C or N atom within group R8or ring Hy (as described herein) such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. Thus, in the description that follows, any of the hydrogen atoms on any of the C or N atoms within group R8or ring Hy may be removed to form the point of attachment of the monovalent moiety M to LINK. Typically, ring Hy is a 5- to 6- membered heterocyclyl ring containing X and at least one N atom, for instance one or two N atoms. X is typically a bond, -N(R11)-, O or -C(R11)2-. Preferably, X is a bond, -N(Me)-, O or -CH2-, most preferably X is a bond. In particular, when ring Hy is a 4- or 5-membered heterocyclyl ring, X is most preferably a bond. For example, ring Hy may be selected from a pyrrolidinyl, piperidinyl, morpholinyl or diazinanyl ring. Preferably, ring Hy is a 5-membered heterocyclyl ring containing X and at least one N atom, for instance one N atom. For example, ring Hy may be a pyrrolidinyl ring. Ring Hy is linked to ring A via a C atom within ring Hy, said C atom also being linked to R2. A N atom within ring Hy is substituted by R1. Typically, the N atom of ring Hy which is substituted by R1is adjacent to the C atom of ring Hy that is bonded to ring A. A C or N atom within ring Hy may be bonded to LINK by a hydrogen atom on that C or N atom being replaced by a bond to LINK. Typically, where ring Hy is bonded to LINK, this is via a C atom on Hy. Preferably, the bond to LINK is via replacement of a hydrogen atom on a C or N within group R8, i.e. the bond to LINK is preferably not via ring Hy. Typically, R1is H, C1-4cycloalkyl, or C1-4alkyl which is itself unsubstituted or substituted with one C1-4alkoxy or one, two or three halo, preferably with one C1-4alkoxy, for example R1may be H or C1-2alkyl which is unsubstituted or substituted with one C1-2alkoxy or one, two or three halo, preferably with one C1-2alkoxy, or R1may be H or C1-2alkyl which is unsubstituted or substituted with one C1-2alkoxy. Preferably, R1is H, methyl, ethyl or methoxyethyl, more preferably methyl or ethyl. Most preferably, R1is methyl. R2is H or methyl. Preferably, R2is H. Typically, each R11is independently selected from H and methyl. When X is -N(R11)- or - S(O)(NR11)-, R11is preferably methyl. When X is -C(R11)2-, optionally one R11is replaced with a single bond to LINK and the other R11is H. When X is -C(R11)2-, each R11is preferably H. Aside from groups R1and R2, ring Hy may further be unsubstituted or substituted by one or two R3. Typically, each R3is independently selected from C1-4alkyl, C1-4alkoxy and halo, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a C5-6 cycloalkyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a C3-6cycloalkyl ring. More typically, each R3is independently selected from methyl, ethyl, t-butyl methoxy and fluoro, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a cyclohexyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a cyclopentyl ring. Preferably, ring Hy is substituted by no R3groups. In another typical emobidment, each R3is independently selected from methyl, ethyl, t-butyl, methoxy and fluoro, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a cyclohexyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a cyclopropyl ring or a cyclopentyl ring. Preferably, ring Hy is substituted by two R3groups which are both C1-4alkyl, for instance both being methyl, or one R3group which is C1-4alkyl, for instance methyl, ethyl or t-butyl. Typically, therefore, ring Hy is a 5- to 6- membered heterocyclyl ring containing X and at least one N atom, for example a pyrrolidinyl, piperidinyl, morpholinyl or diazinanyl ring; the N atom of ring Hy which is substituted by R1is adjacent to the C atom of ring Hy that is bonded to ring A; R1is H or C1-2alkyl which is unsubstituted or substituted with one C1-2alkoxy or one, two or three halo, preferably with one C1-2alkoxy; R2is H or methyl; X is a bond, -N(R11)-, O or - C(R11)2-; R11is H or methyl; ring Hy is further unsubstituted or substituted by one or two R3; and each R3is independently selected from C1-4alkyl, C1-4alkoxy and halo, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a C3-6cycloalkyl ring. Preferably, ring Hy is a pyrrolidinyl ring; the N atom of ring Hy which is substituted by R1is adjacent to the C atom of ring Hy that is bonded to ring A; R1is methyl or ethyl, more preferably methyl; R2is H; and ring Hy is substituted by no R3groups, i.e. ring Hy is not further substituted and carries substituent R1only. In this embodiment, ring Hy may be referred to as being an unsubstituted pyrrolidine ring, wherein the skilled person would understand that ring Hy still carries substituent R1. Alternatively, ring Hy is a pyrrolidinyl ring; the N atom of ring Hy which is substituted by R1is adjacent to the C atom of ring Hy that is bonded to ring A; R1is H, methyl, ethyl or methoxyethyl, more preferably methyl; R2is H; and ring Hy is further substituted by two R3groups which are both C1-4 alkyl, for instance both being methyl, or one R3group which is C1-4alkyl, for instance methyl, ethyl or t-butyl. Typically, no more than two of Y1, Y2and Y3are N. Preferably Y1is N, Y2is -C(R6)-, and Y3is -C(R5)-. Typically, Z1is -C(R4)-, Z3is -N(H)-, and Y1is N. Thus, the bicyclic structure formed by rings A and B has the structure: In one preferred embodiment, Z1is -C(R4)-, Z3is -N(H)-, Y1is N, Y2is -C(R6)-, and Y3is - C(R5)-, such that the bicyclic structure formed by rings A and B has the structure: Typically, R4is selected from H, CN, halo, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; and R5and R6are independently selected from H, halo, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo. For instance, R4is selected from H, halo (e.g. fluoro), methoxy, and methyl; and R5and R6are independently selected from H, halo (e.g. fluoro), methoxy, and methyl. Preferably, either R4, R5and R6are H, or one of R4, R5and R6is not H. More preferably, R4, R5and R6are H. In one preferred embodiment, R5and R6are as defined herein and R4is selected from H, halo, CN, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo. More preferably, R5and R6are as defined herein and R4is selected from H, halo, CN, C1-4alkyl and CF3. Most preferably, R5and R6are as defined herein and R4is selected from H, F, Cl, CN, Me and CF3. In one preferred embodiment, R5is selected from H, cyclopropyl, C1-4 alkoxy, and C1-4 alkyl, for example from H, C1-4alkoxy, and C1-4alkyl. More preferably, R5is selected from H, cyclopropyl, methoxy and methyl, for example H, methoxy and methyl. In one preferred embodiment, R6is H. Typically, therefore, in formula (I): -R4 is selected from H, halo, CN, C1-4 alkoxy, and C1-4 alkyl which is itself unsubstitutedor substituted by one, two or three halo, and R5and R6when present are H; or- R5 is selected from H, cyclopropyl, C1-4 alkoxy, and C1-4 alkyl, typically from H, C1-4alkoxy, and C1-4alkyl, and R4and R6when present are H; or -R4, R5 and R6 are H.Preferably, in formula (I): -R4 is selected from H, F, Cl, Me, CN and CF3, and R5 and R6 when present are H;- R5 is selected from H, cyclopropyl, methoxy and methyl, typically from H, methoxyand methyl, and R4and R6when present are H; or -R4, R5 and R6 are H.In one alternative preferred embodiment, R5and R6are as defined herein and R4is selected from halo, CN, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo. More preferably, R5and R6are as defined herein and R4is selected from halo, CN, C1-4alkyl and CF3. More preferably, R5and R6are as defined herein and R4is selected from halo, and CF3. Most preferably, R5and R6are as defined herein and R4is selected from F, Cl, and CF3. L is -C(O)N(H)-, wherein the C atom of L is bonded to R8, and the N atom of L is bonded to ring B. In one embodiment, R8is a bond to LINK. In another embodiment, R8is a group selected from a 6-membered aryl ring, a 5- to 6- membered heteroaryl ring, a 5- to 6-membered heterocyclyl ring, and a 5- to 6-membered cycloalkyl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkoxy, R10, -(C1-4alkylene)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two R9. R9and R10are as defined herein. Typically, R8is a group selected from a 6-membered aryl ring, a 5- to 6-membered heteroaryl ring, and a 5- to 6-membered heterocyclyl ring. The aryl, heteroaryl and heterocyclyl rings are as defined herein. For instance, R8may be selected from phenyl, thiazolyl, pyrazolyl, pyrimidinyl, pyridinyl, triazolyl, 1,2,4-oxadiazolyl, and pyrazinyl. Preferably, R8is phenyl or a 5- to 6-membered heteroaryl ring preferably containing one, two or three N atoms. More preferably, R8is a phenyl group, a pyridinyl, a pyrimidinyl or a pyrazolyl group. In particular, R8may be a phenyl group. A C or N atom within group R8may be bonded to LINK by a hydrogen atom on that C or N atom being replaced by a bond to LINK. Typically, where group R8is bonded to LINK, this is via a C atom on R8. Preferably, a C or N atom within group R8is bonded to LINK such that a hydrogen atom on that C or N atom is replaced by a bond to LINK. Preferably, the C or N atom that is bonded to LINK is a C or N atom of the aryl, heteroaryl, heterocyclyl or cycloalkyl ring of R8or a C or N atom of the heteroaryl, cycloalkyl, heterocyclyl or phenyl ring of R10. More preferably, the C or N atom that is bonded to LINK is a C or N atom of the aryl, heteroaryl, heterocyclyl or cycloalkyl ring of R8. In addition to any bond to LINK (where present) R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents. Typically, each substituent is independently selected from halo, C1-4alkoxy, R10, -(CH2)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two groups selected from selected from halo and C1-2alkoxy. More typically, each substituent is independently selected from fluoro, chloro, methoxy, R10, -(CH2)-R10, =O, -CN, and C1-2alkyl which is itself unsubstituted or substituted by one or two groups selected from selected from halo (e.g. fluoro) and methoxy. Preferably, each substituent is independently selected from fluoro, R10and methyl. Most preferably, each substituent is independently selected from fluoro and methyl. R10is as defined herein. Typically, R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 5-membered heterocyclyl ring, and a phenyl ring. The cycloalkyl, heteroaryl and heterocyclyl rings are as defined herein. Preferably, R10is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, oxadiazolyl, oxetanyl, phenyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, thiazinyl, thiazolyl and triazolyl, more preferably pyrazolyl. Typically, in addition to any bond to LINK (where present), R10is unsubstituted or substituted by one or two substituents independently selected from fluoro, methyl and methoxy. Preferably, R10is unsubstituted. Typically, therefore, R8is (i) a bond to LINK or (ii) a group selected from a 6-membered aryl ring, a 5- to 6-membered heteroaryl ring, a 5- to 6-membered heterocyclyl ring, and a 5- to 6- membered cycloalkyl ring; the group R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents, each independently selected from halo, C1-4alkoxy, R10, -(CH2)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two groups selected from selected from halo and C1-2alkoxy; wherein R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 5- membered heterocyclyl ring, and a phenyl ring; and R10is unsubstituted or substituted by one or two substituents independently selected from fluoro, methyl and methoxy. Typically, where a C or N atom within group R8is bonded to LINK, the C or N atom that is bonded to LINK is a C or N atom of the aryl, heteroaryl, heterocyclyl or cycloalkyl ring of R8or a C or N atom of the heteroaryl, cycloalkyl, heterocyclyl or phenyl ring of R10. Preferably, R8is phenyl or a 5- to 10-membered heteroaryl ring containing one, two or three N atoms, for example a phenyl group or a pyrazolyl group, a pyrimidinyl group or a pyridinyl group; the group R8is unsubstituted or substituted by one or two substituents, each independently selected from fluoro, R10and methyl; R10is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, oxadiazolyl, oxetanyl, phenyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, thiazinyl, thiazolyl and triazolyl; and R10is unsubstituted. Preferably, a C or N atom within group R8is bonded to LINK, wherein the C or N atom that is bonded to LINK is a C or N atom of the aryl, heteroaryl, heterocyclyl or cycloalkyl ring of R8. In a typical embodiment of formula (I), the bicyclic structure formed by rings A and B has the structure: and: ring Hy is a 5- to 6- membered heterocyclyl ring containing X and at least one N atom, for example a pyrrolidinyl, piperidinyl, morpholinyl or diazinanyl ring; wherein the N atom of ring Hy which is substituted by R1is adjacent to the C atom of ring Hy that is bonded to ring A; R1is H or C1-2alkyl which is unsubstituted or substituted with one C1-2alkoxy or one, two or three halo, preferably with one C1-2alkoxy; R2is H or methyl; X is a bond, -N(Me)-, O or -CH2-; ring Hy is further unsubstituted or substituted by one or two R3; wherein each R3is independently selected from C1-4alkyl, C1-4alkoxy and halo, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a C3-6cycloalkyl ring; R4is selected from H, CN, halo (e.g. fluoro or chloro), methoxy, methyl and trifluoromethyl; R5and R6are independently selected from H, halo (e.g. fluoro or chloro), methoxy, methyl and trifluoromethyl; the C atom of L is bonded to R8, and the N atom of L is bonded to ring B; R8is (i) a bond to LINK or (ii) a group selected from a 6-membered aryl ring, a 5- to 6- membered heteroaryl ring, a 5- to 6-membered heterocyclyl ring, and a 5- to 6-membered cycloalkyl ring; wherein the group R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents, each independently selected from halo, C1-4alkoxy, R10, -(CH2)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two groups selected from halo and C1-2alkoxy; and R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 5-membered heterocyclyl ring, and a phenyl ring; wherein R10is unsubstituted or substituted by one or two substituents independently selected from fluoro, methyl and methoxy; wherein either R8is (i) a bond to LINK, or R8is a group (ii) and M is bonded to LINK via a C or N atom within group R8or ring Hy such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. In a preferred embodiment of formula (I), the bicyclic structure formed by rings A and B has the structure: and: ring Hy is a pyrrolidinyl ring; wherein the N atom of ring Hy which is substituted by R1is adjacent to the C atom of ring Hy that is bonded to ring A; R1is H, methyl, ethyl or methoxyethyl, more preferably methyl; R2is H; and ring Hy is substituted by no R3groups; either R4, R5and R6are H, or one of R4, R5and R6is defined as described above except that it is not H, and the rest are H; the C atom of L is bonded to R8, and the N atom of L is bonded to ring B; R8is phenyl or a 5- to 6-membered heteroaryl ring containing one, two or three N atoms; the group R8is unsubstituted or substituted by one or two substituents, each independently selected from fluoro, R10and methyl; R10is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, oxadiazolyl, oxetanyl, phenyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, thiazinyl, thiazolyl and triazolyl; and R10is unsubstituted; wherein either R8is (i) a bond to LINK, or R8is a group (ii) and M is bonded to LINK via a C or N atom within group R8or ring Hy such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. In a particular embodiment of the compounds of the invention, the MLLT1 and / or MLLT3 binder group M is a monovalent moiety of formula (II): wherein: Z1, Z3, Y1, Y2, Y3, R1, R2, R8, X and L are as defined herein; R3aand R3bare independently selected from H, C1-4alkyl, phenyl, a 5- to 6-membered heteroaryl ring and C1-4alkoxy, or R3aand R3bform, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring, R3cand R3dare independently selected from H, C1-4alkyl, halo, phenyl, a 5- to 6-membered heteroaryl ring and C1-4alkoxy, or R3cand R3dform, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring, or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, with the proviso that when X is -N(R11)-, O, S, -S(O)2- or -S(O)(NR11)-, then neither R3cnor R3dare halo; wherein at least two of R3a, R3b, R3cand R3dare H; and wherein either R8is (i) a bond to LINK, or R8is a group (ii) and M is bonded to LINK via a C or N atom within group R8or ring Hy such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. Typically, in formula (II): R3aand R3bare independently selected from H and methyl; R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, in particular from H, methyl, ethyl, fluoro, methoxy and t-butyl, or R3cand R3dform, together with the C atom to which they are attached, a C5-6cycloalkyl ring (in particular a cyclopentyl ring), with the proviso that when X is -N(R11)-, O, S, -S(O)2- or -S(O)(NR11)-, then neither R3cnor R3dare fluoro; or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring (in particular a cyclohexyl ring); wherein at least two of R3a, R3b, R3cand R3dare H. In an alternative typical embodiment: R3aand R3bare independently selected from H and methyl; R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, in particular from H, methyl, ethyl, fluoro, methoxy and t-butyl, or R3cand R3dform, together with the C atom to which they are attached, a C3-6cycloalkyl ring (in particular a cyclopropyl or cyclopentyl ring), with the proviso that when X is NR11, O, or S, then neither R3cnor R3dare fluoro; or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring (in particular a cyclohexyl ring); wherein at least two of R3a, R3b, R3cand R3dare H. Optionally, one of R3a, R3b, R3cand R3dis replaced with a single bond to LINK. Preferably, in formula (II), R3a, R3b, R3cand R3dare all H, or one of R3a, R3b, R3cand R3dis methyl, ethyl or t-butyl and the rest are H, or R3cand R3dare methyl and the rest are H. More prefereably, R3a, R3b, R3cand R3dare all H. In a typical embodiment of formula (II), the bicyclic structure formed by rings A and B has the structure:

[0003] and: R1is H or C1-2alkyl which is unsubstituted or substituted with one C1-2alkoxy or one, two or three halo, preferably with one C1-2alkoxy; R2is H or methyl; X is a bond, -N(Me)-, O or -CH2-; R3aand R3bare independently selected from H and methyl; R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, in particular from H, methyl, ethyl, fluoro, methoxy and t-butyl, or R3cand R3dform, together with the C atom to which they are attached, a C5-6cycloalkyl ring (in particular a cyclopentyl ring), with the proviso that when X is NR11or O, then neither R3cnor R3dare fluoro; or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring (in particular a cyclohexyl ring); wherein at least two of R3a, R3b, R3cand R3dare H; R4is selected from H, CN, halo (e.g. fluoro or chloro), methoxy, methyl and trifluoromethyl; R5and R6are independently selected from H, halo (e.g. fluoro or chloro), methoxy, methyl and trifluoromethyl; the C atom of L is bonded to R8, and the N atom of L is bonded to ring B; R8is (i) a bond to LINK or (ii) a group selected from a 6-membered aryl ring, a 5- to 6- membered heteroaryl ring, a 5- to 6-membered heterocyclyl ring, and a 5- to 6-membered cycloalkyl ring; wherein the group R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents, each independently selected from halo, C1-4alkoxy, R10, -(CH2)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two groups selected from selected from halo and C1-2alkoxy; and R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 5-membered heterocyclyl ring, and a phenyl ring; wherein R10is unsubstituted or substituted by one or two substituents independently selected from fluoro, methyl and methoxy; wherein either R8is (i) a bond to LINK, or R8is a group (ii) and M is bonded to LINK via a C or N atom within group R8or ring Hy such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. In a preferred embodiment of formula (II), the bicyclic structure formed by rings A and B has the structure: and: X is absent; R1is H, methyl, ethyl or methoxyethyl, more preferably methyl; R2is H; R3a, R3b, R3cand R3dare all H; either R4, R5, and R6, are H, or one of R4, R5, and R6is selected from CN, fluoro, methoxy, methyl and trifluoromethyl, and the rest are H, with the proviso that R5, and R6cannot be CN; the C atom of L is bonded to R8, and the N atom of L is bonded to ring B; R8is phenyl or a 5- to 6-membered heteroaryl ring containing one, two or three N atoms, for example an indazolyl group; the group R8is unsubstituted or substituted by one or two substituents, each independently selected from fluoro, R10and methyl; R10is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, oxadiazolyl, oxetanyl, phenyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, thiazinyl, thiazolyl and triazolyl; and R10is unsubstituted; and wherein either R8is (i) a bond to LINK, or R8is a group (ii) and M is bonded to LINK via a C or N atom within group R8or ring Hy such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. In a particularly preferred embodiment of the compounds of the invention, the MLLT1 and / or MLLT3 binder M is a monovalent moiety of formula (III):

[0004] wherein R1, R2, R3a, R3b, R3c, R3d, X, R4, R5, R6and R8are as defined herein. Typically, in the compounds of formula (III): R1is H or C1-4alkyl which is itself unsubstituted or substituted with C1-4alkoxy; R2is H or methyl; R3aand R3bare independently selected from H, C1-4alkyl, and C1-4alkoxy, or R3aand R3bform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, or R3cand R3dform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, with the proviso that when X is -N(Me)- or O, then neither R3cnor R3dare halo; wherein at least two of R3a, R3b, R3cand R3dare H; X is a bond, -N(Me)-, O or -CH2-; R4is selected from H, halo C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R5and R6are independently selected from H, halo C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R8is (i) a bond to LINK or (ii) a group selected from a 6-membered aryl ring, a 5- to 6- membered heteroaryl ring, a 5- to 6-membered heterocyclyl ring, and a 5- to 6-membered cycloalkyl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkoxy, R10, -(C1-4alkylene)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two R9; each R9is independently selected from halo and C1-4alkoxy; and R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 6-membered heterocyclyl ring, and a phenyl ring, the group R10being unsubstituted or substituted by one or two substituents independently selected from C1-4alkyl, C1-4alkoxy, and halo; wherein either R8is (i) a bond to LINK, or R8is a group (ii) and M is bonded to LINK via a C or N atom within group R8or ring Hy (as described herein) such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. Typically, in formula (III), R1is H, or C1-4alkyl which is itself unsubstituted or substituted with one C1-4alkoxy or one, two or three halo, preferably with one C1-4alkoxy, for example R1may be H or C1-2alkyl which is unsubstituted or substituted with one C1-2alkoxy or one, two or three halo, preferably with one C1-2alkoxy. Preferably, R1is H, methyl, ethyl or methoxyethyl. Most preferably, R1is methyl. In formula (III), R2is H or methyl. Preferably, R2is H. Typically, in formula (III), X is a bond, -N(R11)-, O or -C(R11)2-. Preferably, X is a bond, - N(Me)-, O or -CH2-, most preferably X is a bond. Typically, in formula (III), each R11is independently selected from H and methyl. When X is - N(R11)-, R11is preferably methyl. When X is -C(R11)2-, one R11is optionally replaced with a single bond to LINK and the other R11is H. When X is -C(R11)2-, each R11is preferably H. Typically, in formula (III), R3aand R3bare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, in particular from H and methyl; R3cand R3dare independently selected from H, methyl, ethyl, fluoro, methoxy and t-butyl, or R3cand R3dform, together with the C atom to which they are attached, a C5-6cycloalkyl ring (in particular a cyclopentyl ring), with the proviso that when X is NR11or O, then neither R3cnor R3dare fluoro; or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring (in particular a cyclohexyl ring); wherein at least two of R3a, R3b, R3cand R3dare H. Preferably, in formula (III), R3a, R3b, R3cand R3dare all H. Alternatively, one of R3a, R3b, R3cand R3dis methyl, ethyl or t-butyl, and the rest are H, or R3cand R3dare methyl and the rest are H. In all embodiments of formula (III) described herein, when X is -N(R11)- or O then neither R3cnor R3dare halo (e.g. fluoro). Typically, in formula (III), R4is selected from H, CN, halo, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo. Preferably, R4is selected from H, CN, F, Cl, Me and CF3. Typically, in formula (III), R5is selected from H and C1-4alkyl. Preferably, R5is selected from H and methyl, more preferably H. Typically, in formula (III), R6is H. Typically, therefore, in formula (III): -R4 is selected from H, CN, halo, C1-4 alkoxy, and C1-4 alkyl which is itself unsubstitutedor substituted by one, two or three halo, and R5and R6are H; or -R5 is selected from H and C1-4 alkyl, and R4 and R6 when present are H; or- R4, R5, and R6 when present are H.Preferably, in in formula (III): -R4 is selected from selected from H, CN, F, Cl, Me and CF3, and R5 and R6 are H; or- R5 is selected from H and methyl, and R4 and R6 when present are H; or- R4, R5, and R6 when present are H.In one alternative preferred embodiment, R5and R6are as defined herein and R4is selected from halo, CN, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo. More preferably, R5and R6are as defined herein and R4is selected from halo, CN, C1-4alkyl and CF3. More preferably, R5and R6are as defined herein and R4is selected from halo, and CF3. Most preferably, R5and R6are as defined herein and R4is selected from F, Cl, and CF3. In one preferred embodiment of formula (III), R8is a group selected from phenyl, pyridinyl, thiazolyl, pyrazolyl, pyrimidinyl, triazolyl, 1,2,4-oxadiazolyl, and pyrazinyl. Preferably, R8is phenyl or a 5- to 6-membered heteroaryl ring containing one, two or three N atoms. Typically, in formula (III), R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents, independently selected from halo, C1-4alkoxy, R10, -(CH2)- R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two groups selected from selected from halo and C1-2alkoxy. More typically, each substituent is independently selected from fluoro, chloro, methoxy, R10, -(CH2)-R10, =O, -CN, and C1-2alkyl which is itself unsubstituted or substituted by one or two groups selected from selected from halo (e.g. fluoro) and methoxy. Preferably, each substituent is independently selected from fluoro, R10and methyl. Most preferably, each substituent is independently selected from fluoro and methyl. R10is as defined herein. Typically, in formula (III), R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 5-membered heterocyclyl ring, and a phenyl ring. The aryl, heteroaryl and heterocyclyl rings are as defined herein. Preferably, R10is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, oxadiazolyl, oxetanyl, phenyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, thiazinyl, thiazolyl and triazolyl, more preferably pyrazolyl. Typically, in in formula (III), R10is unsubstituted or substituted by one or two substituents independently selected from fluoro, methyl and methoxy. Preferably, R10is unsubstituted. In typical embodiments of formula (III): R1is H or C1-2alkyl which is unsubstituted or substituted with one C1-2alkoxy or one, two or three halo, preferably with one C1-2alkoxy; R2is H or methyl; X is a bond, -N(Me)- O or -C(H)2-; R3aand R3bare independently selected from H and methyl; R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, in particular from H, methyl, ethyl, fluoro, methoxy and t-butyl, or R3cand R3dform, together with the C atom to which they are attached, a C5-6cycloalkyl ring (in particular a cyclopentyl ring), with the proviso that when X is NR11or O, then neither R3cnor R3dare fluoro; or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring (in particular a cyclohexyl ring); wherein at least two of R3a, R3b, R3cand R3dare H; one of the following options applies: R4is selected from H, CN, halo, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo, and R5and R6are H; or R5is selected from H and C1-4alkyl, and R4and R6when present are H; or R4, R5, and R6when present are H; the group R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents, each independently selected from halo, C1-4alkoxy, R10, -(CH2)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two groups selected from selected from halo and C1-2alkoxy; and R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 5-membered heterocyclyl ring, and a phenyl ring; wherein R10is unsubstituted or substituted by one or two substituents independently selected from fluoro, methyl and methoxy; and R8is a a 6-membered aryl ring, or a 5- to 6-membered heteroaryl ring; wherein either R8is (i) a bond to LINK, or R8is a group (ii) and M is bonded to LINK via a C or N atom within group R8or ring Hy such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. In preferred embodiments of formula (III), X is absent; R1is H, methyl, ethyl or methoxyethyl, more preferably methyl; R2is H; R3a, R3b, R3cand R3dare all H; R5and R6are H, and R4is selected from H, CN, F, Cl, Me and CF3, preferably H, CN or Cl, more preferably H; R8is phenyl or a 5- to 6-membered heteroaryl ring containing one, two or three N atoms; the group R8is unsubstituted or substituted by one or two substituents, each independently selected from fluoro, R10and methyl; R10is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, oxadiazolyl, oxetanyl, phenyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, thiazinyl, thiazolyl and triazolyl, preferably pyrazolyl; and R10is unsubstituted; wherein either R8is (i) a bond to LINK, or R8is a group (ii) and M is bonded to LINK via a C or N atom within group R8or ring Hy such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK. In a most preferred embodiment of the compounds of the invention, the MLLT1 and / or MLLT3 binder M is a monovalent moiety of formula (IV): wherein R8is as defined herein. In particular in formula (IV), the group R8may be unsubstituted or substituted by one, two or three substituents independently selected from R10, halo and C1-4alkyl; wherein either R8is (i) a bond to LINK, or R8is a group (ii) and M is bonded to LINK via a C or N atom within group R8such that a hydrogen atom on the C or N atom within group R8is replaced with a bond to LINK. Typically, in formula (IV), R8is a group selected from phenyl, thiazolyl, pyrazolyl, pyrimidinyl, triazolyl, 1,2,4-oxadiazolyl, pyridinyl and pyrazinyl. Typically, in formula (IV), R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents, independently selected from halo and C1-4alkyl and / or by one group R10, wherein R10is preferably pyrazolyl; preferably R8is unsubstituted or substituted by one, two or three substituents, for instance one or two substituents, independently selected from halo and C1-4alkyl. Preferably, each substituent is independently selected from fluoro and methyl. In a particularly preferred embodiment, in formula (IV), R8is selected from one of the following structures:

[0005] wherein: represents the point of attachment of R8to the rest of moiety M; and represents the point of attachment of R8to LINK or R10. When represents the point of attachment to R10, then R10is attached to LINK. For the avoidance of doubt, the group R8is further unsubstituted or substituted as described above. Preferably, the group R8is further unsubstituted or substituted by one or two substituents independently selected from fluorine and chlorine. For example, the group R8may be selected from one of the following structures: wherein: represents the point of attachment of R8to the rest of moiety M; and represents the point of attachment of R8to LINK. For the avoidance of doubt, R8may be selected from any one of the above structures defined herein in any of formulae (I), (II) and (III). In preferred embodiments of the compounds of the invention, the MLLT1 and / or MLLT3 binder M is a monovalent moiety: wherein R4and R8are as defined herein. In some of these preferred embodiments, R4is selected from H and halo (such as flouro or chloro). In one such embodiment, R4is H. In another such embodiment, R4is halo (such as flouro or chloro). In a particularly preferred embodiment, the MLLT1 and / or MLLT3 binder M is a monovalent moiety:

[0006] E3 ubiquitin ligase binding moieties The presence of the E3 ubiquitin ligase binding moiety U in the compound of the invention means that the compound is a so-called “PROTAC”. The term PROTAC is an acronym for proteolysis targeting chimera. In general, PROTACs are, as is known in the art, heterobifunctional molecules that comprise two active moieties attached covalently by a linker group. In a PROTAC, the first active moiety (the MLLT1 and / or MLLT3 binder M in the compound of the present invention) binds to a target protein that is intended for degradation (target proteins for the compound of the present invention are MLLT1 and / or MLLT3). The second active moiety (U in the compound of the present invention) is capable of binding to an E3 ubiquitin ligase, thereby inducing selective intracellular proteolysis. Recruitment of the E3 ligase to the target protein results in ubiquitination and subsequent degradation of the target protein by the proteasome. E3 ubiquitin ligase moities are known in the art. Substantially any such moiety can be used. The sole limitation on the moiety is that it be capable of binding to an E3 ubiquitin ligase. Those skilled in the art would appreciate that entirely routine laboratory methods can be used to determine whether a given substance binds to an E3 ubiquitin ligase (including but not limited to any of those disclosed specifically herein). Thus, those skilled in the art would have no difficulty in identifying E3 ubiquitin ligase moieties, nor in establishing whether any existing chemical moiety falls within the bounds of this definition. In certain embodiments, the moiety shows activity or binds to the E3 ubiquitin ligase with an IC50of less than about 200 mM. The IC50can be determined according to any method known in the art, e.g., a fluorescent polarization assay. Merely by way of example of the extensive disclosure in the field concerning PROTACs, and hence E3 ubiquitin ligase binding moieties, reference can be made to Gu et al. (BioEssays 2018, 40, 1700247), Sun et al. (Signal Transduction and Targeted Therapy (2019) 4:64), WO 2020 / 041331, and WO 2019 / 140003, the contents of all of which are herein incorporated by reference in their entireties. Any of the numerous E3 ubiquitin ligase binding moieties disclosed in these documents can be used as an E3 ubiquitin ligase binding moiety in the compounds of the present invention. For the avoidance of doubt, Gu et al. refer to such moieties as ligands to recruit E3 ubiquitin ligase, Sun et al. refer to such moieties as E3 ubiquitin ligase (E3) recruiting ligands, in WO 2020 / 041331 such moieties are referred to as a “ULM” or (small molecule) E3 ubiquitin ligase binding moiety (that binds an E3 ubiquitin ligase) (and noting that the term “ULM” includes each of “ILM”, “CLM”, “VLM” and “MLM”, any of which can be used in the present compounds), and in WO 2019 / 140003 such moieties (labelled “B” in WO 2019 / 140003’s formula (I)) are referred to as a ubiquitin ligase ligand / binder. Further examples of documents disclosing suitable moieties that can be used in the compounds of the present invention are WO2013 / 106643, US2016 / 0045607, WO2014187777, US20140356322 and US 9,249, 153, US2016 / 0058872, US2015 / 0291562 and Winter et al (Science, June 19, 2015, p.1376), the contents of all of which are herein incorporated by reference in their entireties. Thalidomide, lenalidomide, pomalidomide and analogs thereof are still further examples of suitable moieties. Examples of E3 ubiquitin ligases include von Hippel-Lindau (VHL) and cereblon (CRBN). Preferably the E3 ubiquitin ligase binding moiety (U) is capable of binding to CRBN or VHL. Such moieties are referred to herein as CRBN or VHL E3 ubiquitin ligase binding moieties. In one embodiment, U is a CRBN E3 ubiquitin ligase binding moiety. In another embodiment, U is a VHL E3 ubiquitin ligase binding moiety. In some embodiments, the E3 ubiquitin ligase binding moiety (U) is: (a) a CRBN E3 ubiquitin ligase binding moiety of formula (U1):

[0007] wherein: RU1is H; Q is selected from -CH(RU6)-, -N(RU6)-, -O-, -C(O)-, -NH-CH(RU6)-, -N=C(RU6)-, or -N=N-; RU6is H or C1-4alkyl; RU2and RU5are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; RU3and RU4are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU2, RU3, RU4and RU5is a single bond to LINK; (b) a CRBN E3 ubiquitin ligase binding moiety of formula (U4): wherein: RU1’is H; W is N or CRU16; Q’ is N and LUis a single bond, or Q’ is CH and LUis selected from a single bond or - C(O)N(H)-, wherein either (i) the C atom of LUis bonded to phenyl, and the N atom of LUis bonded to Q’; or (ii) the C atom of LUis bonded to Q’, and the N atom of LUis bonded to phenyl; RU12, RU13and RU14are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU12, RU13and RU14is a single bond to LINK; RU15and RU16are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN and CF3; (c) a CRBN E3 ubiquitin ligase binding moiety of formula (U5): wherein: RU17is H; RU18, RU19, RU20and RU21are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU18, RU19, RU20and RU21is a single bond to LINK; or (d) a VHL E3 ubiquitin ligase binding moiety of formula (U2):

[0008] wherein: RU7is a group selected from phenyl, a 5- to 6-membered heteroaryl ring, a 5- to 6-membered heterocyclyl ring, and a 5- to 6-membered cycloalkyl ring, the group RU7being unsubstituted or substituted by C1-4alkyl; RU11is H or C1-4alkyl; RU8is selected from C1-4alkyl, phenyl and a 3- to 8-membered cycloalkyl ring; and RU9is a single bond to LINK. For the avoidance of doubt, in formula (U1), when Q is -NH-CH(RU6)- or -N=C(RU6)-, the N atom of Q is bonded to the phenyl ring in U, and the C atom of Q (not including any C atom that may be in RU6) is bonded to the N atom in U that is adjacent to group Q. In some embodiments, the E3 ubiquitin ligase binding moiety (U) is preferably a CRBN E3 ubiquitin ligase binding moiety of formula (U1). Typically, in formula (U1), Q is selected from -CH(RU6)- and -C(O)-. Preferably, Q is selected from -CH2- and -C(O)-. Most preferably, Q is -CH2-. Typically, in formula (U1), RU6is H or methyl. Preferably, RU6is H. Typically, in formula (U1), RU2and RU5are each independently selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK. Preferably, RU2and RU5are each independently selected from H and a single bond to LINK. Most preferably, RU2is H, and RU5is a single bond to LINK. Typically, in formula (U1), RU3and RU4are each independently selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN, CF3and a single bond to LINK. Preferably, RU3and RU4are each independently selected from H and a single bond to LINK. Typically, in formula (U1), two or three of RU2, RU3, RU4and RU5are H. Preferably, three of RU2, RU3, RU4and RU5are H. More preferably, RU2and RU3are H, one of RU4and RU5is a single bond to LINK, and the other of RU4and RU5is H. Most preferably, RU2, RU3and RU4are H, and RU5is a single bond to LINK. Typically, therefore, in formula (U1): Q is selected from -CH(RU6)- and -C(O)-; RU6is H or methyl; RU2and RU5are each independently selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; RU3and RU4are each independently selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN, CF3and a single bond to LINK; and two or three of RU2, RU3, RU4and RU5are H. Preferably, in formula (U1): Q is selected from -CH2- and -C(O)-; RU6is H; one of RU2, RU3, RU4and RU5is a single bond to LINK, and the rest are H, for instance wherein RU2and RU3are H, one of RU4and RU5is a single bond to LINK, and the other of RU4and RU5is H. Most preferably, in formula (U1): Q is -CH2-; RU6is H; RU2, RU3and RU4are H, and RU5is a single bond to LINK. Typically, in formula (U4), Q’ is N and LUis a single bond, or Q’ is CH and LUis -C(O)N(H)-. Preferably, Q’ is N and LUis a single bond. Typically, in formula (U4), when LUis -C(O)N(H)-, then the C atom of LUis bonded to phenyl, and the N atom of LUis bonded to Q’. Typically, in formula (U4), RU12, RU13and RU14are each independently selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK (wherein one and only one of RU12, RU13and RU14is a single bond to LINK). Preferably, one of RU12, RU13and RU14is a single bond to LINK, one of RU12, RU13and RU14is H and the other of RU12, RU13and RU14is selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN, CF3, preferably from H, fluoro and methyl. More preferably, one of RU12, RU13and RU14is a single bond to LINK and the other two are H, for instance wherein RU12and RU14are H, and RU13is a single bond to LINK. Typically, in formula (U4), RU15and RU16(when present) are each independently selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN and CF3. Preferably, RU15and RU16(when present) are each independently selected from H, F and Me. In one embodiment of formula (U4), RU15and RU16(when present) are H, and two of RU12, RU13and RU14are H. Preferably, RU13, RU14and RU15are H, RU12is a single bond to LINK, and RU16(when present) is selected from H, F and Me. Typically, therefore, in formula (U4): Q’ is N and LUis a single bond, or Q’ is CH and LUis -C(O)N(H)-; RU12, RU13and RU14are each independently selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; and RU15and RU16(when present) are each independently selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN and CF3; wherein one and only one of RU12, RU13and RU14is a single bond to LINK. Preferably, in formula (U4): Q’ is N and LUis a single bond; one of RU12, RU13and RU14is a single bond to LINK and the other two are H, for instance wherein RU12and RU14are H, and RU13is a single bond to LINK, or RU13, RU14and RU15are H, RU12is a single bond to LINK, and RU16(when present) is selected from H, F and Me. Typically, in formula (U5), RU18, RU19, RU20and RU21are each independently selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK (wherein one and only one of RU18, RU19, RU20and RU21is a single bond to LINK). Preferably, one of RU18, RU19, RU20and RU21is a single bond to LINK, one or two, preferably two of RU18, RU19, RU20and RU21are H and the other one or two, preferably one of RU18, RU19, RU20and RU21are selected from H, fluoro, methyl, NH2, NO2, OH, COOH, CN, CF3, preferably from H, fluoro and methyl. More preferably, one of RU18, RU19, RU20and RU21is a single bond to LINK and the other three are H, for instance wherein RU19, RU20and RU21are H, and RU18is a single bond to LINK. Typically, in formula (U2), RU7is a 5- to 6-membered heteroaryl ring. Preferably, RU7is a 5- membered heteroaryl ring containing one S atom and optionally one N atom. Typically, in formula (U2), RU7is unsubstituted or substituted by C1-4alkyl. Preferably, RU7is unsubstituted or substituted by methyl. Typically, in formula (U2), RU11is H or methyl. Preferably, RU11is H. Typically, in formula (U2), RU8is C1-4alkyl or phenyl. Preferably, RU8is t-butyl or phenyl, more preferably t-butyl. Typically, therefore, in formula (U2), RU7is a 5- to 6-membered heteroaryl ring, the group RU7being unsubstituted or substituted by C1-4alkyl, RU11is H or methyl, and RU8is C1-4alkyl or phenyl. Preferably, in formula (U2), RU7is a 5-membered heteroaryl ring containing one S atom and optionally one N atom, the group RU7being unsubstituted or substituted by methyl, RU11is H, and RU8is t-butyl or phenyl, more preferably t-butyl. In a preferred embodiment, the E3 ubiquitin ligase binding moiety (U) is a VHL E3 ubiquitin ligase binding moiety of formula (U3): wherein: V is S or O; W is N or CH; RU10is H or C1-4alkyl; RU11is H or C1-4alkyl; RU8is selected from C1-4alkyl, phenyl and a 3- to 8-membered cycloalkyl ring; and RU9is a single bond to LINK. Typically, in formula (U3), V is S. Typically, in formula (U3), W is N or CH. Preferably, W is N. Typically, in formula (U3), RU10is H or methyl. Preferably, RU10is methyl. Typically, in formula (U3), RU11is H or methyl. Preferably, RU11is H. Typically, in formula (U3), RU8is C1-4alkyl or phenyl. Preferably, RU8is t-butyl or phenyl, more preferably t-butyl. Typically, therefore, in formula (U3), V is S, W is N or CH, RU10is H or methyl, RU11is H or methyl, and RU8is C1-4 alkyl or phenyl. Preferably, V is S, W is N, RU10is methyl, RU11is H, RU8is t-butyl or phenyl, more preferably t-butyl. The moieties U of formulae (U1), (U4) when Q’ is CH and (U5) typically contain at least one chiral centre at the carbon atoms marked with an asterisk as depicted below:

[0009] ; Moiety U may therefore be provided in the form of the R-enantiomer at said carbon atom, in the form of the S-enantiomer at said carbon atom, or in the form of a mixture (for example a 1:1 mixture) of the two enantiomers. A pure enantiomeric form of either the R- or the S-enantiomer may be preferred. In some embodiments, the S-enantiomer at said carbon atom is preferred. In other embodiments, the R-enantiomer at said carbon atom is preferred. The substance or agent described herein may contain at least 50%, preferably at least 60, 75%, 90% or 95% of a compound which is enantiomerically or diasteriomerically pure at moiety U. Unless otherwise stated, the moiety U may typically be provided in the form of a 1:1 mixture of the two enantiomers. In some embodiments, the S-enantiomer at said carbon atom is preferred. These compounds have been shown to be the more active enantiomer in the literature. The preferred stereochemistry at said carbon atom is also depicted by the following illustrative structure of formula (U1):

[0010] . where LINK is attached to moiety U at the RU5position. In some preferred embodiments, the E3 ubiquitin ligase binding moiety (U) has the following structure: . Linkers As discussed herein, in the compounds of the invention, the binder of MLLT1 and / or MLLT3 (M) is covalently attached to an E3 ubiquitin ligase binding moiety (U). This covalent attachment is labelled LINK and may be a direct single bond or a divalent chemical linker group that forms covalent bonds both to the binder of MLLT1 and / or MLLT3 (M), and to the E3 ubiquitin ligase binding moiety (U). Typically, LINK is a divalent chemical linker group that forms covalent bonds both to the binder of MLLT1 and / or MLLT3 (M), and to the E3 ubiquitin ligase binding moiety (U). There is no particular limitation on the nature of LINK in the compounds of the present invention (beyond that the respective active moieties, e.g., U and M, are able to exert their desired function and LINK is capable of covalently attaching them together). Those skilled in the art would recognise that chemical linker groups are routinely used in the construction of bifunctional molecules and would be able routinely to provide appropriate chemical linker groups for attaching particular U and M moieties together. Typically, a chemical linker group for use in the present invention is an organic group. When LINK is a divalent chemical linker group, it may be represented by formula (L): wherein: LINK is attached to M via L1; LINK is attached to U via L3; L1 and L3 are each independently selected from a single bond, -N(R’)-, -C(O)N(R’)-, -O-, - N(R’)C(O)-, -C(O)-, -S(O2)N(R’)-, -N(R’)S(O2)-, -(C1-6alkylene)-, ethynylene, -(C2-6alkenylene)-, -C=C=C-, phenylene, a divalent 3- to 6-membered cycloalkyl ring and a divalent 4- to 7-membered heterocyclyl ring, the phenylene, cycloalkyl and heterocyclyl rings being unsubstituted or substituted by one or two C1-4alkyl; L2 is represented by the formula -(L4)m-; each L4 is independently a unit of formula: each XLis independently selected from a single bond, -N(R’)-, -O-, -C(O)-, -S-, -SO-, -SO2-, - C(R”)=C(R”)- and -C≡C-; each YLis independently selected from a divalent 3- to 6-membered cycloalkyl ring, a divalent 4- to 7-membered heterocyclyl ring, or one of the following structures: , the cycloalkyl and heterocyclyl rings being unsubstituted or substituted by one or two C1-4alkyl; n is selected from 0 to 4; n’ is selected from 0 or 1; n + n’ ≥ 1; m is selected from 1 to 30; each R’ is independently selected from H and C1-4alkyl; and each R” is independently selected from H and halo. When m is not 1 (i.e. when there are two or more L4 groups present), then the XLgroup of any L4 group is not directly bonded to the XLgroup of any other L4 group that is present. When the phenylene, cycloalkyl or heterocyclyl rings referred to herein are substituted, they are prefereably substituted by one methyl group. In a preferred embodiment, L1 and L3 are each independently selected from a single bond, - C(O)N(R’)-, -O-, -N(R’)C(O)-, -C(O)-, -S(O2)N(R’)-, -N(R’)S(O2)-, -(C1-6alkylene)-, ethynylene, -(C2-6alkenylene)-, -C=C=C-, phenylene, a divalent 3- to 6-membered cycloalkyl ring and a divalent 4- to 7-membered heterocyclyl ring, the phenylene, cycloalkyl and heterocyclyl rings being unsubstituted or substituted by one methyl group. Typically, in formula (L), L1 is selected from a single bond, branched or straight-chain -(C1-6alkylene)-, -C(O)N(R’)-, -N(R’)C(O)-, -O-, -S(O2)N(R’)-, -N(R’)S(O2)-, and a divalent 4- to 7- membered heterocyclyl ring which is unsubstituted or substituted by one or two C1-4 alkyl. When present, the divalent 4- to 7-membered heterocyclyl ring of L1 typically contains at least one N atom, for instance one or two N atoms. Preferably, when L1 is a divalent 4- to 7- membered heterocyclyl ring, it is a divalent 5- to 6-membered heterocyclyl ring, more preferably a saturated divalent 5- to 6-membered heterocyclyl ring, for instance a divalent moiety of piperidine or diazinane. Preferably, in formula (L), L1 is selected from a single bond, branched or straight-chain -(C1-6alkylene)-, -C(O)N(H)-, -N(H)C(O)-, and a divalent moiety of piperidine or diazinane which is unsubstituted or substituted by one methyl group. For instance, L1 may be a single bond. Typically, in formula (L), L3 is selected from a single bond, -N(R’)-, -C(O)N(R’)-, -O-, - N(R’)C(O)-, -S(O2)N(R’)-, -N(R’)S(O2)-, ethynylene, -C=C=C-, phenylene and a divalent 4- to 7-membered heterocyclyl ring, the phenylene and heterocyclyl rings being unsubstituted or substituted by one or two C1-4alkyl. When present, the divalent 4- to 7-membered heterocyclyl ring of L3 typically contains at least one N atom, for instance one or two N atoms. Preferably, when L3 is a divalent 4- to 7-membered heterocyclyl ring, it is a divalent 5- to 6-membered heterocyclyl ring, more preferably a saturated divalent 5- to 6-membered heterocyclyl ring, for instance a divalent moiety of piperidine or diazinane, preferably 1,4-diazinane. Preferably, in formula (L), L3 is selected from a single bond, -N(H)-, -C(O)N(H)-, -O-, -N(H)C(O)-, ethynylene, -C=C=C-, phenylene and a divalent moiety of piperidine or diazinane, the phenylene and divalent moiety of piperidine or diazinane being unsubstituted or substituted by one methyl group. Most preferably, L3 is selected from a single bond, ethynylene and a divalent moiety of piperidine or diazinane. L2 is represented by the formula -(L4)m-. In formula (L), each L4 is independently a unit of described above. Typically, each XLis independently selected from a single bond, -O-, -S-, - C(R”)=C(R”)- and -C≡C-, for example a single bond, -O- and -S-. Preferably, each XLis independently selected from a single bond and -O-. Typically, each YLis independently selected from a divalent moiety of piperidine or diazinane, or one of the following structures: the divalent moiety of piperidine or diazinane being unsubstituted or substituted by one methyl group. In formula (L), n is selected from 0 to 4; n’ is selected from 0 or 1; and n + n’ ≥ 1. In one embodiment, each L4 is the same. Alternatively, L2 may comprise two or more blocks, wherein in each block, each L4 is the same. For instance, L2 may be represented by the formula -(L4’)p-(L4’’)q-(L4’’’)r-, wherein L4’, L4’’ and L4’’’ are selected from those moieties described above for L4, and wherein each L4’ is the same, each L4’’ is the same and each L4’’’ is the same. Preferably, L4’, L4’’ and L4’’’ are selected from -CH2-, -CH2CH2O-, -OCH2CH2-, - CH2CH2S- and -SCH2CH2-. More preferably, L4’, L4’’ and L4’’’ are selected from -CH2-, - CH2CH2O- and -OCH2CH2-. p, q and r are integers of from 0 to 30, wherein p+q+r=m. In one embodiment, each L4 unit is the same. For instance, each L4 in formula (L) may be - CH2-, each L4 in formula (L) may be -CH2CH2O-, each L4 in formula (L) may be -OCH2CH2-, each L4 in formula (L) may be -CH2CH2S-, or each L4 in formula (L) may be -SCH2CH2-. More preferably, each L4 in formula (L) is -CH2-, each L4 in formula (L) is -CH2CH2O- or each L4 in formula (L) is -OCH2CH2-. Most preferably, each L4 in formula (L) is -CH2-. Typically, in formula (L), m is selected from 1 to 10. For instance, m may be selected from 1 to 8, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1. Typically, in formula (L), each R’ is independently selected from H and methyl. Preferably, each R’ is H. When L2 comprises one or more divalent 4- to 7-membered heterocyclyl rings, typically L2 comprises only one or two, e.g. one divalent 4- to 7-membered heterocyclyl rings. Typically, therefore, L2 comprises none, one or two divalent 4- to 7-membered heterocyclyl rings, for example none or one divalent 4- to 7-membered heterocyclyl rings. When L2 comprises one or more divalent 4- to 7-membered heterocyclyl rings, then in one embodiment L1 and L3 do not contain a divalent 4- to 7-membered heterocyclyl ring. Typically, therefore, in formula (L): L1 is selected from a single bond, branched or straight-chain -(C1-6alkylene)-, -C(O)N(R’)-, - N(R’)C(O)-, -O-, -S(O2)N(R’)-, -N(R’)S(O2)-, and a divalent 4- to 7-membered heterocyclyl ring which is unsubstituted or substituted by one or two C1-4alkyl, the divalent 4- to 7- membered heterocyclyl ring typically containing at least one N atom, for instance one or two N atoms; L3 is selected from a single bond, -N(R’)-, -C(O)N(R’)-, -O-, -N(R’)C(O)-, -S(O2)N(R’)-, - N(R’)S(O2)-, ethynylene, -C=C=C-, phenylene and a divalent 4- to 7-membered heterocyclyl ring, the phenylene and heterocyclyl rings being unsubstituted or substituted by one or two C1-4alkyl, the divalent 4- to 7-membered heterocyclyl ring typically containing at least one N atom, for instance one or two N atoms;each XLis independently selected from a single bond, -O-, -S-, -C(R”)=C(R”)- and -C≡C-, for example a single bond, -O- and -S-; each YLis independently selected from a divalent moiety of piperidine or diazinane, or one of the following structures: the divalent moiety of piperidine or diazinane being unsubstituted or substituted by one methyl group; n is selected from 0 to 4; n’ is selected from 0 or 1; and n + n’ ≥ 1; m is selected from 1 to 10, preferably from 1 to 4 (for example 1, 2 or 3); each R’ is independently selected from H and methyl; and each R” is independently selected from H, fluro and chloro, for instance H and chloro. Preferably, in formula (L): L1 is selected from a single bond, branched or straight-chain -(C1-6alkylene)-, -C(O)N(H)-, - N(H)C(O)-, and a divalent moiety of piperidine or diazinane which is unsubstituted or substituted by one methyl group; L3 is selected from a single bond, -C(O)N(H)-, -O-, -N(H)C(O)-, ethynylene, -C=C=C-, phenylene and a divalent moiety of piperidine or diazinane, the phenylene and divalent moiety of piperidine or diazinane being unsubstituted or substituted by one methyl group; each XLis independently selected from a single bond and -O-; each YLis independently selected from a divalent moiety of piperidine or diazinane, or one of the following structures: the divalent moiety of piperidine or diazinane being unsubstituted or substituted by one methyl group; n is selected from 0 to 4; n’ is selected from 0 or 1; and n + n’ ≥ 1;m is selected from 1 to 4 (for example 1, 2 or 3); each R’ is H; and each R” is H or chloro, for instance H. In a typical embodiment, L2 is -(C1-10alkylene)- or -(C1-10alkylene)-C(O)-, preferably -(C1-10alkylene)-. In this embodiment, L1 is preferably selected from a single bond, -C(O)N(H)-, - N(H)C(O)-, -O-, and a divalent moiety of piperidine or diazinane. In this embodiment, L3 is preferably selected from a single bond, -C(O)N(H)-, -O-, -N(H)C(O)-, ethynylene and a divalent moiety of piperidine or diazinane. More preferably, L1 and L3 are selected from the following options: -L1 is -C(O)N(H)- or -N(H)C(O)-, and L3 is -C(O)N(H)- or -N(H)C(O)-;- L1 is a divalent moiety of piperidine and L3 is a divalent moiety of diazinane;- L1 is -C(O)N(H)- or -N(H)C(O)-, and L3 is a divalent moiety of diazinane;- L1 is a single bond and L3 is a divalent moiety of diazinane;- L1 is a single bond and L3 is a divalent moiety of piperidine;- L1 is a single bond and L3 is -O-;- L1 is a single bond and L3 is ethynylene;- L1 is a single bond and L3 is a single bond; and- L1 is -C(O)N(H)- or -N(H)C(O)-, and L3 is -O-.In particularly preferred embodiments: -L1 is a divalent moiety of piperidine, L2 is -(C1-10 alkylene)- and L3 is a divalent moietyof diazinane; -L1 is a single bond, L2 is -(C1-10 alkylene)- and L3 is -O-;- L1 is a single bond, L2 is -(C1-10 alkylene)- and L3 is a divalent moiety of piperidine ordiazinane; -L1 is a single bond, L2 is -(C1-10 alkylene)- and L3 is ethynylene;- L1 is a divalent moiety of piperidine, L2 is -(C1-10 alkylene)- and L3 is ethynylene;- L1 is a divalent moiety of diazinane, L2 is -(C1-10 alkylene)- and L3 is ethynylene;- L1 is a divalent moiety of diazinane, L2 is -(C1-10 alkylene)- and L3 is a divalent moietyof piperidine; -L1 is a single bond, L2 is a divalent moiety of piperidine and L3 is phenylene;- L1 is a divalent moiety of piperidine or diazinane, L2 is -(C1-10 alkylene)- and L3 isphenylene; -L1 is -O-, L2 is -(C1-10 alkylene)- and L3 is ethynylene;- L1 is a divalent moiety of piperidine, L2 is -(C1-10 alkylene)-O- and L3 is a divalentmoiety of piperidine. In one preferred embodiment, LINK has the following structure: wherein T is -O- or –(CH2)-, and t is selected from 1 to 10, preferably 1 to 5, more preferably 2. In another preferred embodiment, L1 is a single bond, L2 is -(C1-10alkylene)- and L3 is ethynylene or a divalent moiety of piperidine (for instance ethynylene), preferably wherein L2 is -(C3-8alkylene)-, more preferably wherein L2 is -(C7alkylene)-. Alternatively, when LINK is a divalent chemical linker group, it may be represented by formula (L’): wherein: LINK is attached to M via L1; LINK is attached to U via L3; L1 and L3 are each independently selected from a single bond, -N(R’)-, -C(O)N(R’)-, -O-, - N(R’)C(O)-, -C(O)-, -S(O2)N(R’)-, -N(R’)S(O2)-, -(C1-6alkylene)-, ethynyl, -(C2-6alkenylene)-, a divalent 3- to 6-membered cycloalkyl ring and a divalent 4- to 7-membered heterocyclyl ring; L2 is represented by the formula -(L4)m-; each L4 is independently selected from a divalent 3- to 6-membered cycloalkyl ring, a divalent each XLis independently selected from a single bond, -N(R’)-, -O-, -C(O)-, -S-, -SO-, -SO2-, - C(H)=C(H)- and -C(H)≡C(H)-; n is selected from 1 to 4; m is selected from 1 to 30; and each R’ is independently selected from H and C1-4alkyl. In one embodiment of formula (L’), L1 and L3 are each independently selected from a single bond, -N(R’)-, -C(O)N(R’)-, -O-, -N(R’)C(O)-, -C(O)-, -S(O2)N(R’)-, -N(R’)S(O2)-, -(C1-6alkylene)-, -(C2-6alkenylene)-, ethynyl, a divalent 3- to 6-membered cycloalkyl ring and a divalent 4- to 7-membered heterocyclyl ring; L2 is represented by the formula -(L4)m-; and each L4 is independently selected from a divalent 3- to 6-membered cycloalkyl ring, a divalent When m is not 1 (i.e. when there are two or more L4 groups present), then the XLgroup of any L4 group is not directly bonded to the XLgroup of any other L4 group that is present. Typically, in formula (L’), L1 is selected from a single bond, branched or straight-chain -(C1-6alkylene)-, -C(O)N(R’)-, -N(R’)C(O)-, -O-, -S(O2)N(R’)-, -N(R’)S(O2)-, and a divalent 4- to 7- membered heterocyclyl ring. When present, the divalent 4- to 7-membered heterocyclyl ring of L1 typically contains at least one N atom, for instance one or two N atoms. Preferably, when L1 is a divalent 4- to 7-membered heterocyclyl ring, it is a divalent 5- to 6-membered heterocyclyl ring, more preferably a saturated divalent 5- to 6-membered heterocyclyl ring, for instance a divalent moiety of piperidine or diazinane. Preferably, in formula (L), L1 is selected from a single bond, branched or straight-chain -(C1-6alkylene)-, -C(O)N(H)-, -N(H)C(O)-, and a divalent moiety of piperidine or diazinane. Typically, in formula (L’), L3 is selected from a single bond, -N(R’)-, -C(O)N(R’)-, -O-, - N(R’)C(O)-, -S(O2)N(R’)-, -N(R’)S(O2)-, ethynyl and a divalent 4- to 7-membered heterocyclyl ring. When present, the divalent 4- to 7-membered heterocyclyl ring of L3 typically contains at least one N atom, for instance one or two N atoms. Preferably, when L3 is a divalent 4- to 7- membered heterocyclyl ring, it is a divalent 5- to 6-membered heterocyclyl ring, more preferably a saturated divalent 5- to 6-membered heterocyclyl ring, for instance a divalent moiety of piperidine or diazinane, preferably 1,4-diazinane. Preferably, in formula (L), L3 is selected from a single bond, -N(H)-, -C(O)N(H)-, -O-, -N(H)C(O)-, ethynyl and a divalent moiety of piperidine or diazinane. L2 is represented by the formula -(L4)m-. Typically, in formula (L’), each L4 is independently selected from a divalent 4- to 7-membered heterocyclyl ring and a unit of formula described above. Typically, each XLis independently selected from a single bond, -O-, -S-, -C(H)=C(H)- and -C(H)≡C(H)-, for example a single bond, -O- and -S-, and n is selected from 1 or 2. In one embodiment, each L4 is the same. Alternatively, L2 may comprise two or more blocks, wherein in each block, each L4 is the same. For instance, L2 may be represented by the formula -(L4’)p-(L4’’)q- (L4’’’)r-, wherein L4’, L4’’ and L4’’’ are selected from those moieties described above for L4, and wherein each L4’ is the same, each L4’’ is the same and each L4’’’ is the same. Preferably, L4’, L4’’ and L4’’’ are selected from -CH2-, -CH2CH2O-, -OCH2CH2-, -CH2CH2S- and - SCH2CH2-. More preferably, L4’, L4’’ and L4’’’ are selected from -CH2-, -CH2CH2O- and - OCH2CH2-. p, q and r are integers of from 0 to 30, wherein p+q+r=m. In one embodiment of formula (L’), each L4 unit is the same. For instance, each L4 in formula (L’) may be -CH2-, each L4 in formula (L’) may be -CH2CH2O-, each L4 in formula (L’) may be -OCH2CH2-, each L4 in formula (L’) may be -CH2CH2S-, or each L4 in formula (L’) may be -SCH2CH2-. More preferably, each L4 in formula (L’) is -CH2-, each L4 in formula (L’) is - CH2CH2O- or each L4 in formula (L’) is -OCH2CH2-. Most preferably, each L4 in formula (L’) is -CH2-. Typically, in formula (L’), m is selected from 1 to 10. Typically, in formula (L’), each R’ is independently selected from H and methyl. Preferably, each R’ is H. When one or more L4 is a divalent 4- to 7-membered heterocyclyl ring, typically only one or two, e.g. one L4 is a divalent 4- to 7-membered heterocyclyl ring. Typically, therefore, none, one or two L4 is a divalent 4- to 7-membered heterocyclyl ring, for example none or one L4 is a divalent 4- to 7-membered heterocyclyl ring. Typically, therefore, in formula (L’): L1 is selected from a single bond, branched or straight-chain -(C1-6alkylene)-, -C(O)N(R’)-, - N(R’)C(O)-, -O-, -S(O2)N(R’)-, -N(R’)S(O2)-, and a divalent 4- to 7-membered heterocyclyl ring typically containing at least one N atom, for instance one or two N atoms; L3 is selected from a single bond, -N(R’)-, -C(O)N(R’)-, -O-, -N(R’)C(O)-, - S(O2)N(R’)-, -N(R’)S(O2)-, ethynyl and a divalent 4- to 7-membered heterocyclyl ring typically containing at least one N atom, for instance one or two N atoms; each L4 is independently selected from -CH2-, -CH2CH2O-, -OCH2CH2-, -CH2CH2S-, - SCH2CH2-, and a divalent 4- to 7-membered heterocyclyl ring, wherein when one or more L4 is a divalent 4- to 7-membered heterocyclyl ring, only one or two, e.g. one L4 is a divalent 4- to 7- membered heterocyclyl ring; m is selected from 1 to 10; and each R’ is independently selected from H and methyl. Preferably, in formula (L’): L1 is selected from a single bond, branched or straight-chain -(C1-6alkylene)-, -C(O)N(H)-, - N(H)C(O)-, and a divalent moiety of piperidine or diazinane; L3 is selected from a single bond, -N(H)-, -C(O)N(H)-, -O-, -N(H)C(O)-, ethynyl and a divalent moiety of piperidine or diazinane; each L4 in formula (L) is -CH2-, each L4 in formula (L) is -CH2CH2O-, each L4 in formula (L) is -OCH2CH2-, each L4 in formula (L) is -CH2CH2S-, or each L4 in formula (L) is -SCH2CH2-, with each L4 preferably being -CH2-; m is selected from 1 to 10; and each R’ is H. In a typical embodiment of formula (L’), L2 is -(C1-10alkylene)- or -(C1-10alkylene)-C(O)-, preferably -(C1-10alkylene)-. In this embodiment, L1 is preferably selected from a single bond, - C(O)N(H)-, -N(H)C(O)-, and a divalent moiety of piperidine or diazinane. In this embodiment, L3 is preferably selected from a single bond, -N(H)-, -C(O)N(H)-, -O-, -N(H)C(O)-, ethynyl and a divalent moiety of piperidine or diazinane. More preferably, L1 and L3 are selected from the following options: -L1 is a single bond and L3 is -N(H)-;- L1 is a divalent moiety of piperidine and L3 is -N(H)-;- L1 is -C(O)N(H)- or -N(H)C(O)-, and L3 is -C(O)N(H)- or -N(H)C(O)-;- L1 is a divalent moiety of piperidine and L3 is a divalent moiety of diazinane;- L1 is -C(O)N(H)- or -N(H)C(O)-, and L3 is a divalent moiety of diazinane;- L1 is a single bond and L3 is a divalent moiety of diazinane;- L1 is a single bond and L3 is a divalent moiety of piperidine;- L1 is a single bond and L3 is -O-;- L1 is a single bond and L3 is ethynyl;- L1 is a single bond and L3 is a single bond; and- L1 is -C(O)N(H)- or -N(H)C(O)-, and L3 is -O-.For the avoidance of doubt, the skilled person would readily appreciate that each of the definitions of moieties U, M and LINK provided herein may be taken together in any combination to arrive at a definition of the compound of the present invention. As examples that are in no way limiting, definitions of moieties U, M and LINK labelled “typically” may be combined to arrive at a definition of a typical compound of the present invention, and definitions of moieties U, M and LINK labelled “preferably” may be combined to arrive at a definition of a preferred compound of the present invention. However, the skilled person would appreciate that a definition labelled “typically” of one moiety may be combined with a definition labelled “preferably” of another moiety to arrive at a definition of a compound of the present invention. In preferred compounds of the present invention, M is of formula (III): wherein R1, R2, R3a, R3b, R3c, R3d, X, R4, R5, R6and R8are as defined herein. Typically, in such preferred compounds: R1is H or C1-4alkyl which is itself unsubstituted or substituted with C1-4alkoxy; R2is H or methyl; R3aand R3bare independently selected from H, C1-4alkyl, and C1-4alkoxy, or R3aand R3bform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, or R3cand R3dform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, with the proviso that when X is O or -N(Me)-, then neither R3cnor R3dare halo; wherein at least two of R3a, R3b, R3cand R3dare H; X is a bond, -N(Me)-, O or -CH2-; R4is selected from H, halo C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R5and R6are independently selected from H, halo C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R8is phenyl or a 5- to 6-membered heteroaryl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkoxy, R10, -(C1-4alkylene)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two R9; each R9is independently selected from halo and C1-4alkoxy; and R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 6-membered heterocyclyl ring, and a phenyl ring, the group R10being unsubstituted or substituted by one or two substituents independently selected from C1-4alkyl, C1-4alkoxy, and halo; wherein either R8is (i) a bond to LINK, or R8is a group (ii) and M is bonded to LINK via a C or N atom within group R8or ring Hy (as described herein) such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK; and LINK is (a) a single bond, or (b) a chemical linker group represented by formula (L): wherein: LINK is attached to M via L1; LINK is attached to U via L3; L1 and L3 are each independently selected from a single bond, -N(R’)-, -C(O)N(R’)-, -O-, - N(R’)C(O)-, -C(O)-, -S(O2)N(R’)-, -N(R’)S(O2)-, -(C1-6alkylene)-, ethynylene, -(C2-6alkenylene)-, -C=C=C-, phenylene, a divalent 3- to 6-membered cycloalkyl ring and a divalent 4- to 7-membered heterocyclyl ring, the phenylene, cycloalkyl and heterocyclyl rings being unsubstituted or substituted by one or two C1-4alkyl; L2 is represented by the formula -(L4)m-; each L4 is independently a unit of formula: or each XLis independently selected from a single bond, -N(R’)-, -O-, -C(O)-, -S-, -SO-, -SO2-, - C(R”)=C(R”)- and -C≡C-; each YLis independently selected from a divalent 3- to 6-membered cycloalkyl ring, a divalent 4- to 7-membered heterocyclyl ring, or one of the following structures: the cycloalkyl and heterocyclyl rings being unsubstituted or substituted by one or two C1-4alkyl; n is selected from 0 to 4; n’ is selected from 0 or 1; n + n’ ≥ 1; m is selected from 1 to 10, preferably from 1 to 4 (for example 1, 2 or 3); each R’ is independently selected from H and C1-4alkyl; each R” is independently selected from H and halo;U is: (a) a CRBN E3 ubiquitin ligase binding moiety of formula (U1): wherein: RU1is H; Q is selected from -CH(RU6)-, -N(RU6)-, -O-, -C(O)-, -NH-CH(RU6)-, -N=C(RU6)-, or -N=N-; RU6is H or C1-4alkyl; RU2and RU5are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; RU3and RU4are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU2, RU3, RU4and RU5is a single bond to LINK; (b) a CRBN E3 ubiquitin ligase binding moiety of formula (U4): wherein: RU1’is H; Q’ is N and LUis a single bond, or Q’ is CH and LUis selected from a single bond or - C(O)N(H)-, wherein either (i) the C atom of LUis bonded to phenyl, and the N atom of LUis bonded to Q’; or (ii) the C atom of LUis bonded to Q’, and the N atom of LUis bonded to phenyl; RU12, RU13and RU14are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU12, RU13and RU14is a single bond to LINK; RU15and RU16are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN and CF3; (c) a CRBN E3 ubiquitin ligase binding moiety of formula (U5):

[0011] wherein: RU17is H; RU18, RU19, RU20and RU21are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU18, RU19, RU20and RU21is a single bond to LINK; or (d) a VHL E3 ubiquitin ligase binding moiety of formula (U2): wherein: RU7is a group selected from phenyl, a 5- to 6-membered heteroaryl ring, a 5- to 6-membered heterocyclyl ring, and a 5- to 6-membered cycloalkyl ring, the group RU7being unsubstituted or substituted by C1-4alkyl; RU11is H or C1-4alkyl; RU8is selected from C1-4alkyl, phenyl and a 3- to 8-membered cycloalkyl ring; and RU9is a single bond to LINK. Alternatively, in such preferred compounds: R1is H or C1-4alkyl which is itself unsubstituted or substituted with C1-4alkoxy; R2is H or methyl; R3aand R3bare independently selected from H, C1-4alkyl, and C1-4alkoxy, or R3aand R3bform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, or R3cand R3dform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, with the proviso that when X is O or -N(Me)-, then neither R3cnor R3dare halo; wherein at least two of R3a, R3b, R3cand R3dare H; X is a bond, -N(Me)-, O or -CH2-; R4is selected from H, halo C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R5and R6are independently selected from H, halo C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R8is phenyl or a 5- to 6-membered heteroaryl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkoxy, R10, -(C1-4 alkylene)-R10, =O, -CN, and C1-4 alkyl which is itself unsubstituted or substituted by one or two R9; each R9is independently selected from halo and C1-4alkoxy; and R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 6-membered heterocyclyl ring, and a phenyl ring, the group R10being unsubstituted or substituted by one or two substituents independently selected from C1-4alkyl, C1-4alkoxy, and halo; wherein either R8is (i) a bond to LINK, or R8is a group (ii) and M is bonded to LINK via a C or N atom within group R8or ring Hy (as described herein) such that a hydrogen atom on the C or N atom within group R8or ring Hy is replaced with a bond to LINK; and LINK is (a) a single bond, or (b) a chemical linker group represented by formula (L’): wherein: LINK is attached to M via L1; LINK is attached to U via L3; L1 and L3 are each independently selected from a single bond, branched or straight-chain -(C1-6alkylene)-, -N(R’)-, -C(O)N(R’)-, -O-, -N(R’)C(O)-, -C(O)-, -S(O2)N(R’)-, -N(R’)S(O2)-, -(C1-6alkylene)-, ethynyl, -(C2-6alkenylene)-, a divalent 3- to 6-membered cycloalkyl ring and a divalent 4- to 7-membered heterocyclyl ring; L2 is represented by the formula -(L4)m-; each L4 is independently selected from a divalent 3- to 6-membered cycloalkyl ring, a divalent each XLis independently selected from a single bond, -N(R’)-, -O-, -C(O)-, -S-, -SO-, -SO2-, - C(H)=C(H)- and -C(H)≡C(H)-; n is selected from 1 to 4; m is selected from 1 to 30; each R’ is independently selected from H and C1-4alkyl; and U is: (a) a CRBN E3 ubiquitin ligase binding moiety of formula (U1): wherein: RU1is H; Q is selected from -CH(RU6)-, -N(RU6)-, -O-, -C(O)-, -NH-CH(RU6)-, -N=C(RU6)-, or -N=N-; RU6is H or C1-4alkyl; RU2and RU5are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; RU3and RU4are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU2, RU3, RU4and RU5is a single bond to LINK; (b) a CRBN E3 ubiquitin ligase binding moiety of formula (U4): wherein: RU1’is H; Q’ is N and LUis a single bond, or Q’ is CH and LUis selected from a single bond or - C(O)N(H)-, wherein either (i) the C atom of LUis bonded to phenyl, and the N atom of LUis bonded to Q’; or (ii) the C atom of LUis bonded to Q’, and the N atom of LUis bonded to phenyl; RU12, RU13and RU14are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU12, RU13and RU14is a single bond to LINK; RU15and RU16are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN and CF3; (c) a CRBN E3 ubiquitin ligase binding moiety of formula (U5):

[0012] wherein: RU17is H; RU18, RU19, RU20and RU21are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU18, RU19, RU20and RU21is a single bond to LINK; or (d) a VHL E3 ubiquitin ligase binding moiety of formula (U2): wherein: RU7is a group selected from phenyl, a 5- to 6-membered heteroaryl ring, a 5- to 6-membered heterocyclyl ring, and a 5- to 6-membered cycloalkyl ring, the group RU7being unsubstituted or substituted by C1-4alkyl; RU11is H or C1-4alkyl; RU8is selected from C1-4alkyl, phenyl and a 3- to 8-membered cycloalkyl ring; and RU9is a single bond to LINK. In one preferred aspect of these embodiments, M is of formula (IV): wherein R8is as described herein, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from R10, halo and C1-4alkyl; wherein either R8is (i) a bond to LINK, or R8is a group (ii) and M is bonded to LINK via a C or N atom within group R8such that a hydrogen atom on the C or N atom within group R8is replaced with a bond to LINK. In this embodiment, R8is preferably selected from one of the following structures: wherein: represents the point of attachment of R8to the rest of moiety M; represents the point of attachment of R8to LINK or R10; and the group R8is further unsubstituted or substituted by one or two substituents independently selected from R10, fluorine and methyl. For example, the group R8may be selected from one of the following structures: wherein: represents the point of attachment of R8to the rest of moiety M; and represents the point of attachment of R8to LINK. Alternatively, the group R8may be unsubstituted phenylene, for instance as depicted by structure A above. In this embodiment, L2 is preferably selected from -(CH2)m-, -(CH2CH2O)m-, -(OCH2CH2)m-, - (CH2CH2S)m-, -(SCH2CH2)m-, and a divalent 4- to 7-membered heterocyclyl ring, preferably from -(CH2)mand a divalent 4- to 7-membered heterocyclyl ring. In this embodiment, preferably L1 and L3 are each independently selected from a single bond, branched or straight-chain -(C1-6alkylene)-, -N(R’)-, -C(O)N(R’)-, -N(R’)C(O)-, -O-, ethynyl and a divalent 4- to 7-membered heterocyclyl ring, preferably L1 and L3 are each independently selected from a single bond, branched or straight-chain -(C1-6 alkylene)-, -N(R’)-, -C(O)N(R’)-, -N(R’)C(O)-, ethynyl, piperidinyl and diazinanyl. Preferably in this embodiment, R’ is H and the divalent 4- to 7-membered heterocyclyl ring is piperidine or diazinane. More preferably, L1 is a single bond, L2 is -(C1-10alkylene)- and L3 is ethynylene or a divalent moiety of piperidine (for instance ethynylene), preferably wherein L2 is -(C3-8alkylene)-, more preferably wherein L2 is -(C7alkylene)- or -(C3alkylene)-. In this embodiment, U is preferably (i) of formula (U1) wherein preferably Q is selected from - CH2- and -C(O)-, RU6is H, one of RU2, RU3, RU4and RU5is a single bond to LINK, and the rest are H, for instance wherein RU2and RU3are H, one of RU4and RU5is a single bond to LINK, and the other of RU4and RU5is H, or (ii) of formula (U3) wherein preferably V is S, W is N, RU10is methyl, RU11is H, and RU8is t-butyl or phenyl, more preferably t-butyl. Most preferably, in formula (U1): Q is -CH2-; RU6is H; and RU2, RU3and RU4are H, and RU5is a single bond to LINK. Particularly preferred compounds of the invention may be selected from: 4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)but-3-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3, 2-c]pyridin-6-yl)piperidine-1-carboxamide; 6-((3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)methyl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)ethyl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)methyl)piperazin- 1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)piperazin-1-yl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; N-((S)-2,6-dioxopiperidin-3-yl)-6-(6-(4-((2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)carbamoyl)phenyl)hex-1-yn-1-yl)picolinamide; 4-(6-(2-(2, 6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; (R)-4-(6-(6-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)pyridin-2-yl)hex-5-yn-1-yl)-N-(2-(1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(6-(2-(2, 6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl) hex-5-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c] pyridin-6-yl) nicotinamide; N-((S)-2,6-dioxopiperidin-3-yl)-5-(5-(4-((2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)carbamoyl)phenyl)pent-1-yn-1-yl)picolinamide; 6-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c] pyridin-6-yl)-9-(2-(2, 6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl) non-8-ynamide; 3-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)piperidin-1-yl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)ethynyl)piperidin-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4- yl)methoxy)piperidin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)nicotinamide; 4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)but-3-yn-1-yl)oxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(1-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-1H-pyrazol-3-yl)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(1-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-1H-pyrazol-4-yl)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(1-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)pent-4-yn-1-yl)-1H-pyrazol-4-yl)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 3-chloro-4-((3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(((2S)-4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)but-3-yn-2-yl)oxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(((2R)-4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)but-3-yn-2-yl)oxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 3-((9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)non-8-yn-1-yl)oxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 7-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]amino}-N-{2-[(2R)-1-methylpyrrolidin- 2-yl]-1H-pyrrolo[3,2-c] pyridin-6-yl}heptanamide; 7-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]amino}-N-{2-[(2S)-1-methylpyrrolidin- 2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}heptanamide; 7-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}-N-{2-[(2R)-1-methylpyrrolidin- 2-yl]-1H-pyrrolo[3,2-c] pyridin-6-yl}heptanamide; 9-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}-N-{2-[(2R)-1-methylpyrrolidin- 2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}nonanamide; 12-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}-N-{2-[(2R)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}dodecanamide; 12-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}-N-{2-[(2S)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}dodecanamide; N-{3-chloro-2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}-7-{[2-(2,6- dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}heptanamide; ^4-[1-(3-{1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]piperidin-4-yl}propyl)pyrazol- 4-yl]-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}benzamide; 4-[1-(3-{1-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]piperidin-4-yl}propyl)pyrazol- 4-yl]-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}benzamide; 4-(3-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}propyl)-N-{2-[(2R)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}benzamide; 4-(3-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}propyl)-N-{2-[(2S)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}benzamide; 1-(3-{1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]piperidin-4-yl}propyl)-N-{2-[(2R)- 1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}pyrazole-4-carboxamide; 2-(((1r,4R)-4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)cyclohexyl)oxy)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)acetamide; 2-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butoxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)acetamide; 4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)butanamide; 5-(1-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)pentanamide; 6-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)hexanamide; 4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-3-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)butanamide; 3-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 3-(((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)methyl)amino)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 3-(1-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)propyl)-1H- pyrazol-4-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)azetidin-3-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)butanamide; 5-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)but-3-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)picolinamide; 5-[3-[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-4-yl]prop-2-ynoxy]-N-[2-(1-methylpyrrolidin- 2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl]pyridine-2-carboxamide; 4-((3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)but-3-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)but-3- yn-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-(2-(2, 6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl) but-3-yn-1-yl)-2-fluoro-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c] pyridin-6-yl) benzamide; 4-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-((5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)oxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-((3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)-2-fluoro-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 3-((3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(1-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-1H-pyrazol-4-yl)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; N-((S)-2,6-dioxopiperidin-3-yl)-6-(4-(3-(4-(4-((2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)carbamoyl)phenyl)-1H-pyrazol-1-yl)propyl)piperidin-1-yl)picolinamide; N-((S)-2,6-dioxopiperidin-3-yl)-6-(4-(2-(4-(4-((2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)carbamoyl)phenyl)-1H-pyrazol-1-yl)ethoxy)piperidin-1-yl)picolinamide; N-((S)-2,6-dioxopiperidin-3-yl)-6-(5-(4-(4-((2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)carbamoyl)phenyl)-1H-pyrazol-1-yl)pent-1-yn-1-yl) picolinamide; (R)-4-(5-(6-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)pyridin-2-yl)pent-4-yn-1-yl)-N-(2-(1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazin-1-yl)piperidin-1-yl)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 2-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)ethynyl)piperidin-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)pyrimidine-5-carboxamide; 4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)prop- 2-yn-1-yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)phenyl)piperidin-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 7-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}-N-{2-[(2R)-1-methylpyrrolidin- 2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}heptanamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-(11-{[4-({2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2- c]pyridin-6-yl}carbamoyl)phenyl]formamido}undecanamido)butanoyl]-4-hydroxy-N-{[4-(4- methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-(11-{[4-({2-[(2S)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2- c]pyridin-6-yl}carbamoyl)phenyl]formamido}undecanamido)butanoyl]-4-hydroxy-N-{[4-(4- methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-6-(6-(2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)nicotinamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-6-(4-(3-(2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)piperazin-1-yl)nicotinamide; 6-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)piperidin-1-yl)-N-(2- ((R)-1-ethylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-N-(2-((R)-1- ethylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(1'-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-[4,4'-bipiperidin]-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)propyl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(3-(1-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)propyl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(3-(1-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)propyl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(1-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(1-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) piperidin-4-yl) ethoxy)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c] pyridin-6-yl)benzamide; 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)ethoxy)-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-3,5-difluoro-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl benzamide; 4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)benzyl)oxy)piperidin-1-yl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-N-(2-((rel-R)-5-methyl- 5-azaspiro[2.4]heptan-6-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)but-3-yn-1-yl) (methyl)amino)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)acetyl) piperazin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide ; 2-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)piperazin-1-yl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)pyrimidine-5-carboxamide; 4-(5-(2-(2,6-dioxopiperidin-3-yl)-7-fluoro-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperazin-1-yl)methyl)piperidin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-3-fluoro-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-2-fluoro-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 3-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 3-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; N-((S)-2,6-dioxopiperidin-3-yl)-6-(5-(4-((2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)carbamoyl)phenyl)pent-1-yn-1-yl)picolinamide; 4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)benzyl)piperazin-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-3-methylphenyl)piperidin-1-yl)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-4-(5-(2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)benzamide; 4-(5-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(5-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(5-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(6-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(6-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(5-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(1-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)acetyl)piperidin-4- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)acetyl)piperazin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)benzyl)oxy)piperidin-1-yl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-(5-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-N-(2-((R)-1-(methyl- d3)pyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-2-fluoro-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c]pyridin-6-yl)benzamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-4-(6-(2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-2-fluorobenzamide; 4-(6-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)hex-5-yn-1-yl)-2-fluoro-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-2-methoxy-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)piperazin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-((1-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4- yl)methyl)piperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 4-(4-((1-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4- yl)methyl)piperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 6-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)piperidin-4- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)piperazin-1- yl)-2-fluoro-6-methoxy-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 4-((1-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)piperidin-4- yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-((1-((1-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4- yl)methyl)piperidin-4-yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 4-((1-((1-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4- yl)methyl)piperidin-4-yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 4-((1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperidin- 4-yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-((1-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)piperidin-4- yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)piperazin-1- yl)-2-methoxy-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-((2S)-4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)-2- methylpiperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)nicotinamide; 4-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)propyl)-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)benzyl)piperazin-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazin-1-yl)propyl)-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperazin-1-yl)propyl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-((2S)-4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)-2- methylpiperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 4-((2R)-4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)-2- methylpiperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 4-((R)-4-((1-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)-2- methylpiperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 4-((R)-4-((1-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)-2- methylpiperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)oxy)piperidin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)oxy)piperidin-1-yl)- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperazin-1-yl)ethyl)piperidin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-4-yl)oxy)piperidin-1-yl)- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(4-(((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4- yl)oxy)methyl)piperidin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)nicotinamide; 4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-1-yl)ethoxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperazin-1-yl)ethoxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-((1-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-4-yl)methyl)piperidin-4- yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-((1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)methyl)piperidin- 4-yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)oxy)piperidin-1-yl)- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methoxy)piperidin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methoxy)piperidin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-[4-[[1-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]-4-piperidyl]oxy]-1-piperidyl]-N- [2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl]pyridine-3-carboxamide; 6-(4-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)piperazin-1-yl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-((5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)oxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4- yl)methoxy)piperidin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 6-(1'-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-[4,4'-bipiperidin]-1-yl)-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)piperidin-1-yl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)pyridazine-3-carboxamide; 5-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)piperidin-1-yl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)pyrazine-2-carboxamide; 4-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)piperazin-1-yl)-2- fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-3,5-difluoro-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-((1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)azetidin- 3-yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methoxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-4-(2-(1-(2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)benzamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-4-(2-(1-(2-((rel-S)- 2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)benzamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-4-(2-(1-(2-((rel-R)- 2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)benzamide; 6-((2R)-4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)-2- methylpiperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)nicotinamide; 4-(2-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-3,9-diazaspiro[5.5]undecan-3- yl)ethoxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-3,9-diazaspiro[5.5]undecan-3- yl)ethoxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-3,9-diazaspiro[5.5]undecan-3- yl)ethoxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)piperidin-4- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)piperazin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-(4-((1-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5- yl)piperidin-4-yl)methyl)piperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)benzamide; 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-2-fluoro-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(1-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-2- fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(1-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-2- fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)propyl)-2-fluoro-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(3-(1-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)propyl)-2- fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(3-(1-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)propyl)-2- fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethyl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)phenyl)piperidin-1-yl)-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidin-4- yl)methyl)piperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; N-((S)-2,6-dioxopiperidin-3-yl)-5-(4-((4-(4-((2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)carbamoyl)phenyl)piperazin-1-yl)methyl)piperidin-1-yl)picolinamide; N-((S)-2,6-dioxopiperidin-3-yl)-6-(4-((4-(4-((2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)carbamoyl)phenyl)piperazin-1-yl)methyl)piperidin-1-yl)picolinamide; 4-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)azetidin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-((1-((1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidin-4- yl)methyl)piperidin-4-yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 6-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)ethynyl)piperidin-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)pyridazine-3-carboxamide; 5-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)ethynyl)piperidin-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)pyrazine-2-carboxamide; 6-((3S)-3-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)pyrrolidin-1-yl)- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(4-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)piperidin-1-yl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-(4-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4- yl)propanoyl)piperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-4-(2-(1-(2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-2-fluorobenzamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-6-(4-((1-(2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methoxy)piperidin-1-yl)nicotinamide; 3-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-4-yl)methyl)piperazin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethyl)piperazin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-((4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)piperazin-1- yl)methyl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-((3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)propa-1,2-dien-1-yl)oxy)piperidin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-3-methylphenoxy)piperidin-1-yl)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 5-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)picolinamide; 4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-1-yl)propyl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)phenyl)propyl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-((7-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-7-azaspiro[3.5]nonan-2-yl)oxy)-2- fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-((7-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-7-azaspiro[3.5]nonan-2-yl)methoxy)-2- fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-3,9-diazaspiro[5.5]undecan-3-yl)-2- fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-3-methylphenoxy)piperidin-1-yl)-2- fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-2-methyl-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 2-chloro-4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-3-fluoro-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)phenethoxy)-2-fluoro-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-3-methylphenethoxy)-2-fluoro-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)propoxy)-2-fluoro-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(1-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)propyl)-1H- pyrazol-4-yl)-2-fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 5-(1-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)propyl)-1H- pyrazol-4-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)picolinamide; 4-(1-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)propyl)-1H-pyrazol- 4-yl)-2-fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-((5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)oxy)-2-fluoro-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methoxy)-2-fluoro-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; N-((S)-2,6-dioxopiperidin-3-yl)-2-fluoro-4-(4-(2-(3-fluoro-4-((2-((R)-1-methylpyrrolidin-2-yl)- 1H-pyrrolo[3,2-c]pyridin-6-yl)carbamoyl)phenoxy)ethyl)piperidin-1-yl)benzamide; 5-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)picolinamide; 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-2-fluoro- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)phenyl)piperidin-1-yl)-2-fluoro-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; N-((S)-2,6-dioxopiperidin-3-yl)-2-fluoro-3-(5-(4-((2-((R)-1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl)carbamoyl)phenyl)pent-1-yn-1-yl)benzamide; 3-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperazin- 1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperazin- 1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-4-yl)methyl)piperazin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)hex-5-yn-1-yl)-2-fluoro-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)prop-2-yn-1-yl)piperidin-1-yl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-(5-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c] pyridin-6-yl)benzamide; 6-((3R)-3-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)pyrrolidin-1-yl)- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-((1-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)ethyl)azetidin- 3-yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-4-yl)methoxy)piperidin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-4-(2-(1-(2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-3-fluorobenzamide; 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-2,5-difluoro- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-2,3-difluoro- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(3-(1-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)propyl)-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; and N-[3-chloro-2-[(R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl]-4-[3-[1-[2-[(rel-S)- 2,6-dioxo-3-piperidyl]-1-oxo-isoindolin-4-yl]-4-piperidyl]propyl]benzamide; and the pharmaceutically acceptable salts thereof. Therapeutic Efficacy The compounds of the present invention are therapeutically useful. The present invention therefore provides compounds as described herein, for use in medicine. The present invention provides compounds as described herein, for use in treating the human or animal body. For the avoidance of doubt, the agent may comprise a compound of the invention in the form of a solvate. Also provided is a pharmaceutical composition comprising a compound of the invention together with a pharmaceutically acceptable carrier or diluent. Typically, the composition contains up to 85 wt% of a compound of the invention. More typically, it contains up to 50 wt% of a compound of the invention. Preferred pharmaceutical compositions are sterile and pyrogen free. Further, when the pharmaceutical compositions provided by the invention contain a compound of the invention which is optically active, the compound of the invention is typically a substantially pure optical isomer. The composition of the invention may be provided as a kit comprising instructions to enable the kit to be used in the methods described herein or details regarding which subjects the method may be used for. As explained above, the compounds of the invention are useful in treating or preventing various disorders. Disorders for treatment using the compounds of the invention may include cancer. In particular, the compounds of the invention are useful for inducing selective degradation of MLLT1 and / or MLLT3, and / or inhibiting MLLT1 and / or MLLT3. Cancer, e.g. acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, aids-related lymphoma, primary CNS lymphoma, anal cancer, astrocytomas, brain cancer, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer (e.g. ewing sarcoma, osteosarcoma and malignant fibrous histiocytoma), breast cancer, bronchial tumors, medulloblastoma and other CNS embryonal tumors, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative neoplasms, colorectal cancer, craniopharyngioma, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, ewing sarcoma, extragonadal germ cell tumor, intraocular melanoma, retinoblastoma, fallopian tube cancer, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumors (gist), germ cell tumors, extragonadal germ cell tumors, ovarian germ cell tumors, testicular cancer, gestational trophoblastic disease, hairy cell leukemia, hepatocellular cancer, histiocytosis, langerhans cell, hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumors, pancreatic neuroendocrine tumors, kaposi sarcoma, kidney (renal cell) cancer, langerhans cell histiocytosis, laryngeal cancer, leukemia, liver cancer, lung cancer (non-small cell, small cell, pleuropulmonary blastoma, and tracheobronchial tumor), lymphoma, malignant fibrous histiocytoma of bone and osteosarcoma, merkel cell carcinoma, mesothelioma, mouth cancer, multiple endocrine neoplasia syndromes, multiple myeloma / plasma cell neoplasms, mycosis fungoides, myelodysplastic syndromes, myelodysplastic / myeloproliferative neoplasms, myelogenous leukemia, neuroblastoma, non-hodgkin lymphoma, oropharyngeal cancer, osteosarcoma and undifferentiated pleomorphic sarcoma, pancreatic cancer, pancreatic neuroendocrine tumors (islet cell tumors), papillomatosis, paraganglioma, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pituitary tumor, prostate cancer, rectal cancer, retinoblastoma, rhabdomyosarcoma, t-cell lymphoma, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, tracheobronchial tumors and the like is particularly suitable to being treated with the compounds of the invention provided herein. Typically, the compounds of the invention are for use in treating cancers which are transcriptionally addicted cancers, such as breast cancer, acute leukemia, chronic leukemia, prostate cancer, bladder cancer, cholangiocarcinoma, colon adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, kidney chromophobe, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, pheochromocytoma and paraganglioma, rectum adenocarcinoma, stomach adenocarcinoma, uterine corpus endometrial carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, lung squamous cell carcinoma and sarcoma (Cell Rep, 2021, 16, 1087). Preferably, the compounds of the invention are for use in treating acute myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL), such as mixed-lineage leukaemia (MLL) rearranged acute leukemia (AML and ALL), NPM1 mutant acute leukemia, RUNX1-fusion acute leukemia, E2A-fusion acute leukemia, PML-fusion acute leukemia or NUP98-fusion acute leukemia. The compounds of the invention may be used as standalone therapeutic agents. Alternatively, they may be used in combination with other active agents such as chemotherapeutic agents, targeted precision medicines or immune oncology agents. For example, they may be used in combination with a menin inhibitor (for example revumenib, ziftomenib, bleximenib), Bcl2 targeted drug (for instance venetoclax), FLT3 inhibitor (for instance sorafenib, quizartinib or gilteritinib), IDH inhibitor (for instance enasideniob), EGFR inhibitor (for instance erlotinib, gefitinib, lapatinib or osimertinib), CDK4 / 6 inhibitor (for instance abemaciclib, palbociclib or ribociclib), a chemotherapy (for instance cytarabine, daunorubicin, azacitidine, cedazuridine, all trans retinoic acid, doxorubicin, gemcitabine, cisplatin or paclitaxel) or an immune checkpoint inhibitor (for instance pembrolizumab, nivolumab, durvalumab or cemiplimab). When used to treat a cancer, the compounds of the invention may be used in alleviating, ameliorating or preventing aggravation of the symptoms of the cancer. Typically, treating a cancer may comprise reducing progression of the cancer, e.g. increasing progression free survival (PFS) and / or increasing survival e.g. increasing overall survival (OS). Treating a cancer may comprise preventing or inhibiting growth of a tumour associated with the cancer. Treating a cancer may comprise preventing metastasis of the cancer. Preferably, treating a cancer may comprise reducing the size of a tumour associated with the cancer. As such, the treatment may cause tumour regression in the cancer. Treating a cancer may comprise reducing the number of tumours or lesions present in the patient. When the treatment reduces the size of a tumour associated with the cancer, the size of the tumour is typically reduced from base line by at least 10%. Base line is the size of the tumour at the date treatment with the compound is first started. The size of the tumour is typically as measured in accordance with version 1.1 of the RECIST criteria (for instance as described in Eisenhauer et al, European Journal of Cancer 45 (2009) 228-247). The response to the treatment with the compound may be complete response, partial response or stable disease, in accordance with version 1.1 of the RECIST criteria. Preferably, the response is partial response or complete response. The treatment may achieve progression free survival for at least 60 days, at least 120 days or at least 180 days. The reduction in tumour size may be greater 20%, greater than 30% or greater than 50% reduction relative to base line. The reduction in tumour size may be observed after 30 days of treatment or after 60 days of treatment. In haematological cancers, treating a cancer preferentially may lead to complete remission (CR) of the cancer or it may lead to complete remission with incomplete haematological recovery (CRh) or complete remission but with incomplete platelet recovery (CRp). Additionally, treatment may lead to an increase in duration of remission (DoR), an increase in minimal residual disease (MRD), or an increase in relapse free survival (RFS) (Blood 20071091815 and Leukemia Res 2018, 68, 32). As explained here, the compounds of the invention are useful in treating or preventing various disorders. The present invention therefore provides a compound of the invention for use in medicine. The invention also provides the use of a compound of the invention in the manufacture of a medicament. The invention also provides compositions and products comprising the compounds of the invention. Such compositions and products are also useful in treating or preventing disorders. The present invention therefore provides a composition or product as defined herein for use in medicine. The invention also provides the use of a composition or product of the invention in the manufacture of a medicament. Also provided is a method of treating a subject in need of such treatment, said method comprising administering to the subject a compound of the invention. In some embodiments the subject suffers from or is at risk of suffering from one of the disorders disclosed herein. In one aspect, the subject is a mammal, in particular a human. However, it may be non-human. Preferred non-human animals include, but are not limited to, primates, such as marmosets or monkeys, commercially farmed animals, such as horses, cows, sheep or pigs, and pets, such as dogs, cats, mice, rats, guinea pigs, ferrets, gerbils or hamsters. The subject can be any animal that is capable of being infected by a bacterium. A subject is typically a human patient. The patient may be male or female. The age of the patient is typically at least 18 years, for instance from 30 to 70 years or from 40 to 60 years. Alternatively, the patient may be a child, for instance the patient may be under 18 years of age, or under 12 years of age. In one embodiment, the patient is a child under ten years of age or an infant under two years of age. In one embodiment the invention provides a compound as defined herein for use in treating cancer in paediatric patients. A compound or composition of the invention can be administered to the subject in order to treat one or more symptoms of the disorder. In this embodiment, the subject is typically symptomatic. A therapeutically effective amount of the agent or formulation is administered to such a subject. A therapeutically effective amount is an amount effective to ameliorate one or more symptoms of the disorder. The compound or composition of the invention may be administered in a variety of dosage forms. Thus, it can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules. The compound or composition of the invention may also be administered parenterally, whether subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques. The compound or composition may also be administered as a suppository. Preferably, the compound, composition or combination may be administered orally. The compound or composition of the invention is typically formulated for administration with a pharmaceutically acceptable carrier or diluent. For example, solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and / or polyethylene glycols; binding agents; e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non toxic and pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tableting, sugar coating, or film coating processes. Liquid dispersions for oral administration may be syrups, emulsions and suspensions. The syrups may contain as carriers, for example, saccharose or saccharose with glycerine and / or mannitol and / or sorbitol. Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspension or solutions for intramuscular injections or inhalation may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride. Solutions for inhalation, injection or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions. Pharmaceutical compositions suitable for delivery by needleless injection, for example, transdermally, may also be used. A therapeutically effective amount of the compound or composition of the invention is administered to a subject. The dose may be determined according to various parameters, especially according to the compound used; the age, weight and condition of the subject to be treated; the route of administration; and the required regimen. Again, a physician will be able to determine the required route of administration and dosage for any particular subject. A typical daily dose is from about 0.01 to 100 mg per kg, preferably from about 0.1 mg / kg to 50 mg / kg, e.g. from about 1 to 10 mg / kg of body weight, according to the activity of the specific compound, the age, weight and conditions of the subject to be treated, the type and severity of the disease and the frequency and route of administration. Preferably, daily dosage levels are from 5 mg to 2 g. When the compound or composition of the invention is administered to a subject in combination with another active agent, the dose of the other active agent can be determined as described above. The dose may be determined according to various parameters, especially according to the agent used; the age, weight and condition of the subject to be treated; the route of administration; and the required regimen. Again, a physician will be able to determine the required route of administration and dosage for any particular subject. A typical daily dose is from about 0.01 to 100 mg per kg, preferably from about 0.1 mg / kg to 50 mg / kg, e.g. from about 1 to 10 mg / kg of body weight, according to the activity of the specific agent, the age, weight and conditions of the subject to be treated, the type and severity of the disease and the frequency and route of administration. Preferably, daily dosage levels are from 5 mg to 2 g. Synthesis Compounds of the invention can be prepared by the synthetic methods described in the Examples that follow, or by analogy with such methods using appropriate starting materials and methodologies familiar to the skilled chemist. The following examples illustrate the invention. They do not however limit the invention in any way. In this regard, it is important to understand that the particular assay used in the Examples section is designed only to provide an indication of biological activity. There are many assays available to determine biological activity, and a negative result in any one particular assay is therefore not determinative. The invention is defined according to the claims. Examples In the examples which follow below, compounds may be produced in racemic form. Compounds in racemic form are indicated by use of the term rac- in advance of the IUPAC name. In some instances, as indicated, enantiomers and / or diastereomers are separated. In general, the enantiomers and / or diastereomers of the invention can be separated using chiral chromatography. The separated enantiomers and / or diastereomers may be identified in the order in which they elute, for example the first, second, third or fourth eluting isomer respectively, as obtained by separation using chiral chromatography. The isomers may alternatively or additionally be identified using IUPAC naming conventions. Thus, where enantiomers and / or diastereomers have been assigned an absolute stereochemistry, this is indicated as R or S stereochemistry, as appropriate, and by use of a wedge-shaped bond (e.g. the chemical formula. Where enantiomers have been separated but have undefined absolute stereochemistry the term “rel-R” or “rel-S” has been used. In these examples it is understood that the absolute configuration is unknown and the “rel-R” and “rel-S” labels are used merely to distinguish the two enantiomers form one another. The absolute stereochemistry of an enantiomer labelled as “rel-R” may be either R or S. In either case, the corresponding “rel-S” enantiomer has the opposite configuration to the “rel-R” enantiomer. In these examples the use of a rectangular bond (e.g. ) has been used to define the “rel” configuration. This labelling convention also applies where diastereomers have been separated and the absolute configuration of a first chiral centre is known but the absolute configuration of a second chiral centre is unknown. In these examples, the known absolute configuration of the first chiral centre is indicated as R or S stereochemistry, as appropriate, and by use of a wedge-shaped bond (e.g. ) in the chemical formula, while the unknown absolute configuration of the second chiral centre is indicated as “rel-R” or “rel-S”, and by use of a rectangular bond (e.g. ) in the chemical formula. Alternatively, where diastereomers have been separated and the absolute configuration of both chiral centres is unknown they may be assigned a relative stereochemistry, which denotes the stereochemistry of a first chiral centre with respect to a second chiral centre. Where a relative stereochemistry has been assigned, this is indicated by the term “rel” in the IUPAC name, and by use of a rectangular-shaped bond (e.g. ). Where diastereomers have been separated and the relative and absolute configuration is unknown, the compounds have been labelled by the order in which they elute, for example the first, second, third or fourth eluting isomer respectively, as obtained by separation using chiral chromatography. The moieties U of formulae (U1), (U4) when Q’ is CH and (U5) typically contain at least one chiral centre at the carbon atoms marked with an asterisk as depicted below: . Specifically in relation to the examples that follow, unless otherwise stated, it is understood that the moiety U is typically in the form of a 1:1 mixture of the R- and S-enantiomers at said carbon atom, indicated specifically in the examples that follow by the use of a simple line-shaped bond (e.g. In certain examples, the enantiomers or diastereomers have been separated such that the compounds are in enantiomerically or diastereomerically pure form. In these examples, when the stereochemistry at the chiral carbon atom in moiety U is known, the known absolute configuration is indicated as R or S stereochemistry, as appropriate, and by use of a wedge- shaped bond (e.g. ). When the stereochemistry at the chiral carbon atom in moiety U is unknown, the unknown absolute configuration is indicated as “rel-R” or “rel-S”, and by use of a rectangular bond (e.g. ). Temperatures are given in degrees Celsius (°C). The reactants used in the examples below may be obtained from commercial sources or they may be prepared from commercially available starting materials as described herein or by methods known in the art. All the compounds of the invention are synthesized according to the Examples described herein. The progress of the reactions described herein were followed as appropriate by e.g. LC, GC or TLC, and as the skilled person will readily realize, reaction times and temperatures may be adjusted accordingly. NMR spectroscopy: Solids / oils were solubilized in DMSO-d6or MeOH-d4, vortexed vigorously until the solution was clear and transferred to an NMR tube for data acquisition. Liquid-state NMR experiments were recorded using: -600 MHz (14.1 Tesla) Bruker Avance III NMR spectrometer (600 MHz for 1H, 151MHz for13C) using a triple-resonance1H,15N,13C CP-TCI 5 mm cryoprobe (Bruker Biospin, Germany) -500 MHz (11.75 Tesla) Bruker Avance I NMR spectrometer (500 MHz for 1H, 125MHz for13C) using a Dual Resonance BBI 5 mm probe (Bruker Biospin, Germany) -400 MHz (9.4 Tesla) Bruker Avance NEO NMR spectrometer (400 MHz for 1H, 100MHz for13C) using a SEI 5 mm probe (Bruker Biospin, Germany) -400 MHz (9.4 Tesla) Bruker Avance NEO NMR spectrometer using a PI HR-BBO400S1-BBF / H / D-5.0-Z SP probe (Bruker Biospin, Germany) -300 MHz Bruker AVANCE III HD NMR spectrometer using a PA BBO 300S1 BBF-H-D-05 Z probe (Bruker Biospin, Germany) -300 MHz Bruker Avance NEO NMR spectrometer using a PA BBO BBF-H-D-05 Z(Bruker Biospin, Germany) All the experiments used for the resonance assignment procedure and the elucidation of the products structure (1D1H, 2D1H-1H-COSY, 2D1H-1H-ROESY, 2D1H-13C-HSQC, 2D1H-13C- HMBC) were recorded at 300 K.1H chemical shifts are reported in δ ppm as s (singlet), d (doublet), t (triplet), q (quartet), dd (double doublet), m (multiplet) or br s (broad singlet). UPLC-MS chromatography: UPLC-MS chromatography analysis were recorded using the following apparatus using: -Waters UPLC: Acquity, UV: Acquity PDA, MS: Qda, ELSD- Waters UPLC: Acquity, UV: Acquity TUV, MS: Qda- Waters UPLC: Acquity, UV: Acquity PDA, MS: QdaThe apparatus was tested using a CSH C18 Waters column (50 x 2.1 mm), 1.7 µm. It used a combination of the following eluents: H2O + 0.05% TFA (v / v) (solvent A) and MeCN + 0.035% TFA (v / v) (solvent B) and a positive electrospray ES+ as ionization mode. The UV detection was set at 220 and 254 nm. The methods used were the following: -Polar method (1.7 min run): gradient t=02% B, t=0.5 min 2% B, t=1.5 min 98% B,t=1.52 min 2% B, t=1.7 min 2% B -Polar method (3.5 min run): gradient t=02% B, t=1.0 min 2% B, t=2.4 min 98% B,t=3.00 min 98% B, t=3.03 min 2% B, t=3.5 min 2% B -Normal method (1.7 min run): gradient t=02% B, t=1.0 min 98% B, t=1.5 min 98% B,t=1.52 min 2% B, t=1.7 min 2% B -Normal method (3.5 min run): gradient t=02% B, t=2.4 min 98% B, t=3.0 min 98% B,t=3.03 min 2% B, t=3.5 min 2% B Where it is observed mass spectra analysis is reported as [M+H]+for the molecular ion; Someone skilled in the art will also appreciate that isotope patterns may be reported where evident, for example [M+H+2]+represents the higher mass isotopic peak of Br if it is present in the molecule; Additionally, some fragmentation ions may be included in the analysis, for example [M+H-tBu]+, [M+H-100]+, [M+H-Boc]+and [M-Cl+MeOH]+. Preparative HPLC Where Example purification has been performed by preparative HPLC (chiral or achiral) the conditions are included in the reaction Step where the purification was performed or one of the general Methods below was used: Method A: Gilson system used for preparative HPLC purification purposes. The system is equipped with a 333 pump A and a 334 pump B, Gilson Verity 1741 detector and GX-271 liquid handler fraction collector. The reverse phase purification was carried out by using a preparative column X-BRIDGE C18 (250 x 30 mm), 5 µM. Gradient elution was done using 10 mmol ammonium bicarbonate in water (as Phase A) and 100% Acetonitrile (as Phase B) with a gradient Program (B%): 10% B at 0 min hold until 3 min, 35% B at 10.0 min, 65% B at 35 min, 99% B at 35.1 min hold till 40.0 min, 10% B at 40.1 min hold until 45 min. Flow rate: 25 mL / min. Method B: Gilson system used for preparative HPLC purification purposes. The system is equipped with a 333 pump A and a 334 pump B, Gilson Verity 1741 detector and GX-271 liquid handler Fraction collector. The reverse phase purification is carried out by using preparative column YMC-ACTUS C18 (250*20mm) 5 µM. Gradient elution is done with 0.1% Formic acid in water (as Phase A) and 100% Acetonitrile (Phase B) with a gradient Program (B%): 5% B at 0 min hold till 5min,15%B at 200.0 min, 35% B at 35 min, 99% B at 35.1min hold till 40.0 min, 5% B at 40.1min hold till 45 min. Flow rate: 18 mL / min. Abbreviations: In addition to the definitions above, the following abbreviations are used in the Example experimental procedures below. If an abbreviation used herein is not defined, it has its generally accepted meaning: Ac Acetyl AcOH Acetic acid AIBN 2,2′-Azobis(2-methylpropionitrile) BINAP 2,2′-Bis(diphenylphosphino)-1,1′-binaphthalene Boc tert-butyloxycarbonyl Boc2O Di-tertbutyl decarbonate BrettPhos 2-(Dicyclohexylphosphino)3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′- biphenyl BrettPhos Pd G3 [(2-Di-cyclohexylphosphino-3,6-dimethoxy-2′,4′,6′- triisopropyl-1,1′- biphenyl)-2-(2′-amino-1,1′ -biphenyl)]palladium(II) methanesulfonate methanesulfonate CataCXium A Di(1-adamantyl)-n-butylphosphine CBr4tetrabromomethane Cs2CO3Cesium carbonate CuI Copper (I) iodide CyJohnPhos 2-(Dicyclohexylphosphino)biphenyl DavePhos 2-Dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene DCE 1,2-dichloroethane DCM Dichloromethane DHP 3,4-Dihydro-2H-pyran DIAD Diisopropyl azodicarboxylate DIPEA N,N-Diisopropylethylamine Dioxane 1,4-dioxane DMAP 4-Dimethylaminopyridine DMEDA N,N’-dimethylethylenediamine DMF Dimethylformamide DMP 1,1,1-Tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one (Dess- Martin Periodinane) DMSO Dimethylsulfoxide DMSO-d6Hexadeuterodimethylsulfoxide ee Enantiomeric excess Et Ethyl EtOAc Ethyl acetate Et3N Triethylamine EtOH Ethanol Et2O Diethylether EPhos Pd G4 Methanesulfonato{Dicyclohexyl[3-(1-methylethoxy)-2',4',6'-tris(1- methylethyl)[1,1'-biphenyl]-2-yl]phosphine}(2'-methylamino-1,1'- biphenyl-2-yl)palladium(II) FeCl3Iron(III) chloride GC Gas chromatography GPhos (3-(tert-Butoxy)-2′,6′-diisopropyl-6-methoxy-[1,1′-biphenyl]-2- yl)dicyclohexylphosphane Gphos Pd G6TES GPhos OAc precatalyst TES h hour H2O water HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate HCl Hydrochloric acid Het Heteroaromatic HPLC High performance liquid chromatography K2CO3Potassium carbonate KI Potassium iodide LC Liquid chromatography LDA Lithium diisopropylamide LiBH4Lithium borohydride LiHMDS Lithium bis(trimethylsilyl)amide LiOH Lithium hydroxide min Minutes Me Methyl MeCN Acetonitrile MeOH Methanol MeTHF 2-Methyltetrahydrofuran MgSO4Magnesium sulfate MS Mass spectrometry MsCl Methanesulfonyl chloride MsOH Methanesulfonic acid MTBE Methyl tert-butyl ether MW Microwave N2Nitrogen NaH Sodium hydride NaOCN Sodium cyanate NaOH Sodium hydroxide Na2SO4 Sodium sulfate NaBH3CN Sodium cyanoborohydride NBS N-bromosuccinimide NCS N-chlorosuccinimide NH4Cl Ammonium chloride NIS N-iodosuccinimide NMP N-methyl-2-pyrrolidone Pd / C Palladium on carbon Pd(dppf)Cl2[1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) Pd-PEPPSI-IHept-Cl Palladium) 1,3-bis[2,6-bis(heptan-4-yl)phenyl]-4,5-dichloro-1,2- didehydro-1λ⁵-imidazole 3-chloropyridine dichloride Pd(PPh3)2Cl2Bis(triphenylphosphine)palladium(II) dichloride PE Petroleum ether PPh3Triphenylphosphine PMB-Cl 4-methoxybenzyl chloride rt room temperature (18 to 22 °C) RuPhos 2-Dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl RuPhos Pd G3 (2-Dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl)[2-(2′- amino-1,1′-biphenyl)]palladium(II) methanesulfonate Selectfluor 1-(Chloromethyl)-4-fluoro-1,4-diazabicyclo[2.2.2]octane-1,4-diium ditetrafluoroborate SEM-Cl 2-(Trimethylsilyl)ethoxymethyl chloride TBS-Cl tert-Butyldimethylsilyl chloride tBuOK Potassium tert-butoxide TFA Trifluoroacetic acid TfOH Trifluoromethanesulfonic acid TLC Thin layer chromatography THF Tetrahydrofuran TsCl p-Toluenesulfonyl chloride TsOH p-Toluenesulfonic acid monohydrate UPLC Ultra Performance Liquid Chromatography Xantphos 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene Example 1 was synthesised following Scheme 1 Scheme 1 Step 1 Intermediate 1: tert-butyl 4-(3-oxopropyl)piperidine-1-carboxylate To a solution of tert-butyl 4-(3-hydroxypropyl)piperidine-1-carboxylate (CAS No: 156185-63- 6, 5.00 g, 20.55 mmol) in dichloromethane (100 mL) at 0°C was added Dess-Martin periodinane (13.48 g, 30.83 mmol) and the reaction stirred at room temperature for 6h. The reaction mixture was diluted with a mixture of sodium bicarbonate (200 mL) and sodium thiosulphate (200 mL) and extracted with dichloromethane (3 × 150 mL). The combined organic phases were dried over anhydrous Na2SO4and concentrated in vacuo. The crude material was purified by combi-flash column chromatography by eluting with 20% ethyl acetate in heptane to afford tert-butyl 4-(3-oxopropyl)piperidine-1-carboxylate (Intermediate 1, 3.60 g, 73%) as a yellow liquid.1H NMR (400 MHz, DMSO-d6) δ ppm 0.88-1.00 (m, 2H), 1.38 (s, 9H), 1.41-1.50 (m, 3H), 1.58-1.64 (m, 2H), 2.42-2.47 (m, 2H), 2.60-2.70 (m, 2H), 3.88-3.94 (m, 2H), 9.67 (s, 1H). Mass spec: m / z: Mass spec: m / z: 240.0 [M-H]-. Step 2 Intermediate 2: tert-butyl 4-(but-3-yn-1-yl) piperidine-1-carboxylate To a solution of tert-butyl 4-(3-oxopropyl) piperidine-1-carboxylate (Intermediate 1, 3.60 g, 15 mmol) in methanol (50 mL) was added potassium carbonate (4.10 g, 30 mmol) followed bydimethyl (1-diazo-2-oxopropyl)phosphonate (3.20 g, 16 mmol) and the reaction mixture wasstirred at room temperature for 3h. The reaction mixture was diluted with water (200 mL) and extracted with ethyl acetate (3 × 200 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by combi-flash column chromatography by eluting with 20% ethyl acetate in heptane to afford tert-butyl 4-(but-3-yn-1-yl)piperidine-1-carboxylate (Intermediate 2, 2.70 g, 69%d) as a yellowliquid.1H NMR (400 MHz, DMSO-d6) δ ppm 0.89-1.00 (m, 2H), 1.38 (s, 9H), 1.41-1.55 (m, 3H), 1.58-1.64 (m, 2H), 2.11-2.23 (m, 2H), 2.58-2.71 (m, 2H), 2.73(s, 1H), 3.86-3.94 (m, 2H). Step 3 Intermediate 3: 4-(but-3-yn-1-yl)piperidine hydrochlorideTo a solution of tert-butyl 4-(but-3-yn-1-yl) piperidine-1-carboxylate (Intermediate 2, 2.70 g,11 mmol) in 1, 4-dioxane (30 mL) was added 4M hydrochloric acid in 1,4-dioxane (30 mL) at 0°C and the reaction mixture was stirred at room temperature for 4h. The reaction mixture was concentrated in vacuo to afford 4-(but-3-yn-1-yl)piperidine hydrochloride (Intermediate 3, 1.60 g) as a white solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 1.21-1.35 (m, 2H), 1.38-1.44 (m, 2H), 1.58-1.64 (m, 1H), 1.76- 1.82 (m, 2H), 2.12-2.26 (m, 2H), 2.73-2.88 (m, 3H), 3.17-3.27 (m, 2H), 8.72 (br s, 2H). Step 4 Intermediate 5: tert-butyl (R)-6-amino-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridine-1-carboxylate To a solution of tert-butyl (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine- 1-carboxylate (Intermediate 4, 1.00 g, 2.63 mmol) in tetrahydrofuran (20 mL) was added 2- (dicyclohexylphosphino)biphenyl (CyJohnPhos, 0.19 g, 0.52 mmol) followed by Pd2(dba)3(0.25 g, 0.26 mmol) at room temperature and the reaction mixture was purged with argon for 15 min. LiHMDS (1M in THF, 7.89 mL, 7.89 mmol) was then added and the reaction mixture was further purged with argon for 10 min and then stirred at 100°C for 2h. The reaction mixture was quenched with saturated aqueous NH4Cl solution (50 mL) and extracted with ethyl acetate (2 × 50 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by combi-flash chromatography by eluting with 90% ethyl acetate in heptane to afford tert-butyl (R)-6-amino-2-(1- methylpyrrolidin-2-yl)-1H-pyrrolo[3, 2-c]pyridine-1-carboxylate (Intermediate 5, 0.80 g, 96%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.52-1.58 (m, 1H), 1.63 (s, 9H), 1.68- 1.75 (m, 2H), 2.25-2.28 (m, 1H), 2.31 (s, 3H), 2.34-2.36 (m, 1H), 3.06-3.13 (m, 1H), 3.76-3.82 (m, 1H), 5.69 (br s, 2H), 6.49 (s, 1H), 7.01 (s, 1H), 8.12 (s, 1H). Mass spec: m / z: 317 [M+H]+. Step 5 Intermediate 6: tert-butyl (R)-2-(1-methylpyrrolidin-2-yl)-6-((phenoxycarbonyl) amino)- 1H-pyrrolo[3, 2-c]pyridine-1-carboxylate To a solution of tert-butyl (R)-6-amino-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3, 2-c]pyridine- 1-carboxylate (Intermediate 5, 1.00 g, 3.161 mmol) in acetonitrile (15 mL) was added pyridine (0.52 mL, 6.32 mmol) at room temperature and stirred for 15 min. Phenyl chloroformate (0.54 g, 3.48 mmol) was added and the reaction stirred at room temperature for 16h. The reaction mixture was quenched with ice cold water (50 mL) and extracted with ethyl acetate (2 × 50 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo to afford tert-butyl (R)-2-(1-methylpyrrolidin-2-yl)-6- ((phenoxycarbonyl)amino)-1H-pyrrolo[3, 2-c]pyridine-1-carboxylate (Intermediate 6, 0.65 g, 47%) as a white solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 1.52-1.58 (m, 1H), 1.61 (s, 9H), 1.69-1.79 (m, 2H), 2.25-2.29 (m, 1H), 2.34 (s, 3H), 2.38-2.42 (m, 1H), 3.09-3.14 (m, 1H), 3.86-3.92 (m, 1H), 6.72 (s, 1H), 7.19- 7.30 (m, 3H), 7.40-7.47 (m, 2H), 8.48 (s, 1H), 8.53 (s, 1H), 10.62 (s, 1H). Mass spec: m / z: 437.3 [M+H]+. Step 6 Intermediate 7: tert-butyl (R)-6-(4-(but-3-yn-1-yl)piperidine-1-carboxamido)-2-(1- methylpyrrolidin-2-yl)-1H-pyrrolo[3, 2-c]pyridine-1-carboxylateTo a solution of 4-(but-3-yn-1-yl)piperidine hydrochloride (Intermediate 3, 0.068 g, 0.39mmol) in dichloromethane (2.0 mL) was added tert-butyl (R)-2-(1-methylpyrrolidin-2-yl)-6- ((phenoxycarbonyl)amino)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 6, 0.17 g, 0.38 mmol) followed by triethylamine (0.28 mL, 2.0 mmol) and the reaction mixture was stirred at room temperature for 16h. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by combi-flash column chromatography by eluting with 80% ethyl acetate in heptane to afford tert-butyl (R)-6- (4-(but-3-yn-1-yl) piperidine-1-carboxamido)-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3, 2- c]pyridine-1-carboxylate (Intermediate 7, 0.09g, 48%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 0.98-1.11 (m, 2H), 1.36-1.44 (m, 2H), 1.56-1.60 (m, 2H), 1.65 (s, 9H), 1.68- 1.78 (m, 4H), 2.18-2.22 (m, 2H), 2.27-2.31 (m, 1H), 2.33 (s, 3H), 2.36-2.38 (m, 1H), 2.71-2.80 (m, 3H), 3.10-3.16 (m, 1H), 3.84-3.90 (m, 1H), 4.14-4.18 (m, 2H), 6.66 (s, 1H), 8.42 (s, 1H), 8.50 (s, 1H), 8.90 (s, 1H). Mass spec: m / z: 480.1 [M+H]+. Step 7 Intermediate 9: tert-butyl 6-(4-(4-(2-(2,6-dioxo-1-((2- (trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisoindolin-4-yl)but-3-yn-1- yl)piperidine-1-carboxamido)-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine- 1-carboxylate To a solution of tert-butyl (R)-6-(4-(but-3-yn-1-yl) piperidine-1-carboxamido)-2-(1- methylpyrrolidin-2-yl)-1H-pyrrolo[3, 2-c]pyridine-1-carboxylate (Intermediate 7, 0.33 g, 0.69 mmol) in 1, 4-dioxane (7.0 mL) was added 3-(4-iodo-1-oxoisoindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione (Intermediate 8, 0.34 g, 0.68 mmol)followed by triethylamine (3.50 mL, 25.0 mmol). The reaction mixture was purged with argon for 15 min then PdCl2(PPh3)2(0.05 g, 0.070 mmol) and copper(I) iodide (0.014 g, 0.072 mmol) were added. The reaction mixture was further purged with argon for 10 min and then stirred at room temperature for 2h. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (2 × 100 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by combi-flash column chromatography by eluting with 80% ethyl acetate in heptane to afford tert-butyl 6-(4- (4-(2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisoindolin-4-yl)but- 3-yn-1-yl)piperidine-1-carboxamido)-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridine-1-carboxylate (Intermediate 9, 0.29 g, 49%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm -0.07 (s, 9H), 0.76-0.82 (m, 2H), 1.05-1.10 (m, 3H), 1.46-1.56 (m, 3H), 1.62 (s, 9H), 1.63-1.65 (m, 1H), 1.67-1.78 (m, 4H), 2.00-2.09 (m, 1H), 2.26-2.28 (m, 2H), 2.31 (s, 3H), 2.36-2.38 (m, 1H), 2.69-2.83 (m, 3H), 2.97-3.12 (m, 2H), 3.33-3.40 (m, 1H), 3.46-3.52 (m, 2H), 3.82-3.86 (m, 1H), 4.14-4.18 (m, 2H), 4.23-4.27 (m, 1H), 4.43-4.48 (m, 1H), 4.95-5.08 (m, 2H), 5.23-5.28 (m, 1H), 6.63 (s, 1H), 7.48-7.52 (m, 1H), 7.63 (d, J=7.40 Hz, 1H), 7.69 (d, J=7.40 Hz, 1H), 8.39 (s, 1H), 8.48 (s, 1H), 8.88 (br s, 1H). Mass spec: m / z: 852.0 [M+H]+. Step 8 Example 1: 4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)but-3-yn-1-yl)-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3, 2-c]pyridin-6-yl)piperidine-1-carboxamide To a solution of tert-butyl 6-(4-(4-(2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin- 3-yl)-1-oxoisoindolin-4-yl)but-3-yn-1-yl)piperidine-1-carboxamido)-2-((R)-1-methylpyrrolidin- 2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 9, 0.60 g, 0.70 mmol) in acetonitrile (10 mL) was added methanesulfonic acid (0.47 mL, 7.1 mmol) at room temperature and the reaction mixture was stirred at 50°C for 2h. N,N’-dimethylethylenediamine (0.43 mL, 3.6 mmol) and triethylamine (1.98 mL, 14.1 mmol) were added and the reaction stirred at room temperature for 3h. The reaction mixture was concentrated in vacuo to obtain crude compound. Water (50 mL) was added resulting in a precipitate which was collected by filtration and driedin vacuo. The crude material was purified by preparative HPLC (Method A) to afford 4-(4-(2-(2, 6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl) but-3-yn-1-yl)-N-(2-((R)-1-methylpyrrolidin-2- yl)-1H-pyrrolo [3, 2-c] pyridin-6-yl) piperidine-1-carboxamide (Example 1, 0.15 g, 35%) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.04-1.17 (m, 2H), 1.53-1.58 (m, 2H), 1.60-1.68 (m, 1H), 1.70-1.78 (m, 2H), 1.80-1.95 (m, 2H), 1.99-2.06 (m, 1H), 2.08-2.13 (m, 1H), 2.14 (s, 3H), 2.21-2.28 (m, 1H), 2.40-2.46 (m, 2H), 2.53-2.64 (m, 3H), 2.72-2.80 (m, 2H), 2.87- 2.96 (m, 1H), 3.10-3.16 (m, 1H), 3.24-3.28 (m, 1H), 4.13-4.23 (m, 2H), 4.29-4.36 (m, 1H), 4.44-4.50 (m, 1H), 5.09-5.18 (m, 1H), 6.30 (s, 1H), 7.49-7.55 (m, 1H), 7.63-7.66 (m, 1H), 7.71- 7.46 (m, 1H), 7.74 (s, 1H), 8.35 (s, 1H), 8.60 (s, 1H), 11.05 (s, 1H), 11.13 (s, 1H). Mass spec: m / z: 622.1 [M+H]+. Intermediate 4 was synthesised following Scheme 2

[0013] Scheme 2 Step 1 Intermediate 10: 2-bromo-5-iodopyridin-4-amine To solution of 2-bromopyridin-4-amine (CAS No: 7598-35-8, 200 g, 1156.0 mmol) in acetonitrile (1 L) was added N-iodosuccinimide (297.23 g, 1294.7 mmol) and the reaction mixture was heated at 80°C for 16h. The reaction mixture was then cooled to room temperature and concentrated in vacuo. The obtained residue was diluted with aqueous saturated sodium thiosulphate solution (2 L) and extracted with ethyl acetate (3 × 2 L). The combined organic layers were dried over anhydrous Na2SO4and concentrated in vacuo to obtain the crude compound. The crude material was purified by combi-flash chromatography, by eluting with 5% ethyl acetate in heptane, to afford 2-bromo-5-iodo-pyridin-4-amine (Intermediate 10, 115 g, 33%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 6.48 (br s, 2H), 6.77 (s, 1H), 8.16 (s, 1H). Mass spec: m / z: 300.8 [M+H]+. Step 2 Intermediate 11: N-(2-bromo-5-iodopyridin-4-yl)-N-(methylsulfonyl)methanesulfonamide To a cooled (0°C) solution of 2-bromo-5-iodo-pyridin-4-amine (Intermediate 10, 100 g, 334.55 mmol) in dichloromethane (2.50 g, 29 mmol) was added triethylamine (234 mL, 1673 mmol) followed by methanesulfonyl chloride (106 mL, 1338.2 mmol) in dichloromethane (300 mL). After the addition was complete, the reaction mixture was stirred at room temperature for 3h. The reaction mixture was quenched with aqueous saturated NaHCO3solution (2 L) and extracted with dichloromethane (2 × 2 L). The combined organic layers were dried over anhydrous Na2SO4and concentrated in vacuo to afford N-(2-bromo-5-iodopyridin-4-yl)-N- (methylsulfonyl)methanesulfonamide (Intermediate 11, 150 g, 98%) as a yellow liquid, which was used for next step without further purification.1H NMR (400 MHz, DMSO-d6) δ 3.65 (s, 6H), 8.10 (s, 1H), 8.92 (s, 1H). Mass spec: m / z: 456 [M+H]+. Step 3 Intermediate 12: N-(2-bromo-5-iodopyridin-4-yl)methanesulfonamide To a solution of N-(2-bromo-5-iodopyridin-4-yl)-N-(methylsulfonyl)methanesulfonamide (Intermediate 11, 150 g, 329.6 mmol) in tetrahydrofuran (2 L) and water (2 L) was added sodium hydroxide (79.9 g, 1978 mmol) and the reaction mixture was stirred at room temperature for 3h. The reaction mixture was poured into water (500 mL), extracted with ethyl acetate (3 × 1000 mL) and acidified with citric acid solution (1 L) to pH ~ 4. The resultant precipitate was collected by filtration, washed with water (100 mL) and dried in vacuo to afford N-(2-bromo-5-iodopyridin-4-yl) methanesulfonamide (Intermediate 12, 75 g, 60%) as a yellow solid, which was used for next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 3.28(s, 3H), 7.54 (s, 1H), 8.64 (s, 1H), 9.51 (s, 1H). Mass spec: m / z: 378.7 [M+H]+. Step 4 Intermediate 14: tert-butyl (R)-2-(6-bromo-1-(methylsulfonyl)-1H-pyrrolo[3,2-c]pyridin-2- yl)pyrrolidine-1-carboxylate To a solution of N-(2-bromo-5-iodopyridin-4-yl)methanesulfonamide (Intermediate 12, 50.0 g, 132.63 mmol) and tert-butyl (R)-2-ethynylpyrrolidine-1-carboxylate (Intermediate 13, 25.89 g, 132.63 mmol) in THF (500 mL) was added N,N-diisopropylethylamine (138 g, 1061.0 mmol). The reaction mixture was purged with argon gas for 15 min then PdCl2(PPh3)2(9.60 g, 13.263 mmol) and copper(I) iodide (2.55 g, 13.26 mmol) were added. The reaction mixture was further purged with argon gas for 10 min and then heated at 60°C for 3h. The reaction mixture was diluted with water (500 mL) and extracted with ethyl acetate (3 × 300 mL). The combined organic layers were dried over anhydrous Na2SO4and concentrated in vacuo to obtain crude compound. The crude material was purified by combi-flash chromatography, by eluting with 30% ethyl acetate in heptane, to afford tert-butyl (R)-2-(6-bromo-1-(methylsulfonyl)-1H- pyrrolo[3,2-c]pyridin-2-yl)pyrrolidine-1-carboxylate (Intermediate 14, 38.0 g, 62%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.40 ppm (s, 9H), 1.85-1.91 (m, 4H), 3.18- 3.21 (m, 1H), 3.37-3.41 (m, 1H), 3.62 (s, 3H), 5.23-5.31 (m, 1H), 6.72 (s, 1H), 7.97 (s, 1H), 8.69 (s, 1H). Mass spec: m / z: 445.9 [M+H]+. Step 5 Intermediate 15: (R)-6-bromo-1-(methylsulfonyl)-2-(pyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridine hydrochloride To a cooled (0°C) solution of tert-butyl (R)-2-(6-bromo-1-(methylsulfonyl)-1H-pyrrolo[3,2- c]pyridin-2-yl)pyrrolidine-1-carboxylate (Intermediate 14, 200 g, 450.1 mmol) in 1,4-dioxane (1 L) was added 4M hydrochloric acid in 1,4-dioxane (2 L) and the reaction mixture was stirred at room temperature for 6h. The reaction mixture was concentrated in vacuo to afford (R)-6- bromo-1-(methylsulfonyl)-2-(pyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine hydrochloride (Intermediate 15, 160 g) as a yellow solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 1.87-2.20 (m, 2H), 2.33-2.46 (m, 2H), 3.15- 3.34 (m, 2H), 3.75 (s, 3H), 5.12-5.17 (m, 1H), 7.38 (s, 1H), 7.98 (s, 1H), 8.78 (s, 1H), 9.45 (s, 2H). Mass spec: m / z: 345.8 [M+H]+. Step 6 Intermediate 16: (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1-(methylsulfonyl)-1H-pyrrolo [3,2-c]pyridine To a cooled (0°C) solution of (R)-6-bromo-1-(methylsulfonyl)-2-(pyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridine hydrochloride (Intermediate 15, 90.0 g, 236.4 mmol) in methanol (900 mL) was added triethylamine (192 g, 1891 mmol) followed by formaldehyde (60.83 g, 709.2 mmol). The reaction mixture was stirred for 5 min and then sodium cyanoborohydride (34.96 g, 472.8 mmol) was added at 0°C. The reaction mixture was then heated at 60°C for 16h. The reaction mixture was diluted with water (500 mL) and extracted with dichloromethane (3 × 500 mL). The combined organic layers were dried over anhydrous Na2SO4 and concentrated in vacuo to the obtain crude compound. The crude material was purified by combi-flash chromatography by eluting with 60% ethyl acetate in heptane, to afford (R)-6-bromo-2-(1- methylpyrrolidin-2-yl)-1-(methylsulfonyl)-1H-pyrrolo[3,2-c]pyridine (Intermediate 16, 60.0 g, 71%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.70-1.78 (m, 3H), 2.33 (s, 3H), 2.36-2.40 (m, 2H), 3.01-3.22 (m, 1H), 3.56 (s, 3H), 3.76-3.81 (m, 1H), 6.89 (s, 1H), 7.97 (s, 1H), 8.68 (s, 1H). Mass spec: m / z: 359.8 [M+H]+. Step 7 Intermediate 17: (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3, 2-c]pyridine To a solution of (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1-(methylsulfonyl)-1H-pyrrolo[3,2- c]pyridine (Intermediate 16, 110 g, 307.1 mmol) in methanol (600 mL) was added tetrahydrofuran (600 mL) and the mixture cooled to 0°C. Cesium carbonate (200 g, 614.2 mmol) was added and the reaction mixture was stirred at room temperature for 4h. The reaction mixture was quenched with water (2 L) and extracted with ethyl acetate (2 × 1 L). The combined organic layers were dried over anhydrous Na2SO4and concentrated in vacuo to afford (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine (Intermediate 17, 60.0 g, 70%) as a yellow solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 1.75-1.91 (m, 3H), 2.14 (s, 3H), 2.21-2.29 (m, 1H), 3.10-3.15 (m, 1H), 3.33-3.36 (m, 2H), 6.45 (s, 1H), 7.43 (s, 1H), 8.48 (s, 1H), 11.57 (br s, 1H). Mass spec: m / z: 279.9 [M+H]+. Step 8: Intermediate 4: tert-butyl (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridine-1-carboxylate To a solution of (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3, 2-c]pyridine (Intermediate 17, 60.0 g, 214.16 mmol) in dichloromethane (600 mL) was added triethylamine (65.3 g, 642.49 mmol) followed by di-tert-butyldicarbonate (94.42 g, 428.33 mmol) and 4- (dimethylamino)pyridine (5.28 g, 42.833 mmol) and the reaction mixture was stirred at room temperature for 3h. The reaction mixture was diluted with water (500 mL) and extracted with diethyl ether (3 × 500 mL). The combined organic layers were dried over anhydrous Na2SO4and concentrated in vacuo to obtain the crude compound. The crude material was purified by combi-flash chromatography, by eluting with 45% ethyl acetate in heptane, followed by SFC purification (Waters SFC Prep 150 Mgm equipped with 2489 PDA detector; Column: Chiralpak IC (30 x 250 mm, 5 µM); Solvent A) CO270 g / min; B) 0.1% Isopropyl amine in isopropyl alcohol and MeCN (50:50) 25 mL / min) to afford tert-butyl-(R)-6-bromo-2-(1-methylpyrrolidin- 2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 4, 43 g, 53%) as an off white solid. Enantiomeric excess (ee) 98.4%.1H NMR (400 MHz, DMSO-d6) δ ppm 1.65 (s, 9H), 1.71-1.75 (m, 3H), 2.30-2.33 (m, 1H), 2.34 (s, 3H), 2.37-2.40 (m, 1H), 3.11-3.14 (m, 1H), 3.87- 3.91 (m, 1H), 6.80 (s, 1H), 8.05 (s, 1H), 8.61 (s, 1H). Mass spec: m / z: 379.9 [M+H]+. Intermediate 4 can also be synthesised following Scheme 3

[0014] Scheme 3 Step 1 Intermediate 18: rac-tert-butyl 2-[2-(4-amino-6-bromopyridin-3-yl)ethynyl]pyrrolidine-1- carboxylate A solution of 2-bromo-5-iodopyridin-4-amine (Intermediate 10, 17 g, 54.2 mmol), rac-tert- butyl 2-ethynylpyrrolidine-1-carboxylate (CAS: 316141-37-4, 13.4 g, 65.04 mmol), Pd(PPh3)2Cl2(3.81 g, 5.42 mmol), CuI (1.03 g, 5.42 mmol) and Et3N (16.4 g, 162.6 mmol) in DMF (400 mL) was stirred for 2h at rt under nitrogen atmosphere. The reaction mixture was quenched with water and the resulting solution was extracted three times with EtOAc. The organic layers were combined, washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude material was purified by flash chromatography on silica gel using petroleum ether / EtOAc (7 / 3) as eluent to afford rac-tert-butyl 2-[2-(4-amino- 6-bromopyridin-3-yl)ethynyl]pyrrolidine-1-carboxylate (Intermediate 18, 18 g, 83%) as a yellow oil. Mass spec: m / z 366 [M+H]+. Step 2 Intermediate 19: rac-tert-butyl 2-{6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}pyrrolidine-1- carboxylate To a solution of rac-tert-butyl 2-[2-(4-amino-6-bromopyridin-3-yl)ethynyl]pyrrolidine-1- carboxylate (Intermediate 18, 8 g, 20.8 mmol) in NMP (40 mL) was added a solution of tBuOK (65.53 mL, 65.53 mmol, 1M in THF). The reaction mixture was stirred for 4h at 80°C. The reaction mixture was quenched with water and the resulting solution was extracted three times with EtOAc. The organic layers were combined, washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude material was purified by flash chromatography on silica gel using DCM / MeOH (95 / 5) as eluent to afford rac-tert-butyl 2- {6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}pyrrolidine-1-carboxylate (Intermediate 19, 6 g, 71%) as a yellow oil. Mass spec: m / z 366 [M+H]+. Step 3 Intermediate 20: rac-2-{6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}pyrrolidine trifluoroacetate To a solution of rac-tert-butyl 2-{6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}pyrrolidine-1- carboxylate (Intermediate 19, 16 g, 41.5 mmol) in DCM (300 mL) was added TFA (30 mL). The reaction mixture was stirred for 2h at rt. The solution was concentrated under reduced pressure to afford rac-2-{6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}pyrrolidine trifluoroacetate (Intermediate 20, 10 g, 77%) as a yellow oil which was used in Step 5 without further purification. Mass spec: m / z 266 [M+H]+. Step 4 Intermediate 21: rac-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine To a solution of rac-6-bromo-2-(pyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine trifluoroacetate (Intermediate 20, 10 g, 35.8 mmol) in MeOH (300 mL) were added Et3N (10.9 g, 108 mmol) and paraformaldehyde (5.37 g, 179 mmol). The reaction mixture was stirred for 1h at rt. NaBH3CN (6.77 g, 107.4 mmol) was added and the reaction mixture was stirred overnight at 60°C. The reaction mixture was quenched with water and the resulting solution was extracted three times with EtOAc. The organic layers were combined, washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was chromatographed by reverse-phase flash chromatography (C18 aq) using MeCN / H2O (45 / 55) as eluent to afford rac-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine (Intermediate 21, 8 g, 69%) as a yellow oil. Mass spec: m / z 280 [M+H]+. Step 5 Intermediate 22: rac-tert-butyl 6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridine-1-carboxylate To a solution of rac-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine (Intermediate 21, 88 g, 25.8 mmol) in DCM (200 mL) were added Boc2O (8.44 g, 38.7 mmol), Et3N (7.82 g, 77.4 mmol) and DMAP (310 mg, 2.58 mmol). The reaction mixture was stirred overnight at rt and then quenched with water. The resulting solution was extracted three times with EtOAc and the organic layers were combined, washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude material was purified by flash chromatography on silica gel using EtOAc / petroleum ether (3 / 2) as eluent to afford rac- tert-butyl 6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 22, 8.1 g, 71%) as a yellow oil. Mass spec: m / z 380 [M+H]+. Step 6 Intermediate 17: (2R)-2-{6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}-1-methylpyrrolidine and Intermediate 23: (2S)-2-{6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}-1-methylpyrrolidine rac-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine (Intermediate 21, 9.00 g, 30.5 mmol) was separated by SFC (Column: CHIRALPAK IH 3*25 cm, 5 μm; Mobile Phase A: CO2, Mobile Phase B: MeOH (+1%-2M NH3in MeOH); Flow rate: 85 mL / min; Gradient: isocratic 20% B) to afford (2R)-2-{6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}-1- methylpyrrolidine (Intermediate 17, 1st eluting peak, 3.5 g, 37%) as a white solid and (2S)-2- {6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}-1-methylpyrrolidine (Intermediate 23, 2nd eluting peak, 4.0 g, 40%) as a white solid. Intermediate 17: (2R)-2-{6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}-1-methylpyrrolidine 1steluting peak from SFC purification. Retention time: 4.35 mins. Enantiomeric excess (ee) 99.8%.1H NMR (400 MHz, DMSO-d6) δ ppm 11.56 (s, 1H), 8.49 (s, 1H), 7.43 (s, 1H), 6.45 (s, 1H), 3.34 (t, J = 9.0 Hz, 1H), 3.13 (t, J = 7.8 Hz, 1H), 2.24 - 2.30 (m, 1H), 2.15 (s, 4H), 1.87 - 1.90 (m, 1H), 1.75 - 1.84 (m, 2H). Intermediate 23: (2S)-2-{6-bromo-1H-pyrrolo[3,2-c]pyridin-2-yl}-1-methylpyrrolidine 2nd eluting peak from SFC purification. Retention time: 4.87 mins. Enantiomeric excess (ee) 99.8%.1H NMR (400 MHz, DMSO-d6) δ ppm 11.56 (s, 1H), 8.49 (s, 1H), 7.43 (s, 1H), 6.45 (s, 1H), 3.35 (t, J = 11.4 Hz, 1H), 3.14 (t, J = 8.0 Hz, 1H), 2.26 (t, J = 8.6 Hz, 1H), 2.15 (s, 4H), 1.88 (d, J = 8.0 Hz, 1H), 1.80 (d, J = 8.0 Hz, 2H). Step 7 Intermediate 4: tert-butyl (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridine-1-carboxylate A 500 mL round-bottom flask was charged with (2R)-2-{6-bromo-1H-pyrrolo[3,2-c]pyridin-2- yl}-1-methylpyrrolidine (Intermediate 17, 500 mg, 1.68 mmol), DCM (10 mL), Et3N (541 mg, 5.35 mmol), DMAP (21.8 mg, 0.178 mmol), (Boc)2O (778 mg, 3.57 mmol) and the reaction was stirred overnight at room temperature. The reaction was quenched with water (200 mL). The resulting solution was extracted with ethyl acetate (3 x 200 mL) and the organic layers were combined, washed with brine (2 x 300 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was chromatographed on a silica gel column, eluting with EtOAc / Petroleum ether (35 / 65) to afford tert-butyl (R)-6-bromo-2-(1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 4, 600 mg, 92%) as an off-white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.65 (s, 9H), 1.71-1.75 (m, 3H), 2.30-2.33 (m, 1H), 2.34 (s, 3H), 2.37-2.40 (m, 1H), 3.11-3.14 (m, 1H), 3.87-3.91 (m, 1H), 6.80 (s, 1H), 8.05 (s, 1H), 8.61 (s, 1H). Mass spec: m / z: 379.9 [M+H]+. Mass spec: m / z: 380.0 [M+H]+. Step 8 Intermediate 24: tert-butyl (S)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridine-1-carboxylate Intermediate 24 was prepared in an analogous manner to Intermediate 4 following Step 7 of Scheme 3 and exhibited the following data:1H NMR (400 MHz, DMSO-d6) δ ppm 1.65 (s, 9H), 1.71-1.75 (m, 3H), 2.30-2.33 (m, 1H), 2.34 (s, 3H), 2.37-2.40 (m, 1H), 3.11-3.14 (m, 1H), 3.87-3.91 (m, 1H), 6.80 (s, 1H), 8.05 (s, 1H), 8.61 (s, 1H). Mass spec: m / z: 379.9 [M+H]+. Mass spec: m / z: 380.0 [M+H]+. Intermediate 13: tert-butyl (R)-2-ethynylpyrrolidine-1-carboxylate To a cooled (-30°C) solution of tert-butyl-(R)-2-formylpyrrolidine-1-carboxylate (CAS No: 73365-02-3, 50.0 g, 250.94 mmol) in methanol (500 mL) was added potassium carbonate (51.94 g, 376.41 mmol). Dimethyl(1-diazo-2-oxopropyl)phosphonate (CAS No: 90965-06-3, 57.85 g, 301.13 mmol) was then added dropwise over 20 min and the reaction mixture was stirred at - 30°C for 3h. The reaction mixture was diluted with water (1000 mL) and extracted with diethyl ether (3 × 500 mL). The combined organic layers were dried over anhydrous Na2SO4and concentrated in vacuo to obtain the crude compound. The crude material was purified by combi- flash chromatography, by eluting with 10% ethyl acetate in heptane, to afford tert-butyl (R)-2- ethynylpyrrolidine-1-carboxylate (Intermediate 13, 35.0 g, 71%) as a yellow liquid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.40 (s, 9H), 1.81-1.89 (m, 3H), 1.99-2.12 (m, 1H), 3.08-3.25 (m, 2H), 3.26-3.35 (m, 1H), 4.32-4.38 (m, 1H). Intermediate 8 was synthesised following Scheme 4 Scheme 4 Step 1 Intermediate 25: 3-(4-iodo-1-oxoisoindolin-2-yl)piperidine-2,6-dione To a solution of 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione (CAS No 191732-72-6, 25.0 g, 96.41 mmol) in acetonitrile (300 mL) was added copper(I) iodide (28.10 g, 144.6 mmol). The reaction mixture was purged with argon gas for 20 min then tert-butyl nitrite (16.57 g, 144.6 mmol) was added and the reaction mixture was heated at 60°C for 12h. The reaction mixture was poured then into water (300 mL), a solid precipitate formed, which was filtered and dried under vacuum to afford 3-(4-iodo-1-oxoisoindolin-2-yl) piperidine-2,6-dione (Intermediate 25, 45.2 g) as an off white solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 1.98-2.04 (m, 2H), 2.82-2.98 (m, 2H), 4.11-4.32 (m, 2H), 5.13 (m, 1H), 7.31-7.42 (m, 1H), 7.71-7.80 (m, 1H), 7.98-8.06 (m, 1H), 10.99 (br s, 1H). Mass spec: m / z [M+H]+371.0. Step 2 Intermediate 8: 3-(4-iodo-1-oxoisoindolin-2-yl)-1-((2-(trimethylsilyl) ethoxy)methyl) piperidine-2,6-dione To solution of 3-(4-iodo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Intermediate 25, 30.0 g, 81.06 mmol) in dimethylformamide (250 mL) was added DBU (44.07 g, 283.7 mmol) at 0°C, then 2-(trimethylsilyl)ethoxymethyl chloride (52 mL, 283.7 mmol) was added and the reaction mixture was stirred at room temperature for 16h under a nitrogen atmosphere. The reaction mixture was quenched with water (700 mL), diluted with ethyl acetate (500 mL) and filtered through a celite bed. The organic layer was separated, washed with water (500 mL), dried over anhydrous Na2SO4and concentrated in vacuo. The crude material was purified by combi-flash chromatography, eluting with 50% ethyl acetate in heptane to afford 3-(4-iodo-1-oxoisoindolin- 2-yl)-1-((2-(trimethylsilyl) ethoxy) methyl) piperidine-2,6-dione (Intermediate 8, 8.56 g, 21%) as an off-white solid.1H NMR (400 MHz, DMSO-d6) δ ppm -0.02 (s, 9H), 0.78-0.90 (m, 2H), 2.03-2.11 (m, 1H), 2.76-2.82 (m, 1H), 3.02-3.12 (m, 1H), 3.48-3.60 (m, 3H), 4.08-4.13 (m, 1H), 4.28-4.33 (m, 1H), 5.02-5.10 (m, 2H), 5.26-5.31 (m, 1H), 7.31-7.37 (m, 1H), 7.79 (d, J=7.46 Hz, 1H), 8.05 (d, J=7.46 Hz, 1H). Mass spec: m / z [M-H]- 498.8. Example 2 was synthesised following Scheme 5 Scheme 5 Step 1 Intermediate 26: methyl 6-(prop-2-yn-1-yloxy)nicotinate To a solution of methyl 6-hydroxynicotinate (CAS No: 66171-50-4, 2.00 g, 13.060 mmol) in toluene (50 mL) was added 3-bromoprop-1-yne (CAS No: 106-96-7, 1.86 g, 15.67 mmol) followed by silver carbonate (9.47 g, 32.65 mmol) and the reaction mixture was heated at 80°C for 48h. The reaction mixture was diluted with water (500 mL) and extracted with ethyl acetate (3 × 200 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude material was purified by combi-flash chromatography by eluting with 45% ethyl acetate in heptane to afford methyl 6-(prop-2-yn-1-yloxy)nicotinate (Intermediate 26, 0.50 g, 20%) as an off-white solid.1H NMR (400 MHz, CDCl3) δ ppm 2.48 (s, 1H), 3.90 (s, 3H), 5.03 (s, 2H), 6.81 (d, J=8.80 Hz, 1H), 8.17 (dd, J=8.80, 2.40 Hz, 1H), 8.81 (d, J=2.40 Hz, 1H). Mass spec: m / z: 191.9 [M+H]+. Step 2 Intermediate 27: 6-(prop-2-yn-1-yloxy) nicotinic acid To a solution of methyl 6-(prop-2-yn-1-yloxy)nicotinate (Intermediate 26, 1.00 g, 5.23 mmol) in tetrahydrofuran (10 mL), methanol (10 mL) and water (5 mL) was added lithium hydroxide (0.51 g, 20.92 mmol) and the reaction mixture was stirred at room temperature for 16h. The reaction mixture was diluted with water (5 mL), acidified to pH 4 with 0.5 N HCl and extracted with ethyl acetate (2 × 250 mL). The combined organic phases were dried over Na2SO4and concentrated in vacuo to afford 6-(prop-2-yn-1-yloxy)nicotinic acid (Intermediate 27, 0.75 g, 81%) as an off-white solid, which was used for the next step without further purification.1H NMR (400 MHz, CDCl3) δ ppm 2.49 (s, 1H), 5.05 (s, 2H), 6.85 (d, J=8.80 Hz, 1H), 8.22 (dd, J=8.80, 2.0 Hz, 1H), 8.88 (d, J=2.0 Hz, 1H). Mass spec: m / z: 177.9 [M+H]+. Step 3 Intermediate 28: 6-(prop-2-yn-1-yloxy)nicotinamide To a solution of 6-(prop-2-yn-1-yloxy)nicotinic acid (Intermediate 27, 0.75 g, 4.23 mmol) in dimethylformamide (15 mL) was added HATU (2.54 g, 6.35 mmol) and N, N- diisopropylethylamine (1.73 g, 12.70 mmol) at room temperature and stirred for 10 min. Ammonium chloride (1.26 g, 21.16 mmol) was added at room temperature and the reaction mixture was stirred at room temperature for 16h. The reaction mixture was quenched with ice cold water (200 mL) and extracted with ethyl acetate (3 × 150 mL). The combined organic phases were dried over anhydrous Na2SO4and concentrated in vacuo. The crude material was purified by combi-flash chromatography by eluting with 45% ethyl acetate in heptane to afford 6-(prop-2-yn-1-yloxy)nicotinamide (Intermediate 28, 0.25 g, 34%) as a white solid.1H NMR (400 MHz, CDCl3) δ ppm 2.49 (s, 1H), 5.04 (s, 2H), 6.86 (d, J=8.40 Hz, 1H), 8.07 (d, J=8.40, 2.40 Hz, 1H), 8.62 (d, J=2.40 Hz, 1H). Mass spec: m / z: 177.0 [M+H]+. Step 4 Intermediate 29: 6-((3-(2-(2, 6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl) piperidin-3-yl)-1- oxoisoindolin-4-yl) prop-2-yn-1-yl)oxy)nicotinamide To a solution of 6-(prop-2-yn-1-yloxy)nicotinamide (Intermediate 28, 0.22 g, 1.25 mmol) in dimethylformamide (5 mL) was added 3-(4-iodo-1-oxoisoindolin-2-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione (Intermediate 8, 0.31 g, 0.62 mmol) followed by triethylamine (4.78 g, 44.95 mmol). The reaction mixture was purged with argon for 15 min then copper(I) iodide (0.024 g, 0.12 mmol) and PdCl2(PPh3)2(0.092 g, 0.12 mmol) were added. The reaction mixture was further purged with argon for 10 min and stirred at room temperature for 2h. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 × 150 mL). The combined organic phases were dried over anhydrous Na2SO4and concentrated in vacuo. The crude material was purified by combi-flash chromatography by eluting with 90% ethyl acetate in heptane to afford 6-((3-(2-(2, 6-dioxo-1-((2- (trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1- yl)oxy)nicotinamide (Intermediate 29, 0.35 g, 51%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm -0.03 (s, 9H), 0.80-0.88 (m, 2H), 2.02-2.11 (m, 1H), 2.30-2.41 (m, 1H), 2.76- 2.82 (m, 1H), 3.01-3.12 (m, 1H), 3.49-3.57 (m, 2H), 4.18-4.24 (m, 1H), 4.38-4.43 (m, 1H), 5.02-5.09 (m, 2H), 5.24-5.28 (m, 1H), 5.32 (s, 2H), 6.97 (d, J=8.80 Hz, 1H), 7.42 (br s, 1H), 7.57 (t, J=7.60 Hz, 1H), 7.72 (d, J=7.60 Hz, 1H), 7.78 (d, J=7.60 Hz, 1H), 7.99 (br s, 1H), 8.19 (dd, J=8.80, 2.40 Hz, 1H), 8.71 (d, J=2.40 Hz, 1H). Mass spec: m / z: 546.9 [M-H]-. Step 5 Intermediate 30: tert-butyl 6-(6-((3-(2-(2,6-dioxo-1-((2- (trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1- yl)oxy)nicotinamido)-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1- carboxylate To a solution of 6-((3-(2-(2, 6-dioxo-1-((2-(trimethylsilyl) ethoxy) methyl) piperidin-3-yl)-1- oxoisoindolin-4-yl) prop-2-yn-1-yl) oxy) nicotinamide (Intermediate 29, 0.33 g, 0.60 mmol) in 1,4-dioxane (10 mL) was added tert-butyl (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 4, 0.27 g, 0.72 mmol) followed by cesiumcarbonate (0.49 g, 1.50 mmol) at room temperature. The reaction mixture was purged with argon for 15 min then Pd2(dba)3(0.085 g, 0.090 mmol) and Xantphos (0.11 g, 0.18 mmol) were added. The reaction mixture was further purged with argon for 10 min and then heated at 100°C for 2h. The reaction mixture was filtered through celite, washed with ethyl acetate (50 mL) and the filtrate was concentrated in vacuo to obtain crude compound. The crude material was purified by combi-flash chromatography by eluting with 90% ethyl acetate in heptane to afford tert-butyl 6-(6-((3-(2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1- oxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)nicotinamido)-2-((R)-1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 30, 0.25 g, 49%) as yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm -0.05 (s, 9H), 0.78-0.84 (m, 2H), 1.58-1.65 (m, 2H), 1.69 (s, 9H), 1.73-1.79 (m, 2H), 2.01-2.09 (m, 1H), 2.29-2.33 (m, 1H), 2.36 (s, 3H), 2.37-2.43 (m, 1H), 2.72- 2.81 (m, 1H), 2.99-3.18 (m, 2H), 3.45-3.52 (m, 2H), 3.88-3.96 (m, 1H), 4.20-4.24 (m, 1H), 4.40-4.44 (m, 1H), 4.97-5.06 (m, 2H), 5.23-5.27 (m, 1H), 5.36 (s, 2H), 6.76 (s, 1H), 7.02 (d, J=8.40 Hz, 1H), 7.54-7.61 (m, 1H), 7.74 (d, J=7.60 Hz, 1H), 7.79 (d, J=7.60 Hz, 1H), 8.36 (dd, J=8.40, 2.80 Hz, 1H), 8.59 (s, 1H), 8.90 (s, 1H), 8.88 (d, J=2.80 Hz, 1H), 8.92 (s, 1H), 10.84 (s, 1H). Mass spec: m / z: 847.9 [M+H]+. Step 6 Example 2: 6-((3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide To a solution of tert-butyl 6-(6-((3-(2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin- 3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)nicotinamido)-2-((R)-1-methylpyrrolidin-2-yl)- 1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 30, 0.25 g, 0.29 mmol) in acetonitrile (10 mL) was added methane sulfonic acid (0.19 mL, 2.95 mmol) at room temperature and the reaction mixture was heated at 50°C for 2h. To the reaction mixture was added N,N’- dimethylethylenediamine (0.17 mL, 1.47 mmol) followed by triethylamine (0.82 mL, 5.89 mmol) and the reaction stirred at room temperature for 3h. The reaction mixture was concentrated in vacuo and water (50 mL) added, resulting in a precipitate which was filtered and dried under vacuum to obtain crude compound. The crude material was purified by preparative HPLC (Method A) to afford 6-((3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn- 1-yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide (Example 2, 0.045 g, 25%) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.75- 1.95 (m, 3H), 1.97-2.05 (m, 1H), 2.11-2.15 (m, 1H), 2.17 (s, 3H), 2.23-2.30 (m, 1H), 2.41-2.45 (m, 1H), 2.56-2.62 (m, 1H), 2.85-2.96 (m, 1H), 3.10-3.17 (m, 1H), 3.32-3.36 (m, 1H), 4.28-4.35 (m, 1H), 4.42-4.48 (m, 1H), 5.12-5.17 (m, 1H), 5.37 (s, 2H), 6.40 (s, 1H), 7.03 (d, J=8.40 Hz, 1H), 7.54-7.59 (m, 1H), 7.71-7.75 (m, 1H), 7.76-7.80 (m, 1H), 8.19 (s, 1H), 8.36 (dd, J=8.40, 2.40 Hz, 1H), 8.51 (s, 1H), 8.89 (d, J=2.40 Hz, 1H), 10.60 (s, 1H), 11.11 (br s, 1H), 11.39 (br s, 1H). Mass spec: m / z: 618.2 [M+H]+. Example 3 was synthesised following Scheme 6 Scheme 6 Step 1 Intermediate 31: tert-butyl 4-(4-(methoxycarbonyl) benzyl)piperidine-1-carboxylate To a solution of methyl 4-bromobenzoate (CAS No: 619-42-1, 3.00 g, 13.95 mmol) in tetrahydrofuran (30 mL) was added 9-borabicyclo[3.3.1]nonane (4.26 g, 16.74 mmol) and the reaction mixture was heated at 60°C for 1h under a nitrogen atmosphere. tert-butyl 4- methylenepiperidine-1-carboxylate (CAS No: 159635-49-1, 3.30 g, 16.74 mmol) in dimethylformamide (20 mL) followed by potassium carbonate (3.04 g, 20.93 mmol) and PdCl2(dppf) (1.79 g, 2.09 mmol) were added at room temperature and the reaction mixture was stirred at 80°C for 2h. The reaction mixture was cooled to room temperature and diluted with water (100 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic phases were dried over anhydrous Na2SO4and concentrated in vacuo. The crude material was purified by combi-flash chromatography by eluting with 40% ethyl acetate in heptane to afford tert-butyl 4-(4-(methoxycarbonyl) benzyl) piperidine-1-carboxylate (Intermediate 31, 4.80 g, 100%) as a colorless liquid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.37 (s, 9H), 1.49-1.62 (m, 2H), 1.66- 1.82 (m, 3H), 2.55-2.68 (m, 4H), 3.83 (s, 3H), 3.88-3.91 (m, 2H), 7.31 (d, J=7.88 Hz, 2H), 7.87 (d, J=7.88 Hz, 2H). Mass spec: m / z: 234.2 [M-100+H]+. Step 2 Intermediate 32: 4-((1-(tert-butoxycarbonyl) piperidin-4-yl) methyl)benzoic acid To a solution of tert-butyl 4-(4-(methoxycarbonyl) benzyl) piperidine-1-carboxylate (Intermediate 31, 4.80 g, 14.4 mmol) in tetrahydrofuran (20 mL), methanol (10 mL) and water (10 mL) was added lithium hydroxide (1.06 g, 43.2 mmol) and the reaction mixture was stirred at room temperature for 12h. The reaction mixture was concentrated in vacuo to obtain crude compound. The crude material was diluted with water (50 mL) and acidified to pH~4 with 1N HCl (20 mL), resulting in a solid precipitate which was collected by filtration and dried to afford 4-((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)benzoic acid (Intermediate 32, 4.00 g) as a white solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 0.98-1.04 (m, 2H), 1.37 (s, 9H), 1.50-1.54 (m, 2H), 1.67-1.70 (m, 1H), 2.57-2.62 (m, 4H), 3.87-3.91 (m, 2H), 7.28-7.30 (m, 2H), 7.84-7.86 (m, 2H), 12.78 (br s, 1H). Mass spec: m / z: 318.0 [M-H]-. Step 3 Intermediate 33: tert-butyl 4-(4-carbamoylbenzyl) piperidine-1-carboxylate To a solution of 4-((1-(tert-butoxycarbonyl) piperidin-4-yl) methyl)benzoic acid (Intermediate 32, 4.00 g, 12.52 mmol) in dimethylformamide (10 mL) was added HATU (7.36 g, 18.79 mmol) and the reaction mixture stirred at room temperature for 15 min. Ammonium chloride (2.68 g, 50.09 mmol) and N, N-diisopropylethylamine (8.75 mL, 50.09 mmol) were then added and the reaction mixture was stirred at room temperature for 16h. The reaction mixture was diluted with cold water (100 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic phases were dried over anhydrous Na2SO4and concentrated in vacuo. The crude material was purified by combi-flash chromatography by eluting with 50% ethyl acetate in heptane to afford tert-butyl 4-(4-carbamoylbenzyl) piperidine-1-carboxylate (Intermediate 33, 3.00 g, 75%) as a white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 0.99-1.06 (m, 2H), 1.38 (s, 9H), 1.48-1.54 (m, 2H), 1.66-1.72 (m, 1H), 2.52-2.58 (m, 4H), 3.86-3.92 (m, 2H), 7.22-7.24 (m, 3H), 7.77-7.79 (m, 2H), 7.88 (br s, 1H). Mass spec: m / z: 316.9 [M-H]-. Step 4 Intermediate 34: tert-butyl (R)-6-(4-((1-(tert-butoxycarbonyl)piperidin-4- yl)methyl)benzamido)-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c]pyridine-1- carboxylate To a solution of tert-butyl 4-(4-carbamoylbenzyl) piperidine-1-carboxylate (Intermediate 33, 0.42 g, 1.31 mmol) in 1, 4-dioxane (10 mL) was added tert-butyl (R)-6-bromo-2-(1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 4, 0.60 g, 1.64 mmol) followed by cesium carbonate (1.07 g, 3.27 mmol) at room temperature. The reaction mixture was purged with argon for 15 min then Pd2(dba)3(0.15 g, 0.16 mmol) and Xantphos (0.29 g, 0.49 mmol) were added. The reaction mixture was further purged with argon for 10 min and stirred at 100°C for 2h. The reaction mixture was concentrated in vacuo to obtain crude compound. The crude material was purified by combi-flash chromatography by eluting with 80% ethyl acetate in heptane to afford tert-butyl (R)-6-(4-((1-(tert-butoxycarbonyl)piperidin-4- yl)methyl)benzamido)-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 34, 0.54 g, 53%) as a white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.01- 1.09 (m, 2H), 1.38 (s, 9H), 1.53-1.62 (m, 4H), 1.69 (s, 9H), 1.74-1.80 (m, 2H), 2.25-2.31 (m, 1H), 2.35 (s, 3H), 2.38-2.40 (m, 1H), 2.54-2.61 (m, 2H), 2.65-2.72 (m, 2H), 3.11-3.16 (m, 1H), 3.88-3.93 (m, 3H), 6.74 (s, 1H), 7.30 (d, J=7.60 Hz, 2H), 7.97 (d, J=7.20 Hz, 2H), 8.58 (s, 1H), 8.92 (s, 1H), 10.58 (br s, 1H). Mass spec: m / z: 618.1 [M+H]+. Step 5 Intermediate 35: (R)-N-(2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3, 2-c]pyridin-6-yl)-4- (piperidin-4-ylmethyl) benzamide dihydrochloride To a solution of tert-butyl (R)-6-(4-((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)benzamido)- 2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 34, 0.52 g, 0.84 mmol) in 1, 4-dioxane (8.0 mL) was added 4M hydrochloric acid in 1,4-dioxane (8.0 mL) at 0°C and the reaction mixture was stirred at room temperature for 4h. The reaction mixture was concentrated in vacuo to afford (R)-N-(2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3, 2- c]pyridin-6-yl)-4-(piperidin-4-ylmethyl)benzamide dihydrochloride (Intermediate 35, 0.50 g) as a white solid which was used for next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 1.38-1.46 (m, 2H), 1.69-1.74 (m, 2H), 1.86-1.89 (m, 1H), 2.15-2.21 (m, 2H), 2.31-2.40 (m, 2H), 2.66-2.71 (m, 2H), 2.81 (s, 3H), 2.85-2.89 (m, 1H), 3.17-3.24 (m, 3H), 3.70- 3.78 (m, 2H), 4.72-4.78 (m, 1H), 7.29 (s, 1H), 7.42-7.44 (m, 2H), 8.16-8.18 (m, 2H), 8.32 (s, 1H), 8.72-8.76 (m, 1H), 8.99 (br s, 1H), 9.10 (s, 1H), 11.55 (br s, 1H), 12.05 (br s, 1H), 13.33 (br s, 1H). Mass spec: m / z: 418.3 [M+H]+. Step 6 Example 3: 4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4- yl)methyl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide To a solution of (R)-N-(2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3, 2-c]pyridin-6-yl)-4- (piperidin-4-ylmethyl) benzamide dihydrochloride (Intermediate 35, 0.40 g, 0.88 mmol) in dimethyl sulfoxide (5.0 mL) was added 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3- dione (CAS No: 835616-60-9, 0.24 g, 0.88 mmol) followed by N,N-diisopropylethylamine (0.47 g, 3.52 mmol) at room temperature and the reaction mixture was heated at 100°C for 1h. The reaction mixture was diluted with water (50 mL), resulting in a solid precipitate which was collected by filtration and dried to obtain crude compound. The crude material was purified through reverse phase preparative HPLC (Method A) to afford 4-((1-(2-(2,6-dioxopiperidin-3- yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)methyl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl)benzamide (Example 3, 0.08 g, 14%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.40-1.48 (m, 2H), 1.65-1.74 (m, 2H), 1.76-1.95 (m, 4H), 1.99- 2.05 (m, 1H), 2.12-2.15 (m, 1H), 2.17 (s, 3H), 2.23-2.35 (m, 2H), 2.56-2.62 (m, 2H), 2.66-2.70 (m, 2H), 2.81-2.88 (m, 3H), 3.12-3.16 (m, 1H), 3.65-3.72 (m, 2H), 5.06-5.11 (m, 1H), 6.39 (s, 1H), 7.31-7.36 (m, 4H), 7.65-7.69 (m, 1H), 8.00 (d, J=8.26 Hz, 2H), 8.19 (s, 1H), 8.50 (s, 1H), 10.35 (br s, 1H), 10.94 (br s, 1H), 11.35 (br s, 1H). Mass spec: m / z: 674.1 [M+H]+. Example 4 was synthesised following Scheme 7 Scheme 7 Step 1 Intermediate 36: tert-butyl 4-(4-(methoxycarbonyl) phenethyl) piperidine-1-carboxylate To a solution of tert-butyl 4-vinylpiperidine-1-carboxylate (CAS No: 180307-56-6, 3.00 g, 14 mmol) in tetrahydrofuran (50 mL) was added 9-borabicyclo[3.3.1]nonane (30.0 mL, 17 mmol) at 0˚C. The reaction mixture was heated at 70˚C for 2h. The reaction mixture was cooled to room temperature. To the reaction mixture was added methyl 4-bromobenzoate (CAS No: 619- 42-1, 3.70 g, 17 mmol) followed by potassium carbonate (3.1 g, 21.0 mmol) and PdCl2(dppf) (1.6 g, 1.8 mmol) in dimethylformamide (20 mL) and water (3 mL) at room temperature. The reaction mixture was further heated at 70˚C for 3h. Progress of the reaction was monitored by TLC. After completion, the reaction mixture was poured into water (100 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic phases were dried over anhydrous Na2SO4and concentrated in vacuo to obtain crude compound. The crude material was purified by combi-flash chromatography by eluting with 20% ethyl acetate in heptane to afford tert-butyl 4- (4-(methoxycarbonyl) phenethyl) piperidine-1-carboxylate (Intermediate 36, 4.00 g, 82%) as a colorless solid.1H NMR (400 MHz, DMSO-d6) δ ppm 0.98-1.02 (m, 2H), 1.38 (s, 9H), 1.49- 1.57 (m, 2H), 1.60-1.77 (m, 3H), 2.65-2.69 (m, 4H), 3.83 (s, 3H), 3.88-3.93 (m, 2H), 7.35 (d, J=7.60 Hz, 2H), 7.87 (d, J=7.60 Hz, 2H). Mass spec: m / z: 291.9 [M-56+H]+. Step 2 Intermediate 37: 4-(2-(1-(tert-butoxycarbonyl)piperidin-4-yl) ethyl)benzoic acid To a solution of tert-butyl 4-(4-(methoxycarbonyl)phenethyl) piperidine-1-carboxylate (Intermediate 36, 4.00 g, 12 mmol) in tetrahydrofuran:methanol:water (1:1:1, 70 mL) was added lithium hydroxide (0.84 g, 95 mmol) at 0°C and the reaction mixture was stirred at room temperature for 16h. The reaction mixture was concentrated in vacuo and water (100 mL) added and the mixture acidified with 1N HCl, resulting in a precipitate which was filtered and dried to afford 4-(2-(1-(tert-butoxycarbonyl)piperidin-4-yl)ethyl)benzoic acid (Intermediate 37, 2.50 g) as an off white solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 0.98-1.02 (m, 2H), 1.38 (s, 9H), 1.46-1.48 (m, 1H), 1.49-1.55 (m, 2H), 1.65-1.70 (m, 2H), 2.62-2.70 (m, 4H), 3.88-3.94 (m, 2H), 7.32 (d, J=8.0 Hz, 2H), 7.85 (d, J=8.0 Hz, 2H), 12.78 (br s, 1H). Mass spec: m / z: 278.0 [M-56+H]+. Step 3 Intermediate 38: tert-butyl 4-(4-carbamoylphenethyl)piperidine-1-carboxylate To a solution of 4-(2-(1-(tert-butoxycarbonyl) piperidin-4-yl)ethyl)benzoic acid (Intermediate 37, 2.50 g, 7.5 mmol) in dimethylformamide (30 mL) was added HATU (4.4 g, 11 mmol) and N,N-diisopropylethylamine (4.0 g, 30 mmol) at 0°C and the reaction stirred for 10 min. Ammonium chloride (1.6 g, 30.0 mmol) was then added at 0°C and the reaction mixture was stirred at room temperature for 16h. The reaction mixture was poured into water (100 mL), resulting in a precipitate, which was filtered and dried under vacuum to afford tert-butyl 4-(4- carbamoylphenethyl) piperidine-1-carboxylate (Intermediate 38, 1.80 g, 72%) as an off white solid, which was used for next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 0.94-1.06 (m, 2H), 1.39 (s, 9H), 1.46-1.48 (m, 1H), 1.49-1.54 (m, 2H), 1.66-1.69 (m, 2H), 2.61-2.68 (m, 4H), 3.88-3.94 (m, 2H), 7.23 (br s,1H), 7.27 (d, J=7.60 Hz, 2H), 7.78 (d, J=7.60 Hz, 2H), 7.86 (br s, 1H). Mass spec: m / z: 331.3 [M-H]-. Step 4 Intermediate 39: tert-butyl (R)-6-(4-(2-(1-(tert-butoxycarbonyl) piperidin-4-yl) ethyl) benzamido)-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c] pyridine-1-carboxylate To a solution of tert-butyl 4-(4-carbamoylphenethyl)piperidine-1-carboxylate (Intermediate 38, 0.27 g, 0.84 mmol) in 1,4-dioxane (15 mL) was added tert-butyl (R)-6-bromo-2-(1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 4, 0.40 g, 1.05 mmol) followed by cesium carbonate (0.68 g, 2.10 mmol) at room temperature. The reaction mixture was purged with argon for 15 min followed by the addition of Pd2(dba)3(0.15 g, 0.00157 mmol) and Xantphos (0.18 g, 0.31 mmol). The reaction mixture was further purged with argon for 10 min and then heated at 100°C for 2h. The reaction mixture was concentrated in vacuo to obtain crude compound which purified by combi-flash chromatography by eluting with 80% ethyl acetate in heptane to afford tert-butyl (R)-6-(4-(2-(1-(tert- butoxycarbonyl)piperidin-4-yl)ethyl)benzamido)-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridine-1-carboxylate (Intermediate 39, 0.45 g, 68%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.35-1.38 (m, 2H), 1.40 (s, 9H), 1.41-1.45 (m, 2H), 1.52-1.68 (m, 4H), 1.70 (s, 9H), 1.72-1.78 (m, 2H), 2.31-2.34 (m, 2H), 2.36 (s, 3H), 2.64-2.69 (m, 4H), 3.12-3.16 (m, 1H), 3.90-3.96 (m, 3H), 6.75 (s, 1H), 7.31-7.34 (m, 2H), 7.96-7.98 (m, 2H), 8.59 (s, 1H), 8.93 (s, 1H), 10.59 (br s, 1H). Mass spec: m / z: 532.4 [M-100+H]+. Step 5 Intermediate 40: (R)-N-(2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-4-(2- (piperidin-4-yl)ethyl)benzamide dihydrochloride To a solution of tert-butyl (R)-6-(4-(2-(1-(tert-butoxycarbonyl)piperidin-4-yl)ethyl)benzamido)- 2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 39, 0.40 g, 0.63 mmol) in 1, 4-dioxane (5 mL) was added 4M hydrochloric acid in 1,4-dioxane (5 mL) at 0˚C and the reaction mixture was stirred at room temperature for 16h. The reaction mixture was concentrated in vacuo to afford as (R)-N-(2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin- 6-yl)-4-(2-(piperidin-4-yl)ethyl)benzamide dihydrochloride (Intermediate 40, 0.40 g) as a brown solid, which was used for next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 1.34-1.39 (m, 2H), 1.52-1.59 (m, 3H), 1.84-1.87 (m, 2H), 2.10-2.20 (m, 2H), 2.32-2.40 (m, 1H), 2.71-2.76 (m, 3H), 2.81 (s, 3H), 3.22-3.26 (m, 3H), 3.54-3.57 (m, 1H), 3.72- 3.78 (m, 2H), 4.70-4.76 (m, 1H), 7.29 (s, 1H), 7.44-7.46 (m, 2H), 8.12-8.16 (m, 2H), 8.30 (s, 1H), 8.69-8.78 (m, 1H), 8.94 (s, 1H), 9.10 (s, 1H), 11.54 (br s, 1H), 12.04 (br s, 1H), 13.34 (br s, 1H). Mass spec: m / z: 432.0 [M+H]+. Step 6 Example 4: 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4- yl)ethyl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide To a solution of (R)-N-(2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo [3,2-c] pyridin-6-yl)-4-(2- (piperidin-4-yl) ethyl)benzamide dihydrochloride (Intermediate 40, 0.38 g, 0.88 mmol) in dimethyl sulfoxide (5 mL) was added 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (CAS No: 835616-60-9, 0.24 g, 0.88 mmol) followed by N,N-diisopropylethylamine (0.58 g, 4.40 mmol) at room temperature and the reaction mixture was heated at 130°C for 2h. The reaction mixture was poured into water (10 mL), resulting in a precipitate which was filtered and dried under vacuum to obtain the crude compound. The crude material was purified by preparative HPLC (Method A) to afford 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)piperidin-4-yl)ethyl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)benzamide (Example 4, 0.13 g, 22%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.39-1.50 (m, 3H), 1.55-1.68 (m, 2H), 1.78-1.92 (m, 5H), 2.01-2.04 (m, 1H), 2.06-2.12 (m, 1H), 2.16 (s, 3H), 2.23-2.32 (m, 1H), 2.52-2.61 (m, 3H), 2.71-2.75 (m, 2H), 2.82- 2.88 (m, 3H), 3.12-3.16 (m, 1H), 3.68-3.73 (m, 2H), 5.07-5.11 (m, 1H), 6.39 (s, 1H), 7.31-7.37 (m, 4H), 7.66-7.69 (m, 1H), 7.99 (d, J=8.31 Hz, 2H), 8.19 (s, 1H), 8.50 (s, 1H), 10.36 (s, 1H), 11.36 (s, 1H). Mass spec: m / z: 688.3 [M+H]+. Example 5 was synthesised following Scheme 8

[0015] Scheme 8 Step 1 Intermediate 41: tert-butyl 4-(5-carbamoylpyridin-2-yl) piperazine-1-carboxylateTo a solution of tert-butyl piperazine-1-carboxylate (CAS No: 57260-71-6, 5.00 g, 26.8 mmol)in dimethyl sulfoxide (60 mL) was added 6-chloronicotinamide (CAS No: 6271-78-9, 4.20 g, 26.8 mmol) followed by N, N-diisopropylethylamine (14.1 mL, 80.5 mmol) and the reaction mixture was heated at 120°C for 16h. The reaction mixture was poured into ice cold water (500 mL), resulting in a precipitate, which was filtered, washed with cold water (2 × 150 mL), heptane (2 × 100 mL) and dried in vacuo to afford tert-butyl 4-(5-carbamoylpyridin-2-yl) piperazine-1-carboxylate (Intermediate 41, 4.00 g, 49%) as a yellow solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 1.42 (s, 9H), 3.38-3.46 (m, 4H), 3.54-3.65 (m, 4H), 6.84 (d, J=9.20 Hz, 1H), 7.14 (br s, 1H), 7.77 (br s, 1H), 7.89 (d, J=9.20 Hz, 1H), 8.62 (s, 1H). Step 2 Intermediate 42: 6-(piperazin-1-yl)nicotinamide hydrochlorideTo a solution of tert-butyl 4-(5-carbamoylpyridin-2-yl) piperazine-1-carboxylate (Intermediate41, 3.50 g, 11.0 mmol) in 1, 4-dioxane (60 mL) was added 4M hydrochloric acid in 1,4-dioxane(32 mL) at 0°C and the reaction mixture was stirred at room temperature for 4h. The reaction mixture was concentrated in vacuo, washed with ether (2 × 20 mL) and dried under vacuum to afford as 6-(piperazin-1-yl)nicotinamide hydrochloride (Intermediate 42, 2.80 g) as a white solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 3.88-4.02 (m, 4H), 2.52-2.55 (m, 4H), 7.14 (d, J=9.20 Hz, 1H), 7.36 (br s, 1H), 8.02 (br s, 1H), 8.18 (d, J=9.20 Hz, 1H), 8.62 (s, 1H), 9.55 (br s, 1H), 9.58 (br s, 1H). Mass spec: m / z: 207.5 [M+H]+. Step 3 Intermediate 43: tert-butyl 4-((4-(5-carbamoylpyridin-2-yl) piperazin-1-yl) methyl) piperidine-1-carboxylate To a solution 6-(piperazin-1-yl)nicotinamide hydrochloride (Intermediate 42, 2.80 g, 11.5 mmol) in dimethylformamide (60 mL) was added tert-butyl 4-(bromomethyl)piperidine-1-carboxylate (CAS No: 158407-04-6, 3.85 g, 13.8 mmol) followed by potassium iodide (0.19 g,1.15 mmol) and potassium carbonate (7.97 g, 57.7 mmol) and the reaction mixture was heated at 80°C for 16h. The reaction mixture was poured into ice cold water (200 mL), resulting in a precipitate which filtered, washed with water (80 mL), n-pentane (80 mL) and then dried in under vacuum to afford tert-butyl 4-((4-(5-carbamoylpyridin-2-yl) piperazin-1-yl) methyl) piperidine-1-carboxylate (Intermediate 43, 0.80 g, 17%) as an off white solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 0.99-1.14 (m, 3H) 1.38 (s, 9H), 1.66-1.76 (m, 4H), 2.60-2.81 (m, 4H), 3.50-3.63 (m, 4H), 3.86-4.02 (m, 4H), 6.81 (d, J=9.20 Hz, 1H), 7.11 (br s, 1H), 7.74 (br s, 1H), 7.94 (d, J=9.20 Hz, 1H), 8.59 (s, 1H). Mass spec: m / z: 404.3 [M+H]+. Step 4 Intermediate 44: tert-butyl (R)-6-(6-(4-((1-(tert-butoxycarbonyl)piperidin-4- yl)methyl)piperazin-1-yl) nicotinamido)-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3, 2- c]pyridine-1-carboxylate To a solution of tert-butyl 4-((4-(5-carbamoylpyridin-2-yl)piperazin-1-yl)methyl)piperidine-1- carboxylate (Intermediate 43, 0.62 g, 1.53 mmol) in 1,4-dioxane (15 mL) were added tert-butyl (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 4, 0.64 g, 1.69 mmol) and cesium carbonate (1.25 g, 3.84 mmol) at room temperature. The reaction mixture was purged with argon for 15 min, then Pd2(dba)3(0.22 g, 0.23 mmol) and Xantphos (0.27 g, 0.46 mmol) were added. The reaction mixture was further purged with argon for 10 min and then heated at 100°C for 2h. The reaction mixture was filtered through celite, washed with ethyl acetate (100 mL) and the filtrate was concentrated in vacuo to obtain the crude compound. The crude material was purified by combi-flash chromatography by eluting with 5% MeOH in DCM to afford tert-butyl (R)-6-(6-(4-((1-(tert- butoxycarbonyl)piperidin-4-yl)methyl)piperazin-1-yl)nicotinamido)-2-(1-methylpyrrolidin-2- yl)-1H-pyrrolo[3, 2-c]pyridine-1-carboxylate (Intermediate 44, 0.32 g, 30%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 0.90-1.03 (m, 2H), 1.39 (s, 9H), 1.52-1.64 (m, 2H), 1.68 (s, 9H), 1.71-1.80 (m, 4H), 2.11-2.20 (m, 2H), 2.34 (s, 3H), 2.37-2.44 (m, 4H), 2.66-2.72 (m, 3H), 3.08-3.14 (m, 1H), 3.56-3.68 (m, 4H), 3.84-3.98 (m, 4H), 6.73 (s, 1H), 6.86 (d, J=9.20 Hz, 1H), 8.15 (d, J=9.20 Hz, 1H), 8.56 (s, 1H), 8.79 (s, 1H), 8.89 (s, 1H), 10.48 (br s, 1H). Mass spec: m / z: 703.1 [M+H]+. Step 5 Intermediate 45: (R)-N-(2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c] pyridin-6-yl)-6-(4- (piperidin-4-ylmethyl) piperazin-1-yl) nicotinamide dihydrochloride To a solution of tert-butyl (R)-6-(6-(4-((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)piperazin- 1-yl) nicotinamido)-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 44, 0.30 g, 0.42 mmol) in 1, 4-dioxane (10 mL) was added 4M hydrochloric acid in 1, 4-dioxane (5 mL) and the reaction mixture was stirred at room temperature for 4h. The reaction mixture was concentrated in vacuo, the resulting residue was washed with diethyl ether(2 × 50 mL) and dried under reduced pressure to afford (R)-N-(2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c] pyridin-6-yl)-6-(4-(piperidin-4-ylmethyl) piperazin-1-yl) nicotinamide dihydrochloride (Intermediate 45, 0.21 g) as an off-white solid, which was used for the next step without further purification. Mass spec: m / z: 503.34 [M+H]+. Step 6 Example 5: 6-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4- yl)methyl)piperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)nicotinamide To a solution of (R)-N-(2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-6-(4- (piperidin-4-ylmethyl)piperazin-1-yl)nicotinamide dihydrochloride (Intermediate 45, 0.21 g, 0.42 mmol) in dimethyl sulfoxide (10 mL) was added 2-(2,6-dioxopiperidin-3-yl)-4- fluoroisoindoline-1,3-dione (CAS No: 835616-60-9, 0.11 g, 0.42 mmol) followed by N,N- Diisopropylethylamine (0.36 mL, 2.08 mmol) and the reaction mixture was heated at 100°C for 4h. The reaction mixture was concentrated in vacuo. The obtained residue was poured into ice cold water (10 mL), resulting in a precipitate, which was filtered and dried under vacuum to obtain the crude compound. The crude material was purified by preparative HPLC (Method A) to afford 6-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4- yl)methyl)piperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)nicotinamide (Example 5, 0.03 g, 9%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.29-1.41 (m, 2H), 1.73-1.95 (m, 6H), 1.98-2.08 (m, 1H), 2.09-2.14 (m, 1H), 2.16 (s, 3H), 2.22-2.29 (m, 3H), 2.43-2.47 (m, 4H), 2.57-2.62 (m, 2H), 2.82-2.95 (m, 3H), 3.12-3.16 (m, 1H), 3.28-3.30 (m, 1H), 3.60-3.68 (m, 4H), 3.68-3.75 (m, 2H), 5.07-5.12 (m, 1H), 6.38 (s, 1H), 6.88 (d, J=9.20 Hz, 1H), 7.29-7.37 (m, 2H), 7.66-7.70 (m, 1H), 8.14-8.19 (m, 2H), 8.48 (s, 1H), 8.80 (s, 1H), 10.30 (s, 1H), 11.09 (br s, 1H), 11.35 (s, 1H). Mass spec: m / z: 759.2 [M+H]+. Example 6 was synthesised following Scheme 9 Scheme 9 Step 1 Intermediate 46: 6-(4-(prop-2-yn-1-yl)piperazin-1-yl)nicotinamide To a solution of 1-(prop-2-yn-1-yl)piperazine (CAS No: 52070-67-4, 1.50 g, 12 mmol) in dimethylformamide (10 mL) was added 6-chloronicotinamide (CAS No: 6271-78-9, 2.26 g, 14.48 mmol) followed by potassium carbonate (6.00 g, 60 mmol) and the reaction mixture was stirred at 100°C for 12h. The reaction mixture was diluted with water (200 mL) and extracted with ethyl acetate (3 × 200 mL). The combined organic phases were dried over anhydrous Na2SO4and concentrated in vacuo. The crude material was purified by combi-flash column chromatography by eluting with 22% ethyl acetate in heptane to afford 6-(4-(prop-2-yn-1-yl) piperazin-1-yl) nicotinamide (Intermediate 46, 0.60 g, 20%) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 2.42-2.49 (m, 2H), 2.52-2.57 (m, 2H), 3.16 (s, 1H), 3.55-3.67 (m, 6H), 6.84 (d, J=9.0 Hz, 1H), 7.12 (br s, 1H), 7.75 (br s, 1H), 7.95 (d, J=9.0 Hz, 1H), 8.60 (s, 1H). Mass spec: m / z: 245.13 [M+H]+. Step 2 Intermediate 47: 6-(4-(3-(2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)- 1-oxoisoindolin-4-yl)prop-2-yn-1-yl) piperazin-1-yl)nicotinamide To a solution of 6-(4-(prop-2-yn-1-yl)piperazin-1-yl)nicotinamide (Intermediate 46, 0.60 g, 2 mmol) in dimethylformamide (10 mL) was added 3-(4-iodo-1-oxoisoindolin-2-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione (Intermediate 8, 1.00 g, 2 mmol) followed by triethylamine (10 mL, 90 mmol). The reaction mixture was purged with argon for 15 min and then copper(I) iodide (0.05 g, 0.2 mmol) and PdCl2(PPh3)2(0.20 g, 0.2 mmol) were added. The reaction mixture was further purged with argon for 10 min and stirred at room temperature for 3h. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (2 × 100 mL). The combined organic phases were dried over anhydrous Na2SO4,and concentrated in vacuo. The crude material was purified by combi-flash chromatography by eluting with 100% ethyl acetate to afford 6-(4-(3-(2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)- 1-oxoisoindolin-4-yl) prop-2-yn-1-yl)piperazin-1-yl)nicotinamide (Intermediate 47, 0.84 g, 60%) as an yellow solid.1H NMR (401 MHz, DMSO-d6) δ ppm -0.02 (s, 9H), 0.74-0.89 (m, 2H), 2.01-2.10 (m, 1H), 2.38-2.47 (m, 1H), 2.58-2.68 (m, 4H), 2.73-2.83 (m, 1H), 3.00-3.12 (m, 1H), 3.49-3.57 (m, 2H), 3.62-3.68 (m, 6H), 4.28-4.32 (m, 1H), 4.47-4.51 (m, 1H), 5.01-5.08 (m, 2H), 5.23-5.28 (m, 1H), 6.85 (d, J=9.05 Hz, 1H), 7.16 (br s, 1H), 7.53-7.58 (m, 1H), 7.70-7.72 (m, 1H), 7.74-7.78 (m, 2H), 7.96 (dd, J=9.05, 2.32 Hz, 1H), 8.61 (d, J=2.32 Hz, 1H). Mass spec: m / z: 617.42 [M+H]+. Step 3 Intermediate 48: tert-butyl 6-(6-(4-(3-(2-(2,6-dioxo-1-((2- (trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1- yl)piperazin-1-yl)nicotinamido)-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridine-1-carboxylate To a solution of 6-(4-(3-(2-(2, 6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisoindolin-4-yl) prop-2-yn-1-yl) piperazin-1-yl)nicotinamide (Intermediate 47, 0.40 g, 0.6mmol) in 1,4-dioxane (10 mL) was added tert-butyl (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 4, 0.20 g, 0.6 mmol) followed bycesium carbonate (0.4 g, 1 mmol) at room temperature. The reaction mixture was purged with argon for 15 min and then Pd2(dba)3(0.06 g, 0.06 mmol) and Xantphos (0.1 g, 0.2 mmol) were added. The reaction mixture was further purged with argon for 10 min and stirred at 100°C for 2h. The reaction mixture was concentrated in vacuo to obtain the crude compound, which was purified by combi-flash chromatography by eluting with 90% ethyl acetate in heptane to afford tert-butyl 6-(6-(4-(3-(2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1- oxoisoindolin-4-yl)prop-2-yn-1-yl)piperazin-1-yl)nicotinamido)-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 48, 0.54 g, 90%) as a white solid.1H NMR (401 MHz, DMSO-d6) δ ppm -0.03 (s, 9H), 0.80-0.86 (m, 2H), 1.38-1.42 (m, 1H), 1.53-1.65 (m, 2H), 1.69 (s, 9H), 1.73-1.80 (m, 2H), 2.02-2.10 (m, 1H), 2.36 (s, 3H), 2.38-2.41 (m, 2H), 2.62-2.69 (m, 4H), 2.74-2.83 (m, 1H), 3.08-3.18 (m, 1H), 3.48-3.56 (m, 2H), 3.65-3.73 (m, 6H), 3.86-3.95 (m, 1H), 4.29-4.37 (m, 1H), 4.44-4.51 (m, 1H), 5.10-5.15 (m, 2H), 5.22-5.29 (m, 1H), 6.74 (s, 1H), 6.90 (d, J=9.20 Hz, 1H), 7.54-7.58 (m, 1H), 7.70-7.73 (m, 1H), 7.74-7.78 (m, 1H), 8.16 (dd, J=9.20, 2.45 Hz, 1H), 8.58 (s, 1H), 8.81 (d, J=2.45 Hz, 1H), 8.92 (s, 1H), 10.54 (s, 1H). Mass spec: m / z: 916.5 [M+H]+. Step 4 Example 6: 6-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1- yl)piperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)nicotinamide To a solution of tert-butyl 6-(6-(4-(3-(2-(2,6-dioxo-1-((2- (trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)piperazin-1- yl)nicotinamido)-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 48, 0.40 g, 0.4 mmol) in acetonitrile (10 mL) was added methanesulfonic acid (0.4 mL, 7 mmol) and the reaction mixture was stirred at 50°C for 2h. N,N’- dimethylethylenediamine (0.3 mL, 3 mmol) followed by triethylamine (0.9 g, 9 mmol) were then added and the reaction mixture stirred at room temperature for 3h. The reaction mixture was poured into ice cold water (100 mL), resulting in a precipitate, which was collected by filtration and dried under vacuum to obtain crude compound. The crude compound was purified by preparative HPLC (Method A) to afford 6-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)prop-2-yn-1-yl)piperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl)nicotinamide (Example 6, 0.19 g, 60%) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.76-1.96 (m, 3H), 1.96-2.04 (m, 1H), 2.17 (s, 3H), 2.21- 2.31 (m, 2H), 2.41-2.46 (m, 1H), 2.55-2.68 (m, 6H), 2.84-2.95 (m, 1H), 3.12-3.16 (m, 1H), 3.65-3.73 (m, 6H), 4.29-4.37 (m, 1H), 4.44-4.51 (m, 1H), 5.10-5.15 (m, 1H), 6.38 (s, 1H), 6.88 (d, J=9.20 Hz, 1H), 7.51-7.57 (m, 1H), 7.68-7.72 (m, 1H), 7.72-7.76 (m, 1H), 8.13-8.19 (m, 2H), 8.48 (s, 1H), 8.79-8.81 (m, 1H), 10.29 (br s, 1H), 11.00 (br s, 1H), 11.34 (br s, 1H). Mass spec: m / z: 686.0 [M+H]+. Example 7 was synthesised following Scheme 10

[0016] Scheme 10 Step 1 Intermediate 49: methyl 4-(5-hydroxypent-1-yn-1-yl)benzoate To a solution of methyl 4-iodobenzoate (CAS No: 619-44-3, 25.0 g, 95.4 mmol) in tetrahydrofuran (200 mL) was added pent-4-yn-1-ol (CAS No: 5390-04-5, 12.0 g, 143 mmol) followed by triethylamine (200 mL, 1430 mmol) and the reaction mixture was purged with argon gas for 15 min. Pd(PPh3)4(5.51 g, 4.77 mmol) and copper(I) iodide (1.85 g, 9.54 mmol) were added and the reaction mixture was further purged with argon gas for 10 min and then stirred at room temperature for 16h. The reaction mixture was diluted with water (400 mL) and extracted with ethyl acetate (3 × 500 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by combi-flash column chromatography by eluting with 80% ethyl acetate in heptane to afford methyl 4-(5-hydroxypent-1-yn-1-yl)benzoate (Intermediate 49, 16.0 g, 77%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.67-1.73 (m, 2H), 2.50 (t, J=6.40 Hz, 2H), 3.50-3.55 (m, 2H), 3.84 (s, 3H), 4.55 (t, J=5.20 Hz, 1H), 7.49 (d, J=8.30 Hz, 2H), 7.89 (d, J=8.40 Hz, 2H). Mass spec: m / z: 219.4 [M+H]+. Step 2 Intermediate 50: methyl 4-(5-hydroxypentyl)benzoate To a solution of methyl 4-(5-hydroxypent-1-yn-1-yl) benzoate (Intermediate 49, 16.0 g, 73.3 mmol) in methanol (200 mL) was added 10% Pd / C (5.86 g, 55.0 mmol) and the reaction mixture was stirred at room temperature for 16h under H2(110 psi). The reaction mixture was filtered through celite, washed with methanol (500 mL) and the filtrate was concentrated in vacuo to afford methyl 4-(5-hydroxypentyl)benzoate (Intermediate 50, 14.0 g, 86%) as a yellow solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 1.24-1.35 (m, 2H), 1.39-1.48 (m, 2H), 1.54-1.62 (m, 2H), 2.64 (t, J=7.60 Hz, 2H), 3.34-3.41 (m, 2H), 3.83 (s, 3H), 4.33 (t, J=5.20 Hz, 1H), 7.33 (d, J=8.40 Hz, 2H), 7.86 (d, J=8.40 Hz, 2H). Mass spec: m / z: 223.16 [M+H]+. Step 3 Intermediate 51: methyl 4-(5-oxopentyl)benzoate To a solution of methyl 4-(5-hydroxypentyl)benzoate (Intermediate 50, 14.0 g, 62.98 mmol) in dichloromethane (200 mL) was added Dess-Martin periodinane (40.07 g, 94.47 mmol) at 0°C. The reaction mixture was then stirred at room temperature for 2h. The reaction mixture was filtered through celite, filtrates were quenched with saturated NaHCO3solution (200 mL) and extracted with ethyl acetate (3 × 200 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude material was purified by combi-flash chromatography by eluting with 30% ethyl acetate in heptane to afford methyl 4-(5- oxopentyl)benzoate (Intermediate 51, 8.00 g, 58%) as yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.47-1.64 (m, 4H), 2.21-2.25 (m, 1H), 2.43-2.48 (m, 1H), 2.61-2.69 (m, 2H), 3.83 (s, 3H), 7.34 (d, J=8.20 Hz, 2H), 7.87 (d, J=8.20 Hz, 2H), 9.65 (s, 1H). Step 4 Intermediate 52: methyl 4-(hex-5-yn-1-yl)benzoate To a solution of methyl 4-(5-oxopentyl)benzoate (Intermediate 51, 8.00 g, 36.3 mmol) in methanol (200 mL) was added potassium carbonate (6.01 g, 43.6 mmol) at 0°C. Dimethyl (1- diazo-2-oxopropyl)phosphonate (9.08 mL, 54.5 mmol) was added dropwise to the reaction mixture, at 0°C, over 20 min and the reaction mixture was stirred at -30°C for 3h. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic phases were dried over anhydrous Na2SO4and concentrated in vacuo to obtain crude compound. The crude material was purified by combi-flash chromatography by eluting with 10% ethyl acetate in heptane to afford methyl 4-(hex-5-yn-1-yl) benzoate (Intermediate 52, 4.00 g, 51%) as yellow liquid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.40- 1.50 (m, 2H), 1.60-1.72 (m, 2H), 2.17 (t, J=6.40 Hz, 2H), 2.66 (t, J=6.40 Hz, 2H), 2.73 (s, 1H), 3.83 (s, 3H), 7.34 (d, J=8.0 Hz, 2H), 7.87 (d, J=8.0 Hz, 2H). Step 5 Intermediate 53: 4-(hex-5-yn-1-yl)benzoic acid To a solution of methyl 4-(hex-5-yn-1-yl)benzoate (Intermediate 52, 4.00 g, 18.5 mmol) in tetrahydrofuran (50 mL), methanol (100 mL) and water (50 mL) was added lithium hydroxide (0.90 g, 37 mmol) and the reaction mixture was stirred at room temperature for 5h. The reaction mixture was concentrated in vacuo and diluted with water (50 mL) and the aqueous phase was extracted with ethyl acetate (1 × 100 mL). The aqueous layer was then acidified up to pH~4 with 1N HCl and extracted with ethyl acetate (3 × 300 mL). The combined organic phases were dried over Na2SO4,and concentrated in vacuo to afford 4-(hex-5-yn-1-yl) benzoic acid (Intermediate 53, 3.3 g) as a white solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 1.42-1.50 (m, 2H), 1.63-1.72 (m, 2H), 2.12- 2.23 (m, 2H), 2.65 (t, J=7.60 Hz, 2H), 2.74 (s, 1H), 7.31 (d, J=8.0 Hz, 2H), 7.85 (d, J=8.0 Hz, 2H), 12.77 (br s, 1H). Mass spec: m / z: 201.5 [M-H]-. Step 6 Intermediate 54: 4-(hex-5-yn-1-yl)benzamide To a solution of 4-(hex-5-yn-1-yl)benzoic acid (Intermediate 53, 3.3 g, 16 mmol) in dimethylformamide (60 mL) was added HATU (9.6 g, 24 mmol) and N, N- diisopropylethylamine (8.5 mL, 49 mmol) and the reaction was stirred at room temperature for 10 min. Ammonium chloride (4.4 g, 82 mmol) was added at 0°C and the reaction mixture was stirred at room temperature for 16h. The reaction mixture was diluted with ice cold water (200 mL), resulting in a precipitate which was filtered, washed with water (100 mL) and dried under vacuum to afford 4-(hex-5-yn-1-yl)benzamide (Intermediate 54, 2.70 g, 82%) as a white solid, which was used for next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 1.41-1.50 (m, 2H), 1.61-1.70 (m, 2H), 2.13-2.22 (m, 2H), 2.63 (d, J=7.60 Hz, 2H), 2.74 (s, 1H), 7.24 (br s, 1H), 7.26 (d, J=7.60 Hz, 2H), 7.78 (d, J=7.60 Hz, 2H), 7.88 (br s, 1H). Mass spec: m / z: 202.5 [M+H]+. Step 7 Intermediate 55: tert-butyl 6-(6-(4-carbamoylphenyl) hex-1-yn-1-yl)picolinate To a solution of 4-(hex-5-yn-1-yl)benzamide (Intermediate 54, 0.25 g, 1.24 mmol) in dimethylformamide (3 mL) was added tert-butyl 6-bromopicolinate (CAS No: 910044-07-4, 0.42 g, 1.61 mmol) followed by N, N-diisopropylethylamine (0.7 mL, 3.73 mmol). The reaction mixture was purged with argon for 15 min followed by the addition of copper(I) iodide (0.025 g, 0.12 mmol) and PdCl2(PPh3)2(0.14 g, 0.18 mmol). The reaction mixture was further purged with argon for 10 min and then stirred at room temperature for 1h. The reaction mixture was quenched with ice cold water (50 mL) and extracted with ethyl acetate (2 × 100 mL). The combined organic phases were dried over anhydrous Na2SO4and concentrated in vacuo. The crude material was purified by combi-flash chromatography by eluting with 70% ethyl acetate in heptane to afford tert-butyl 6-(6-(4-carbamoylphenyl)hex-1-yn-1-yl)picolinate (Intermediate 55, 0.2 g, 42%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.53 (s, 9H), 1.68-1.77 (m, 2H), 2.64-2.73 (m, 4H), 2.84-2.88 (m, 2H), 7.24 (br s, 1H), 7.26-7.28 (m, 2H), 7.61 (d, J=7.60 Hz, 1H), 7.77 (d, J=7.60 Hz, 2H), 7.86 (br s, 1H), 7.88-7.93 (m, 2H). Mass spec: m / z: 379.3 [M+H]+. Step 8 Intermediate 56: tert-butyl (R)-6-(4-(6-(6-(tert-butoxycarbonyl) pyridin-2-yl)hex-5-yn-1- yl)benzamido)-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3, 2-c]pyridine-1-carboxylate To a solution of tert-butyl 6-(6-(4-carbamoylphenyl)hex-1-yn-1-yl) picolinate (Intermediate 55, 0.16 g, 0.42 mmol) in 1,4-dioxane (3 mL) was added tert-butyl (R)-6-bromo-2-(1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 4, 0.2 g, 0.52 mmol) followed by cesium carbonate (0.54 g, 1.57 mmol) at room temperature. The reaction mixture was purged with argon for 15 min followed by the addition of Pd2(dba)3(0.067 g, 0.078 mmol) and Xantphos (0.096 g, 0.16 mmol). The reaction mixture was further purged with argon for 10 min and then heated at 95°C for 5h. The reaction mixture was concentrated in vacuo to obtain crude compound, which was purified by combi-flash chromatography by eluting with 7% MeOH in DCM to afford tert-butyl (R)-6-(4-(6-(6-(tert-butoxycarbonyl)pyridin-2-yl)hex-5-yn- 1-yl)benzamido)-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 56, 0.2 g, 34%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.55 (s, 9H), 1.57-1.64 (m, 4H), 1.69 (s, 9H), 1.74-1.80 (m, 4H), 2.27-2.33 (m, 1H), 2.35 (s, 3H), 2.38- 2.40 (m, 1H), 2.65-2.77 (m, 3H), 3.12-3.16 (m, 1H), 3.87-3.97 (m, 1H), 6.74 (s, 1H), 7.34-7.36 (m, 1H), 7.59-7.67 (m, 1H), 7.77-7.80 (m, 1H), 7.88-8.01 (m, 4H), 8.58 (s, 1H), 8.92 (s, 1H), 10.59 (br s, 1H). Mass spec: m / z: 678.4 [M+H]+. Step 9 Intermediate 57: (R)-6-(6-(4-((2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)carbamoyl) phenyl) hex-1-yn-1-yl)picolinic acid trifluoroacetate To a solution of tert-butyl (R)-6-(4-(6-(6-(tert-butoxycarbonyl)pyridin-2-yl)hex-5-yn-1- yl)benzamido)-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 56, 0.2 g, 0.29 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (0.57 mL, 7.37 mmol) at 0°C. The reaction mixture was then stirred at room temperature for 16h. The reaction mixture was concentrated in vacuo to obtain crude compound, which was washed with diethyl ether (5 × 2 mL) and dried in vacuo to afford (R)-6-(6-(4-((2-(1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)carbamoyl)phenyl)hex-1-yn-1- yl)picolinic acid trifluoroacetate (Intermediate 57, 0.2 g, 65%) as a red gum, which was used in the next step without further purification. Mass spec: m / z: 522.1 [M+H]+. Step 10 Example 7: N-((S)-2,6-dioxopiperidin-3-yl)-6-(6-(4-((2-((R)-1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl)carbamoyl)phenyl)hex-1-yn-1-yl)picolinamide To a solution of (R)-6-(6-(4-((2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c] pyridin-6-yl)carbamoyl) phenyl) hex-1-yn-1-yl) picolinic acid trifluoroacetate (Intermediate 57, 0.19 g, 0.29mmol) in dimethylformamide (3 mL) was added HATU (0.23 g, 0.59 mmol) and N, N- diisopropylethylamine (0.2 mL, 0.89 mmol) at 0°C and the reaction stirred for 10 min. (S)-3- aminopiperidine-2,6-dione hydrochloride (CAS No: 25181-50-4, 0.074 g, 0.45 mmol) was added at 0°C and the reaction mixture was stirred at room temperature for 3h. The reaction mixture was poured into ice cold water (50 mL), resulting in a precipitate which was filtered and dried under vacuum to obtain the crude compound. The crude material was purified by preparative HPLC (Method A) to afford N-((S)-2,6-dioxopiperidin-3-yl)-6-(6-(4-((2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)carbamoyl)phenyl)hex-1-yn-1- yl)picolinamide (Example 7, 0.025 g, 13%d) as an off white solid.1H NMR (400 MHz, DMSO- d6) δ ppm 1.58-1.66 (m, 2H), 1.75-2.03 (m, 6H), 2.11-2.15 (m, 1H), 2.17 (s, 3H), 2.21-2.30 (m, 2H), 2.53-2.57 (m, 3H), 2.69-2.85 (m, 3H), 3.08-3.19 (m, 1H), 3.28-3.30 (m, 1H), 4.75-4.85 (m, 1H), 6.39 (s, 1H), 7.34-7.36 (m, 2H), 7.66-7.70 (m, 1H), 7.95-8.01 (m, 4H), 8.19 (s, 1H), 8.50 (s, 1H), 8.94-8.98 (m, 1H), 10.33 (br s, 1H), 10.89 (br s, 1H), 11.35 (br s, 1H). Mass spec: m / z: 632.1 [M+H]+. Example 8 was synthesised following Scheme 11 Scheme 11 Step 1 Intermediate 58: 4-(6-(2-(2,6-dioxo-1-((2-(trimethylsilyl) ethoxy) methyl) piperidin-3-yl)- 1-oxoisoindolin-4-yl) hex-5-yn-1-yl)benzamide To a solution of 4-(hex-5-yn-1-yl)benzamide (Intermediate 54, 0.60 g, 2.98 mmol) in dimethylformamide (2 mL) was added 3-(4-iodo-1-oxoisoindolin-2-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione (Intermediate 8, 1.49 g, 2.98 mmol) followed by triethylamine (14.6 mL, 104.3 mmol). The reaction mixture was purged with argon for 15 min, then copper (I) iodide (0.057 g, 0.29 mmol) and PdCl2(PPh3)2(0.22 g, 0.29 mmol) were added. The reaction mixture was further purged with argon for 10 min and stirred at room temperature for 2h. The reaction mixture was then diluted with water (100 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic layers were dried over anhydrous Na2SO4,and concentrated in vacuo. The crude material was purified by combi-flash chromatography, by eluting with 90% ethyl acetate in heptane, to afford 4-(6-(2-(2,6-dioxo-1- ((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)benzamide (Intermediate 58, 1.00 g, 58%) as an off- white solid. 1H NMR (400 MHz,DMSO-d6) δ ppm -0.06 (s, 9H), 0.76-0.87 (m, 2H), 1.52-1.62 (m, 2H), 1.68-1.78 (m, 2H), 1.99- 2.08 (m, 1H), 2.33-2.38 (m, 1H), 2.42-2.46 (m, 2H), 2.64-2.68 (m, 2H), 2.75-2.80 (m, 1H), 2.99-3.10 (m, 1H), 3.46-3.54 (m, 2H), 4.20-4.26 (m, 1H), 4.40-4.44 (m, 1H), 4.98-5.08 (m, 2H), 5.21-5.26 (m, 1H), 7.22 (br s, 1H), 7.25 (d, J=8.0 Hz, 2H), 7.50 (t, J=7.60 Hz, 1H), 7.62 (d, J=7.60 Hz, 1H), 7.69 (d, J=7.60 Hz, 1H), 7.76 (d, J=8.0 Hz, 2H), 7.84 (br s, 1H). Mass spec m / z 572.52 [M+H]+. Step 2 Intermediate 59: tert-butyl-6-(4-(6-(2-(2,6-dioxo-1-((2- (trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1- yl)benzamido)-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate To a solution of 4-(6-(2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1- oxoisoindolin-4-yl)hex-5-yn-1-yl) benzamide (Intermediate 58, 0.40 g, 0.69 mmol) in 1,4- dioxane (10 mL) was added tert-butyl (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridine-1-carboxylate (Intermediate 4, 0.26 g, 0.69 mmol) followed by cesium carbonate (0.46 g, 1.39 mmol). The reaction mixture was purged with argon for 15 min, then Pd2(dba)3(0.098 g, 0.10 mmol) and Xantphos (0.12 g, 0.21 mmol) were added. The reaction mixture was further purged with argon for 10 min and then heated at 100°C for 2h. The reaction mixture was concentrated in vacuo and the crude material was purified by combi-flash chromatography, by eluting with 90% ethyl acetate in heptane, to afford tert-butyl-6-(4-(6-(2-(2,6-dioxo-1-((2- (trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)benzamido)- 2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 59,0.45 g, 74%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ ppm -0.05 (s, 9H), 0.76-0.86(m, 2H), 1.58-1.66 (m, 4H), 1.69 (s, 9H), 1.73-1.82 (m, 4H), 2.02-2.10 (m, 1H), 2.28-2.33 (m, 2H), 2.35 (s, 3H), 2.37-2.42 (m, 1H), 2.66-2.78 (m, 4H), 3.01-3.17 (m, 2H), 3.47-3.54 (m, 2H), 3.88-3.94 (m, 1H), 4.24-4.28 (m, 1H), 4.43-4.50 (m, 1H), 4.98-5.08 (m, 2H), 5.24-5.30 (m, 1H), 6.75 (s, 1H), 7.34 (d, J=8.0 Hz, 2H), 7.53 (t, J=7.20 Hz, 1H), 7.65 (d, J=8.0 Hz, 1H), 7.72 (d, J=7.20 Hz, 1H), 7.97 (d, J=7.20 Hz, 2H), 8.58 (s, 1H), 8.93 (s, 1H), 10.60 (s, 1H). Mass spec m / z 873.57 [M+H]+. Step 3 Example 8: 4-(6-(2-(2, 6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide To a solution of tert-butyl-6-(4-(6-(2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin- 3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)benzamido)-2-((R)-1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 59, 0.40 g, 0.54 mmol) in acetonitrile (5 mL) was added methanesulfonic acid (0.53 mL, 8.07 mmol) at room temperature and the reaction mixture was heated at 50°C for 2h. After cooling to room temperature, N, N’- dimethylethylenediamine (0.39 mL, 3.23 mmol) followed by triethylamine (1.10 g, 10.77 mmol were added the reaction mixture was stirred at room temperature for 3h. The reaction mixture was diluted with water (100 mL), the resultant precipitate was collected by filtration and dried in vacuo. The crude material was purified by preparative HPLC (Method A) to afford 4-(6-(2- (2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-N-(2-((R)-1-methylpyrrolidin-2- yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide (Example 8, 0.15 g, 44%) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.58-1.66 (m, 2H), 1.74-1.95 (m, 5H), 1.97-2.05 (m, 1H), 2.10-2.15 (m, 1H), 2.17 (s, 3H), 2.23-2.30 (m, 1H), 2.40-2.45 (m, 1H), 2.53-2.58 (m, 2H), 2.59-2.64 (m, 1H), 2.70-2.76 (m, 2H), 2.85-2.96 (m, 1H), 3.10-3.17 (m, 1H), 3.32-3.36 (m, 1H), 4.28-4.36 (m, 1H), 4.40-4.48 (m, 1H), 5.11-5.16 (m, 1H), 6.39 (s, 1H), 7.34 (d, J=8.0 Hz, 2H), 7.52 (t, J=8.0 Hz, 1H), 7.63 (d, J=7.60 Hz, 1H), 7.70 (d, J=7.60 Hz, 1H), 7.98 (d, J=8.0 Hz, 2H), 8.18 (s, 1H), 8.49 (s, 1H), 10.33 (s, 1H), 11.01 (br s, 1H), 11.35 (s, 1H). Mass spec m / z 643.5 [M+H]+. Example 9 was synthesised following Scheme 12

[0017] Scheme 12 Step 1 Intermediate 60: 3-(4-methoxybenzyl) dihydropyrimidine-2,4(1H, 3H)-dione To a solution of dihydropyrimidine-2,4(1H,3H)-dione (CAS No: 504-07-4, 5.00 g, 43.82 mmol) in dimethylformamide (150 mL) was added cesium carbonate (28.56 g, 87.64 mmol) followed by 4-methoxybenzyl chloride (4.06 mL, 28.48 mmol) and the reaction mixture was stirred at room temperature for 16h. The reaction mixture was quenched with ice cold water (1500 mL) and stirred for 30 min, resulting in a precipitate, which was filtered and dried in vacuo to afford 3-(4-methoxybenzyl)dihydropyrimidine-2,4(1H,3H)-dione (Intermediate 60, 4.50 g, 44%) as an off white solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 2.62 (t, J=6.80 Hz, 2H), 3.19-3.23 (m, 2H), 3.71 (s, 3H), 4.71 (s, 2H), 6.83-6.85 (m, 2H), 7.16-7.18 (m, 2H), 7.80 (br s, 1H). Step 2 Intermediate 61: 1-(6-bromopyridin-2-yl)-3-(4-methoxybenzyl) dihydropyrimidine-2,4(1H, 3H)-dione To a solution of 2,6-dibromopyridine (CAS No: 626-05-1, 7.00 g, 29.5 mmol) in dimethylformamide (10 mL) was added 3-(4-methoxybenzyl)dihydropyrimidine-2,4(1H, 3H)- dione (Intermediate 60, 4.15 g, 17.7 mmol) followed by K2CO3(12.3 g, 88.6 mmol). The reaction mixture was purged with argon gas for 15 min then copper(I) iodide (0.56 g, 2.95 mmol) and N, N'-dimethylethylenediamine (0.53 g, 5.91 mmol) were added and the reaction mixture was heated at 110°C for 16h. The reaction mixture was filtered and washed with ethyl acetate (100 mL). the organic phases was washed with ice cold water (100 mL), dried over Na2SO4,and concentrated in vacuo. The crude material was purified by combi-flash column chromatography by eluting with 20% ethyl acetate in heptane to afford 1-(6-bromopyridin-2- yl)-3-(4-methoxybenzyl)dihydropyrimidine-2,4(1H,3H)-dione (Intermediate 61, 3.4 g, 29%) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 2.88 (t, J=6.80 Hz, 2H), 3.72 (s, 3H), 4.02 (t, J=6.80 Hz, 2H), 4.83 (s, 2H), 6.84-6.86 (m, 2H), 7.22-7.25 (m, 2H), 7.42-7.47 (m, 1H), 7.76-.7.79 (m, 2H). Step 3 Intermediate 62: 1-(6-bromopyridin-2-yl) dihydropyrimidine-2, 4(1H, 3H)-dione To a solution of 1-(6-bromopyridin-2-yl)-3-(4-methoxybenzyl)dihydropyrimidine-2, 4(1H, 3H)- dione (Intermediate 61, 4.00 g, 10.3 mmol) in trifluoroacetic acid (40 mL) was added trifluoromethanesulfonic acid (10.00 mL) and the reaction was stirred at room temperature for 16h. The reaction mixture was concentrated at a lower temperature. The obtained residue was quenched with saturated NaHCO3,to pH~8, resulting in a precipitate which was collected by filtration, washed with saturated NaHCO3solution (50 mL) and water (50 mL) and dried in vacuo to afford 1-(6-bromopyridin-2-yl) dihydropyrimidine-2,4(1H, 3H)-dione (Intermediate 62, 3.50 g) as a brown solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 2.66-2.70 (m, 2H), 4.01-4.04 (m, 2H), 7.40-7.44 (m, 1H), 7.72-7.79 (m, 1H), 7.80-7.86 (m, 1H), 10.63 (br s, 1H). Mass spec: m / z: 270.2 [M+H]+. Step 4 Intermediate 63: 4-(6-(6-(2, 4-dioxotetrahydropyrimidin-1(2H)-yl) pyridin-2-yl)hex-5-yn- 1-yl)benzamide To a solution of 4-(hex-5-yn-1-yl)benzamide (Intermediate 54, 0.65 g, 3.23 mmol) in dimethylformamide (15 mL) was added 1-(6-bromopyridin-2-yl)dihydropyrimidine-2,4(1H, 3H)-dione (Intermediate 62, 1.04 g, 3.87 mmol) followed by triethylamine (15.8 mL, 113.0 mmol). The reaction mixture was purged with argon for 15 min and then copper(I) iodide (0.064 g, 0.32 mmol) and PdCl2(PPh3)2(0.23 g, 0.32 mmol) were added. The reaction mixture was further purged with argon for 10 min and stirred at room temperature for 2h. The reaction mixture was quenched with ice cold water (80 mL) and extracted with ethyl acetate (2 × 150 mL). The combined organic phases were dried over anhydrous Na2SO4and concentrated in vacuo. The crude material was purified by combi-flash chromatography by eluting with 100% ethyl acetate to afford 4-(6-(6-(2, 4-dioxotetrahydropyrimidin-1(2H)-yl) pyridin-2-yl) hex-5-yn-1-yl)benzamide (Intermediate 63, 0.80 g, 63%) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.51-1.60 (m, 2H), 1.70-1.80 (m, 2H), 2.44-2.47 (m, 2H), 2.63-2.71 (m, 4H), 3.98- 4.04 (m, 2H), 7.21-7.29 (m, 4H), 7.68-7.80 (m, 4H), 7.88 (br s, 1H), 10.54 (s, 1H). Mass spec: m / z: 391.2 [M+H]+. Step 5 Intermediate 64: tert-butyl (R)-6-(4-(6-(6-(2, 4-dioxotetrahydropyrimidin-1(2H)- yl)pyridin-2-yl)hex-5-yn-1-yl)benzamido)-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3, 2- c]pyridine-1-carboxylate To a solution of 4-(6-(6-(2,4-dioxotetrahydropyrimidin-1(2H)-yl) pyridin-2-yl) hex-5-yn-1-yl)benzamide (Intermediate 63, 0.50 g, 1.28 mmol) in 1,4-dioxane (20 mL) was added tert-butyl (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 4, 0.58 g, 1.54 mmol) followed by cesium carbonate (1.25 g, 3.84 mmol) at room temperature. The reaction mixture was purged with argon for 15 min and then Pd2(dba)3(0.18 g, 0.19 mmol) and Xantphos (0.23 g, 0.38 mmol) were added. The reaction mixture was further purged with argon for 10 min and stirred at 100°C for 2h. The reaction mixture was filtered through celite, washed with ethyl acetate (100 mL) and filtrate was concentrated in vacuo to obtain crude compound. The crude material was purified by combi-flash column chromatography by eluting with 5% MeOH in DCM to afford tert-butyl (R)-6-(4-(6-(6-(2, 4- dioxotetrahydropyrimidin-1(2H)-yl)pyridin-2-yl)hex-5-yn-1-yl)benzamido)-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3, 2-c]pyridine-1-carboxylate (Intermediate 64, 0.50 g,57%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.55-1.66 (m, 4H), 1.69 (s, 9H), 1.72-1.81 (m, 4H), 2.29-2.32 (m, 1H), 2.35 (s, 3H), 2.37-2.42 (m, 2H), 2.64-2.77 (m, 4H), 3.07- 3.18 (m, 1H), 3.88-3.95 (m, 1H), 3.98-4.06 (m, 2H), 6.75 (s, 1H), 7.22-7.26 (m, 1H), 7.35 (d, J= 8.20 Hz, 2H), 7.67-7.79 (m, 2H), 7.98 (d, J= 8.20 Hz, 2H), 8.59 (s, 1H), 8.92 (s, 1H), 10.55 (br s, 1H), 10.61 (br s, 1H). Mass spec: m / z: 690.0 [M+H]+. Step 6 Example 9: (R)-4-(6-(6-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)pyridin-2-yl)hex-5-yn-1- yl)-N-(2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide To a solution of tert-butyl (R)-6-(4-(6-(6-(2,4-dioxotetrahydropyrimidin-1(2H)-yl) pyridin-2- yl)hex-5-yn-1-yl) benzamido)-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c]pyridine-1-carboxylate (Intermediate 64, 0.40 g, 0.58 mmol) in dichloromethane (10 mL) was addedtrifluoroacetic acid (5 mL) at 0°C and the reaction mixture was stirred at room temperature for1h. The volatiles were removed under reduced pressure and co-distilled with DCM to obtain the crude compound which was purified by preparative HPLC (Method A) to afford (R)-4-(6-(6- (2,4-dioxotetrahydropyrimidin-1(2H)-yl)pyridin-2-yl)hex-5-yn-1-yl)-N-(2-(1-methylpyrrolidin- 2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide (Example 9, 0.15 g, 44%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.55-1.64 (m, 2H), 1.72-1.94 (m, 5H), 2.10-2.14 (m, 1H), 2.16 (s, 3H), 2.22-2.30 (m, 1H), 2.42-2.47 (m, 1H), 2.52-2.56 (m, 2H), 2.66-2.75 (m, 4H), 3.08- 3.21 (m, 1H), 4.01-4.04 (m, 2H), 6.39 (s, 1H), 7.23-7.25 (m, 1H), 7.32-7.36 (m, 2H), 7.69-7.80 (m, 2H), 7.96-8.00 (m, 2H), 8.18 (s, 1H), 8.49 (s, 1H), 10.35 (br s, 1H), 10.55 (br s, 1H), 11.36 (br s, 1H). Mass spec: m / z: 590.2 [M+H]+. Example 10 was synthesised following Scheme 13 Scheme 13 Step 1 Intermediate 65: methyl 6-(5-hydroxypent-1-yn-1-yl)nicotinate To a solution of methyl 6-bromonicotinate (CAS No: 26218-78-0 , 12.0 g, 54.4 mmol) in dimethylformamide (80 mL) was added pent-4-yn-1-ol (CAS No: 5390-04-5, 7.0 mL, 70.8 mmol) followed by triethylamine (229 mL, 1630 mmol). The reaction mixture was purged with argon gas for 15 min. PdCl2(PPh3)2(5.91 g, 8.17 mmol) and copper(I) iodide (1.64 g, 8.17 mmol) were then added and the reaction mixture was further purged with argon gas for 10 min and stirred at room temperature for 2h. The reaction mixture was diluted with cold water (200 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic phases were washed with brine solution (2 × 100 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by combi-flash chromatography by eluting with 60% ethyl acetate in heptane to afford methyl 6-(5-hydroxypent-1-yn-1-yl) nicotinate (Intermediate 65, 10.0 g, 84%) as a liquid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.68-1.76 (m, 2H), 2.54 (t, J=7.20 Hz, 2H), 3.43 (t, J=6.0 Hz, 1H), 3.51-3.55 (m, 2H), 3.88 (s, 3H), 7.58 (d, J=8.0 Hz, 1H), 8.23 (d, J=8.0 Hz, 1H), 9.00 (s, 1H). Mass spec: m / z: 220.4 [M+H]+. Step 2 Intermediate 66: methyl 6-(5-hydroxypentyl)nicotinate To a solution of methyl 6-(5-hydroxypent-1-yn-1-yl)nicotinate (Intermediate 65, 10.0 g, 45.61 mmol) in methanol (150 mL) was added 10% Pd / C (3.88 g, 36.49 mmol). The reaction mixture was heated at 50°C for 5h under an H2(140 psi). The reaction mixture was filtered through celite, washed with methanol (100 mL) and concentrated in vacuo to afford methyl 6-(5- hydroxypentyl)nicotinate (Intermediate 66, 8.00 g, 79%) as a yellow liquid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 1.25-1.33 (m, 2H), 1.38-1.46 (m, 2H), 1.63-1.70 (m, 2H), 2.78 (t, J=7.60 Hz, 2H), 3.32-3.38 (m, 2H), 3.85 (s, 3H), 4.31 (t, J=4.80 Hz, 1H), 7.40 (d, J=8.40 Hz, 1H), 8.17 (d, J=8.40 Hz, 1H), 8.97 (s, 1H). Step 3 Intermediate 67: methyl 6-(5-oxopentyl)nicotinate To a solution of methyl 6-(5-hydroxypentyl)nicotinate (Intermediate 66, 8.00 g, 36 mmol) in dichloromethane (100 mL) was added Dess-Martin periodinane (23.0 g, 54 mmol) at 0°C. The reaction mixture was then stirred at room temperature for 2h. The reaction mixture was quenched with aqueous saturated NaHCO3 solution (200 mL) followed by aqueous sodium thiosulfate (200 mL) solution and extracted with ethyl acetate (2 × 250 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by combi-flash chromatography by eluting with 25% ethyl acetate in heptane to afford methyl 6-(5-oxopentyl) nicotinate (Intermediate 67, 4.00 g, 50%) as a yellow liquid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.48-1.56 (m, 2H), 1.64-1.72 (m, 2H), 2.41-2.46 (m, 2H), 2.80 (t, J=7.20 Hz, 2H), 3.85 (s, 3H), 7.41 (d, J=7.80 Hz, 1H), 8.17 (d, J=7.80 Hz, 1H), 8.97 (s, 1H), 9.64 (s, 1H). Mass spec: m / z: 222.5 [M+H]+. Step 4 Intermediate 68: methyl 6-(hex-5-yn-1-yl)nicotinateTo a solution of methyl 6-(5-oxopentyl)nicotinate (Intermediate 67, 4.00 g, 18.1 mmol) inmethanol (100 mL) was added potassium carbonate (2.99 g, 21.7 mmol) at 0°C, then dimethyl (1-diazo-2-oxopropyl) phosphonate (Comp-6, 4.52 mL, 27.1 mmol) was added dropwise to the reaction mixture for over 5 min. The reaction mixture was then stirred at room temperature for 16h. The reaction mixture was concentrated and water (50 mL) was added and extracted with ethyl acetate (3 × 50 mL). The combined organic phases were dried over anhydrous Na2SO4, and concentrated in vacuo to obtain crude compound which was purified by combi-flash chromatography by eluting with 10% ethyl acetate in heptane to afford methyl 6-(hex-5-yn-1-yl)nicotinate (Intermediate 68, 2.90 g, 74%) as a colorless liquid. 1H NMR (400 MHz, DMSO-d6)δ ppm 1.42-1.52 (m, 2H), 1.71-1.82 (m, 2H), 2.15-2.23 (m, 2H), 2.74 (s, 1H), 2.82 (t, J=7.60 Hz, 2H), 3.87 (s, 3H), 7.42 (d, J=8.40 Hz, 1H), 8.19 (d, J=8.40 Hz, 1H), 8.99 (s, 1H). Mass spec: m / z: 218.1 [M+H]+. Step 5 Intermediate 69: 6-(hex-5-yn-1-yl)nicotinic acidTo a solution of methyl 6-(hex-5-yn-1-yl)nicotinate (Intermediate 68, 2.80 g, 12.9 mmol) intetrahydrofuran (12 mL), methanol (12 mL) and water (12 mL) was added lithium hydroxide (0.94 g, 38.7 mmol) and the reaction mixture was stirred at room temperature for 16h. The reaction mixture was concentrated in vacuo. The crude residue was acidified by the addition of 1N HCl to pH~5 and then extracted with ethyl acetate (2 × 200 mL). The combined organic phases were dried over anhydrous Na2SO4and concentrated in vacuo to afford 6-(hex-5-yn-1- yl)nicotinic acid (Intermediate 69, 2.2 g, 84%) as an off-white solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 1.41-1.49 (m, 2H), 1.71-1.80 (m, 2H), 2.10-2.23 (m, 2H), 2.73 (s, 1H), 2.80 (t, J=7.60 Hz, 2H), 7.37 (d, J=8.00 Hz, 1H), 8.14 (d, J=8.00 Hz, 1H), 8.95 (s, 1H), 13.21 (br s, 1H). Mass spec: m / z: 204.5 [M+H]+. Step 6 Intermediate 70: 6-(hex-5-yn-1-yl)nicotinamide To a solution of 6-(hex-5-yn-1-yl)nicotinic acid (Intermediate 69, 2.00 g, 9.84 mmol) in dimethylformamide (20 mL) was added HATU (5.79 g, 14.8 mmol) and the reaction stirred at room temperature for 10 min. Ammonium chloride (2.64 g, 49.2 mmol) and N, N- diisopropylethylamine (5.15 mL, 29.5 mmol) were then added and the reaction mixture was stirred at room temperature for 16h. The reaction mixture was poured into ice cold water (100 mL), resulting in a precipitate, which was collected by filtration and washed with water (2 × 50 mL) and dried under reduced pressure to afford 6-(hex-5-yn-1-yl)nicotinamide (Intermediate 70, 1.20 g, 60%) as an off-white solid, which was used for next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 1.41-1.51 (m, 2H), 1.71-1.81 (m, 2H), 2.15-2.22 (m, 2H), 2.75 (s, 1H), 2.79 (t, J=7.60 Hz, 2H), 7.34 (d, J=8.0 Hz, 1H), 7.48 (br s, 1H), 8.06 (br s, 1H), 8.09 (d, J=8.0 Hz, 1H), 8.92 (s, 1H). Mass spec: m / z: 203.5 [M+H]+. Step 7 Intermediate 71: 6-(6-(2-(2, 6-dioxo-1-((2-(trimethylsilyl) ethoxy) methyl) piperidin-3-yl)- 1-oxoisoindolin-4-yl) hex-5-yn-1-yl)nicotinamide To a solution of 6-(hex-5-yn-1-yl) nicotinamide (Intermediate 70, 0.30 g, 1.48 mmol) in dimethylformamide (5 mL) was added 3-(4-iodo-1-oxoisoindolin-2-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione (Intermediate 8, 0.81 g, 1.63 mmol) followed by triethylamine (7.27 mL, 51.91 mmol). The reaction mixture was purged with argon for 15 min then copper (I) iodide (0.029 g, 0.15 mmol) and PdCl2(PPh3)2(0.11 g, 0.15 mmol) were added. The reaction mixture was further purged with argon for 10 min and stirred at room temperature for 2h. The reaction mixture was filtered through celite, washed with ethyl acetate (100 mL) and the filtrate was concentrated in vacuo to obtain crude compound. The crude material was purified by combi-flash chromatography by eluting with 2% MeOH in DCM to afford 6-(6-(2-(2, 6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisoindolin- 4-yl)hex-5-yn-1-yl)nicotinamide (Intermediate 71, 0.45 g, 53%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm -0.04 (s, 9H), 0.77-0.89 (m, 2H), 1.56-1.66 (m, 2H), 1.79-1.93 (m, 3H), 2.02-2.11 (m, 1H), 2.31-2.43 (m, 2H), 2.75-2.88 (m, 3H), 3.01-3.12 (m, 1H), 3.47-3.57 (m, 2H), 4.24-4.28 (m, 1H), 4.43-4.48 (m, 1H), 4.99-5.10 (m, 2H), 5.24-5.28 (m, 1H), 7.35 (d, J=8.0 Hz, 1H), 7.50 (br s, 1H), 7.52-7.54 (m, 1H), 7.64 (d, J=7.46 Hz, 1H), 7.72 (d, J=7.46 Hz, 1H), 8.05 (br s, 1H), 8.10 (d, J=8.0 Hz, 1H), 8.92 (br s, 1H). Mass spec: m / z: 575.1 [M+H]+. Step 8 Intermediate 72: tert-butyl 6-(6-(6-(2-(2,6-dioxo-1-((2- (trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1- yl)nicotinamido)-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate To a solution of 6-(6-(2-(2, 6-dioxo-1-((2-(trimethylsilyl) ethoxy) methyl) piperidin-3-yl)-1- oxoisoindolin-4-yl) hex-5-yn-1-yl) nicotinamide (Intermediate 71, 0.41 g, 0.71 mmol) in 1,4- dioxane (15 mL) was added tert-butyl (R)-6-bromo-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 4, 0.32 g, 0.85 mmol) followed by cesium carbonate(0.69 g, 2.14 mmol) at room temperature. The reaction mixture was purged with argon for 15 min then Pd2(dba)3(0.10 g, 0.11 mmol) and Xantphos (0.13 g, 0.21 mmol) were added. The reaction mixture was further purged with argon for 10 min and then stirred at 100°C for 2h. The reaction mixture was filtered through celite, washed with ethyl acetate (100 mL) and the filtrate was concentrated in vacuo to obtain the crude compound. The crude material was purified by combi-flash chromatography by eluting with 5% MeOH in DCM to afford tert-butyl 6-(6-(6-(2- (2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn- 1-yl)nicotinamido)-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 72, 0.31 g, 50%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm -0.05 (s, 9H), 0.77-0.86 (m, 2H), 1.56-1.66 (m, 4H), 1.69 (s, 9H), 1.74-1.76 (m, 2H), 1.83-1.93 (m, 2H), 2.02-2.11 (m, 1H), 2.28-2.33 (m, 1H), 2.35 (s, 3H), 2.38-2.42 (m, 1H), 2.53-2.58 (m, 2H), 2.74-2.90 (m, 3H), 3.01-3.16 (m, 2H), 3.44-3.55 (m, 2H), 3.90-3.94 (m, 1H), 4.25-4.29 (m, 1H), 4.45-4.49 (m, 1H), 4.98-5.09 (m, 2H), 5.24-5.28 (m, 1H), 6.76 (s, 1H), 7.41 (d, J=8.0 Hz, 1H), 7.50-7.56 (m, 1H), 7.65 (d, J=7.60 Hz, 1H), 7.72 (d, J=7.60 Hz, 1H), 8.28 (d, J=80 Hz, 1H), 8.60 (s, 1H), 8.93 (s, 1H), 9.06 (s, 1H), 10.91 (br s, 1H). Mass spec: m / z: 873.8 [M+H]+. Step 9 Example 10: 6-(6-(2-(2, 6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl) hex-5-yn-1-yl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c] pyridin-6-yl) nicotinamide To a solution of tert-butyl 6-(6-(6-(2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin- 3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)nicotinamido)-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 72, 0.30 g, 0.34 mmol) in acetonitrile (8mL) was added methanesulfonic acid (0.22 mL, 3.43 mmol) and the reaction stirred at 50°C for 2h. N,N’-dimethylethylenediamine (0.41 mL, 3.43 mmol) and triethylamine (0.96 mL, 6.86 mmol) were added at room temperature and the reaction mixture was stirred at room temperature for 2h. The reaction mixture was poured into cold water (80 mL), resulting in a precipitate which was collected by filtration, washed with pentane (2 × 40 mL) and dried invacuo to obtain the crude compound. The crude material was purified by preparative HPLC(Method A) to afford 6-(6-(2-(2, 6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl) nicotinamide (Example 10, 0.09 g, 38%) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.60-1.68 (m, 2H), 1.76-1.95 (m, 5H), 1.97-2.06 (m, 1H), 2.12-2.14 (m, 1H), 2.17 (s, 3H), 2.24-2.30 (m, 1H), 2.41- 2.46 (m, 1H), 2.56-2.62 (m, 3H), 2.84-2.92 (m, 3H), 3.10-3.19 (m, 1H), 3.34-3.41 (m, 1H), 4.28-4.36 (m, 1H), 4.43-4.50 (m, 1H), 5.11-5.16 (m, 1H), 6.40 (s, 1H), 7.38-7.42 (m, 1H), 7.50- 7.55 (m, 1H), 7.64 (d, J=7.40 Hz, 1H), 7.71 (d, J=7.40 Hz, 1H), 8.19 (s, 1H), 8.27-8.30 (m, 1H), 8.51 (s, 1H), 9.08 (s, 1H), 10.68 (br s, 1H), 11.00 (br s, 1H), 11.40 (br s, 1H). Mass spec: m / z: 644.0 [M+H]+. Example 11 was synthesised following Scheme 14

[0018] Scheme 14 Step 1 Intermediate 73: methyl 4-(4-hydroxybut-1-yn-1-yl)benzoateTo a solution of methyl 4-iodobenzoate (CAS No: 619-44-3, 20.0 g, 76.32 mmol) intetrahydrofuran (150 mL) was added but-3-yn-1-ol (CAS No: 927-74-2, 8.02 g, 114.49 mmol) followed by triethylamine (150 mL, 1070.0 mmol). The reaction mixture was purged with argon for 15 min followed by the addition of copper(I) iodide (1.48 g, 7.63 mmol) and Pd(PPh3)4(4.41 g, 3.81 mmol). The reaction mixture was further purged with argon for 10 min and stirred at room temperature for 16h. The reaction mixture was diluted with water (400 mL) and extracted with ethyl acetate (3 × 500 mL). The combined organic phases were dried over anhydrous Na2SO4and concentrated in vacuo. The crude material was purified by combi-flash column chromatography by eluting with 80% ethyl acetate in heptane to afford methyl 4-(4-hydroxybut- 1-yn-1-yl)benzoate (Intermediate 73, 14.00 g, 90%) as yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 2.59 (t, J=6.80 Hz, 2H), 3.56-3.62 (m, 2H), 3.85 (s, 3H), 4.93 (t, J=5.20 Hz, 1H), 7.52 (d, J=7.89 Hz, 2H), 7.91 (d, J=7.89 Hz, 2H). Mass spec: m / z: 205.4 [M+H]+Step 2 Intermediate 74: methyl 4-(4-hydroxybutyl)benzoate To a solution of methyl 4-(4-hydroxybut-1-yn-1-yl)benzoate (Intermediate 73, 16.00 g, 78.35 mmol) in methanol (200 mL) was added 10% Pd / C (5.00 g) at room temperature. The reaction mixture was stirred at room temperature for 16h under H2(110 psi). The reaction mixture was filtered through celite, washed with MeOH (300 mL) and concentrated in vacuo to afford methyl 4-(4-hydroxybutyl) benzoate (Intermediate 74, 15.0 g, 92%) as yellow liquid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 1.37-1.48 (m, 2H), 1.55-1.66 (m, 2H), 2.65 (t, J=7.60 Hz, 2H), 3.37-3.43 (m, 2H), 3.83 (s, 3H), 4.37 (t, J=5.20 Hz, 1H), 7.33 (d, J=8.0 Hz, 2H), 7.85-7.89 (d, J=8.0 Hz, 2H). Mass spec: m / z: 209.5 [M+H]+. Step 3 Intermediate 75: methyl 4-(4-oxobutyl)benzoate To a solution of methyl 4-(4-hydroxybutyl)benzoate (Intermediate 74, 14.00 g, 67.22 mmol) in dichloromethane (300 mL) was added Dess–Martin periodinane (44.09 g, 100.84 mmol) and the reaction mixture was stirred at room temperature for 4h. The reaction mixture was diluted with mixture of saturated sodium bicarbonate and sodium thiosulphate (1:1, 500 mL) solution and extracted with dichloromethane (3 × 300 mL). The combined organic phases were dried over anhydrous Na2SO4and concentrated in vacuo. The crude material was purified by combi-flash chromatography by eluting with 20% ethyl acetate in heptane to afford methyl 4-(4-oxobutyl) benzoate (Intermediate 75, 11.00 g, 82%) as a yellow liquid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.78-1.91 (m, 2H), 2.47 (t, J=7.20 Hz, 2H), 2.66 (t, J=7.20 Hz, 2H), 3.84 (s, 3H), 7.35 (d, J=8.0 Hz, 2H), 7.88 (d, J=8.0 Hz, 2H), 9.66 (s, 1H). Step 4 Intermediate 76: methyl 4-(pent-4-yn-1-yl)benzoate To a solution of methyl 4-(4-oxobutyl)benzoate (Intermediate 75, 11.00 g, 53.33 mmol) in methanol (200 mL) was added potassium carbonate (14.72 g, 106.67 mmol) at -30°C. Dimethyl(1-diazo-2-oxopropyl)phosphonate (Comp-6, 15.37 g, 80.0 mmol) was added and the reactionmixture stirred from -30°C to room temperature and then at room temperature for 3h. The reaction mixture was diluted water (500 mL) and extracted with ethyl acetate (3 × 200 mL). The combined organic phases were dried over anhydrous Na2SO4and concentrated in vacuo. The crude material was purified by combi-flash chromatography by eluting with 10% ethyl acetate in heptane to afford methyl 4-(pent-4-yn-1-yl)benzoate (Intermediate 76, 8.00 g, 74%) as a yellow liquid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.73-1.91 (m, 2H), 2.14-2.18 (m, 2H), 2.73 (t, J=7.60 Hz, 2H), 2.82 (s, 1H), 3.83 (s, 3H), 7.35 (d, J=8.0 Hz, 2H), 7.88 (d, J=8.0 Hz, 2H). Step 5 Intermediate 77: 4-(pent-4-yn-1-yl)benzoic acid To a solution of methyl 4-(pent-4-yn-1-yl)benzoate (Intermediate 76, 8.00 g, 39.56 mmol) in tetrahydrofuran (40 mL), methanol (40 mL) and water (20 mL) was added lithium hydroxide (3.86 g, 158.3 mmol) in water (20 mL). The reaction mixture was then stirred at room temperature for 16h. The reaction mixture was then concentrated in vacuo, the crude was then diluted with water (30 mL) and acidified to pH~4 with 0.5 N HCl. The resulting precipitate was filtered and dried in vacuo to afford 4-(pent-4-yn-1-yl)benzoic acid (Intermediate 77, 6.30 g, 85%) as a white solid, which was used for the next step without further purification.1H NMR (400 MHz, DMSO-d6) δ ppm 1.72-1.80 (m, 2H), 2.12-2.20 (m, 2H), 2.73 (t, J=7.60 Hz, 2H), 2.82 (s, 1H), 7.32 (d, J=7.88 Hz, 2H), 7.86 (d, J=7.88 Hz, 2H), 12.80 (br s, 1H). Step 6 Intermediate 78: 4-(pent-4-yn-1-yl)benzamide To a solution of 4-(pent-4-yn-1-yl)benzoic acid (Intermediate 77, 6.30 g, 33.0 mmol) in dimethylformamide (80 mL) were added HATU (20 g, 50.0 mmol) and N, N- diisopropylethylamine (18 mL, 100.0 mmol). Ammonium chloride (7.2 g, 130.0 mmol) was then added and the reaction stirred at room temperature for 16h. The reaction mixture was diluted water (100 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic phases were dried over anhydrous Na2SO4and concentrated in vacuo. The crude material was purified by combi-flash chromatography by eluting with 80% ethyl acetate in heptane to afford 4-(pent-4-yn-1-yl) benzamide (Intermediate 78, 5.60 g, 89%) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.68-1.80 (m, 2H), 2.09-2.20 (m, 2H), 2.71 (t, J=7.60 Hz, 2H), 2.83 (s, 1H), 7.26 (br s, 1H), 7.27 (d, J=8.0 Hz, 2H), 7.79 (d, J=8.0 Hz, 2H), 7.89 (br s, 1H). Mass spec: 188.5 [M+H]+. Step 7 Intermediate 79: tert-butyl 5-(5-(4-carbamoylphenyl)pent-1-yn-1-yl)picolinate To a solution of 4-(pent-4-yn-1-yl)benzamide (Intermediate 78, 1.00 g, 5.34 mmol) in acetonitrile (20 mL) was added tert-butyl 5-bromopicolinate (CAS No: 845306-08-3, 1.38 g, 5.34 mmol) followed by N, N-diisopropylethylamine (5 mL, 26.704 mmol). The reaction mixture was purged with argon for 15 min followed by the addition of copper(I) iodide (0.11 g, 0.53 mmol), Pd(OAc)2(0.13 g, 0.80 mmol) and PPh3(0.42 g, 1.60 mmol). The reaction mixture was further purged with argon for 10 min and heated at 80°C for 2h. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic phases were dried over anhydrous Na2SO4and concentrated in vacuo. The crude material was purified by combi-flash chromatography by eluting with 2% MeOH in DCM to afford tert-butyl 5-(5-(4-carbamoylphenyl)pent-1-yn-1-yl)picolinate (Intermediate 79, 1.20 g, 62%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.55 (s, 9H), 1.54-1.58 (m, 2H), 1.89 (t, J=7.60 Hz, 2H), 2.82 (t, J=7.60 Hz, 2H), 7.28 (br s, 1H), 7.31 (d, J=8.0 Hz, 2H), 7.80 (d, J=8.0 Hz, 2H), 7.87 (br s, 1H), 7.92-7.96 (m, 2H), 8.70 (s, 1H). Mass spec: m / z: 365.3 [M+H]+. Step 8 Intermediate 80: tert-butyl (R)-6-(4-(5-(6-(tert-butoxycarbonyl) pyridin-3-yl)pent-4-yn-1- yl)benzamido)-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c]pyridine-1-carboxylate To a solution of tert-butyl 5-(5-(4-carbamoylphenyl)pent-1-yn-1-yl)picolinate (Intermediate 79, 1.00 g, 2.7 mmol) in 1,4-dioxane (20 mL) was added tert-butyl (R)-6-bromo-2-(1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 4, 1.1 g, 3.0 mmol) followed by cesium carbonate (1.60 g, 8.2 mmol) at room temperature. The reaction mixture was purged with argon for 15 min followed by the addition of Pd2(dba)3(0.39 g, 0.41 mmol) and Xantphos (0.48 g, 0.82 mmol). The reaction mixture was further purged with argon for 10 min and heated at 100°C for 2h. The reaction mixture was concentrated in vacuo and the crude material was purified by combi-flash chromatography by eluting with 70% ethyl acetate in heptane to afford tert-butyl (R)-6-(4-(5-(6-(tert-butoxycarbonyl)pyridin-3-yl)pent-4-yn-1- yl)benzamido)-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo [3,2-c] pyridine-1-carboxylate (Intermediate 80, 1.20 g, 66%) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 1.55 (s, 9H), 1.58-1.64 (m, 2H), 1.70 (s, 9H), 1.74-1.82 (m, 2H), 1.86-2.00 (m, 3H), 2.11-2.20 (m, 2H), 2.35 (s, 3H), 2.78-2.88 (m, 2H), 3.12-3.18 (m, 1H), 3.88-3.96 (m, 1H), 6.75 (s, 1H), 7.26- 7.46 (m, 3H), 7.96-8.02 (m, 3H), 8.59 (s, 1H), 8.71 (s, 1H), 8.93 (s, 1H), 10.60 (br s, 1H). Mass spec: m / z: 664.1 [M+H]+. Step 9 Intermediate 81: (R)-5-(5-(4-((2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)carbamoyl) phenyl) pent-1-yn-1-yl)picolinic acid trifluoroacetate To a solution of tert-butyl (R)-6-(4-(5-(6-(tert-butoxycarbonyl)pyridin-3-yl)pent-4-yn-1- yl)benzamido)-2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate (Intermediate 80, 0.50 g, 0.75 mmol) in dichloromethane (10 mL) was added trifluoroacetic acid (10 mL) at 0°C. The reaction mixture was then stirred at room temperature for 16h. The reaction mixture was concentrated in vacuo, the crude material was washed with diethyl ether (5 × 2 mL) and dried under reduced pressure to afford (R)-5-(5-(4-((2-(1-methylpyrrolidin-2-yl)- 1H-pyrrolo[3,2-c]pyridin-6-yl)carbamoyl)phenyl)pent-1-yn-1-yl)picolinic acid trifluoroacetate (Intermediate 81, 0.50 g) as a gum, which was used for the next step without further purification. Mass spec: m / z: 508.2 [M+H]+. Step 10 Example 11: N-((S)-2,6-dioxopiperidin-3-yl)-5-(5-(4-((2-((R)-1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl)carbamoyl)phenyl)pent-1-yn-1-yl)picolinamide To a solution of (R)-5-(5-(4-((2-(1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)carbamoyl)phenyl)pent-1-yn-1-yl)picolinic acid trifluoroacetate (Intermediate 81, 0.40 g, 0.78 mmol) in dimethylformamide (10 mL) was added HATU (0.47 g, 1.18 mmol) and the reaction stirred at room temperature for 15 min. (S)-3-aminopiperidine-2,6-dione hydrochloride (CAS No: 25181-50-4, 0.25 g, 1.18 mmol) and N, N-diisopropylethylamine (0.55 mL, 3.15 mmol) were added and the reaction mixture was stirred at room temperature for 3h. The reaction mixture was quenched with ice cold water (100 mL) to afford a precipitate which was filtered and dried in vacuo to obtain crude compound. The crude material was purified by preparative HPLC (Method A) to afford N-((S)-2,6-dioxopiperidin-3-yl)-5-(5-(4-((2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)carbamoyl)phenyl)pent-1-yn-1-yl)picolinamide (Example 11, 0.09 g, 20%) as a white solid.1H NMR (400 MHz, DMSO-d6) δppm 1.78-2.03 (m, 6H), 2.17 (s, 3H), 2.19-2.30 (m, 3H), 2.44-2.48 (m, 2H), 2.54-2.57 (m, 2H), 2.75-2.87 (m, 3H), 3.12-3.16 (m, 1H), 4.74-4.83 (m, 1H), 6.39 (s, 1H), 7.39 (d, J=8.0 Hz, 2H), 7.98-8.07 (m, 4H), 8.19 (s, 1H), 8.50 (s, 1H), 8.70 (s, 1H), 9.08 (d, J=8.0 Hz, 1H), 10.36 (br s, 1H), 10.86 (br s, 1H), 11.35 (br s, 1H). Mass spec: m / z: 618.2 [M+H]+. Example 12 was synthesised following Scheme 15 Scheme 15 Step 1 Inte...

Claims

CLAIMS 1. A compound which is a Proteolysis Targeting Chimera (PROTAC) or a pharmaceutically acceptable salt thereof, wherein the PROTAC has the structure: wherein U is an E3 ubiquitin ligase binding moiety, LINK is a moiety that covalently links M and U, and M is an MLLT1 and / or MLLT3 binder of formula (I):wherein: one of Z1and Z3is -N(H)- and the other is N or -C(R4)-, Y1is N, Y2is N or -C(R6)-, and Y3is N or -C(R5)-; Hy is a 4- to 7-membered heterocyclic ring containing X and at least one N atom, wherein: ring Hy is linked to ring A via a C atom within ring Hy, said C atom also being linked to R2; a N atom within ring Hy is substituted by R1; X is a bond, -N(R11)-, O, S, -S(O)2-, -S(O)(NR11)-, or - C(R11)2-; and the rest of ring Hy is unsubstituted or substituted by one or two R3; L is –C(O)N(H)-, wherein the C atom of L is bonded to R8, and the N atom of L is bonded to ring B; R1is H, C1-4cycloalkyl, or C1-4alkyl which is itself unsubstituted or substituted with one C1-4alkoxy or one, two or three halo; R2is H or methyl; each R3is independently selected from C1-4alkyl, C1-4alkoxy, phenyl, a 5- to 6-membered heteroaryl ring and halo, or (i) two R3linked to adjacent C atoms in ring Hy form, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, or (ii) two R3linked to the same C atom in ring Hy form, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring; R4and R6are independently selected from H, halo, CN, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo;R5is selected from H, halo, C1-4alkoxy, C3-5cycloalkyl and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R8is (i) a bond to LINK or (ii) a group selected from a 6-membered aryl ring, a 5- to 6- membered heteroaryl ring, a 5- to 6-membered heterocyclyl ring, and a 5- to 6-membered cycloalkyl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkoxy, R10, -(C1-4alkylene)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two R9; each R9is independently selected from halo and C1-4alkoxy; R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 6-membered heterocyclyl ring, and a phenyl ring, the group R10being unsubstituted or substituted by one or two substituents independently selected from C1-4alkyl, C1-4alkoxy, and halo; and each R11is independently selected from H, C1-4alkyl, and C1-4cycloalkyl; wherein either R8is (i) a bond to LINK, or R8is a group (ii) and M is bonded to LINK via a C or N atom within group R8such that a hydrogen atom on the C or N atom within group R8is replaced with a bond to LINK.

2. A compound according to claim 1, wherein LINK is (a) a single bond, or (b) a chemical linker group represented by formula (L):wherein: LINK is attached to M via L1; LINK is attached to U via L3; L1 and L3 are each independently selected from a single bond, -N(R’)-, -C(O)N(R’)-, -O-, - N(R’)C(O)-, -C(O)-, -S(O2)N(R’)-, -N(R’)S(O2)-, -(C1-6alkylene)-, ethynylene, -(C2-6alkenylene)-, -C=C=C-, phenylene, a divalent 3- to 6-membered cycloalkyl ring and a divalent 4- to 7-membered heterocyclyl ring, the phenylene, cycloalkyl and heterocyclyl rings being unsubstituted or substituted by one or two C1-4alkyl; L2 is represented by the formula -(L4)m-;each L4 is independently a unit of formula: oreach XLis independently selected from a single bond, -N(R’)-, -O-, -C(O)-, -S-, -SO-, -SO2-, - C(R”)=C(R”)- and -C≡C-; each YLis independently selected from a divalent 3- to 6-membered cycloalkyl ring, a divalent 4- to 7-membered heterocyclyl ring, or one of the following structures:, the cycloalkyl and heterocyclyl rings being unsubstituted or substituted by one or two C1-4alkyl; n is selected from 0 to 4; n’ is selected from 0 or 1; n + n’ ≥ 1; m is selected from 1 to 30; each R’ is independently selected from H and C1-4alkyl; and each R” is independently selected from H and halo.

3. A compound according to claim 1 or 2, wherein U is: (a) a CRBN E3 ubiquitin ligase binding moiety of formula (U1):wherein: RU1is H; Q is selected from -CH(RU6)-, -N(RU6)-, -O-, -C(O)-, -NH-CH(RU6)-, -N=C(RU6)-, or -N=N-; RU6is H or C1-4alkyl; RU2and RU5are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; RU3and RU4are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU2, RU3, RU4and RU5is a single bond to LINK; (b) a CRBN E3 ubiquitin ligase binding moiety of formula (U4):wherein: RU1’is H; W is N or CRU16; Q’ is N and LUis a single bond, or Q’ is CH and LUis selected from a single bond or - C(O)N(H)-, wherein either (i) the C atom of LUis bonded to phenyl, and the N atom of LUis bonded to Q’; or (ii) the C atom of LUis bonded to Q’, and the N atom of LUis bonded to phenyl; RU12, RU13and RU14are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU12, RU13and RU14is a single bond to LINK; RU15and RU16are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN and CF3;(c) a CRBN E3 ubiquitin ligase binding moiety of formula (U5):wherein: RU17is H; RU18, RU19, RU20and RU21are each independently selected from H, halogen, C1-4alkyl, NH2, NO2, OH, COOH, CN, CF3, and a single bond to LINK; wherein one and only one of RU18, RU19, RU20and RU21is a single bond to LINK; or (d) a VHL E3 ubiquitin ligase binding moiety of formula (U2):wherein: RU7is a group selected from phenyl, a 5- to 6-membered heteroaryl ring, a 5- to 6-membered heterocyclyl ring, and a 5- to 6-membered cycloalkyl ring, the group RU7being unsubstituted or substituted by C1-4alkyl; RU11is H or C1-4alkyl;RU8is selected from C1-4alkyl, phenyl and a 3- to 8-membered cycloalkyl ring; and RU9is a single bond to LINK.

4. A compound according to any one of the preceding claims, wherein the N atom of ring Hy which is substituted by R1is adjacent to the C atom of ring Hy that is bonded to ring A.

5. A compound according to any one of the preceding claims, wherein Z1is -C(R4)-, Z3is -N(H)-, Y1is N, Y2is -C(R6)- and Y3is -C(R5)-.

6. A compound according to any one of the preceding claims, wherein M is of formula (II):wherein: Z1, Z3, Y1, Y2, Y3, R1, R2, R8, X and L are as defined in any one of the preceding claims; R3aand R3bare independently selected from H, C1-4alkyl, phenyl, a 5- to 6-membered heteroaryl ring and C1-4alkoxy, or R3aand R3bform, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring, R3cand R3dare independently selected from H, C1-4alkyl, halo, phenyl, a 5- to 6-membered heteroaryl ring and C1-4alkoxy, or R3cand R3dform, together with the C atom to which they are attached, a C3-6cycloalkyl ring or a C3-6heterocycloalkyl ring, or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, with the proviso that when X is -N(R11)-, O, S, -S(O)2- or -S(O)(NR11)-, then neither R3cnor R3dare halo; wherein at least two of R3a, R3b, R3cand R3dare H; and wherein either (i) R8is a bond to LINK, or (ii) R8is a group and M is bonded to LINK via a C or N atom within group R8such that a hydrogen atom on the C or N atom within group R8is replaced with a bond to LINK.

7. A compound according to any one of the preceding claims, wherein M is of formula (III):wherein: R1is H or C1-4alkyl which is itself unsubstituted or substituted with one C1-4alkoxy or one, two or three halo, preferably with one C1-4alkoxy; R2is H or methyl; R3aand R3bare independently selected from H, C1-4alkyl, and C1-4alkoxy, or R3aand R3bform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, R3cand R3dare independently selected from H, C1-4alkyl, halo and C1-4alkoxy, or R3cand R3dform, together with the C atom to which they are attached, a C3-6cycloalkyl ring, or R3aand R3care H, and R3band R3dform, together with the C atoms to which they are attached, a C5-6cycloalkyl ring, with the proviso that when X is -N(Me)- or O, then neither R3cnor R3dare halo; wherein at least two of R3a, R3b, R3cand R3dare H; X is a bond, -N(Me)-, O or -CH2-; R4is selected from H, CN, halo, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R5and R6are independently selected from H, halo, C1-4alkoxy, and C1-4alkyl which is itself unsubstituted or substituted by one, two or three halo; R8is (i) a bond to LINK or (ii) a group selected from a 6-membered aryl ring, a 5- to 6- membered heteroaryl ring, and a 5- to 6-membered heterocyclyl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo,C1-4alkoxy, R10, -(C1-4alkylene)-R10, =O, -CN, and C1-4alkyl which is itself unsubstituted or substituted by one or two R9; each R9is independently selected from halo and C1-4alkoxy; R10is a group selected from a 5- to 6-membered heteroaryl ring, a 3- to 6-membered cycloalkyl ring, a 4- to 6-membered heterocyclyl ring, and a phenyl ring, the group R10being unsubstituted or substituted by one or two substituents independently selected from C1-4alkyl, C1-4alkoxy, and halo; and wherein either R8is (i) a bond to LINK, or R8is a group (ii) and M is bonded to LINK via a C or N atom within group R8such that a hydrogen atom on the C or N atom within group R8is replaced with a bond to LINK.

8. A compound according to any one of the preceding claims, wherein Hy is an unsubstituted pyrrolidine ring, R1is methyl, and R2is H.

9. A compound according to claim 1, wherein the PROTAC structure is selected from: 4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)but-3-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3, 2-c]pyridin-6-yl)piperidine-1-carboxamide; 6-((3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)methyl)-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)ethyl)-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4- yl)methyl)piperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)nicotinamide; 6-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)piperazin-1-yl)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; N-((S)-2,6-dioxopiperidin-3-yl)-6-(6-(4-((2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)carbamoyl)phenyl)hex-1-yn-1-yl)picolinamide; 4-(6-(2-(2, 6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; (R)-4-(6-(6-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)pyridin-2-yl)hex-5-yn-1-yl)-N-(2-(1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(6-(2-(2, 6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl) hex-5-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c] pyridin-6-yl) nicotinamide;N-((S)-2,6-dioxopiperidin-3-yl)-5-(5-(4-((2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)carbamoyl)phenyl)pent-1-yn-1-yl)picolinamide; 6-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c] pyridin-6-yl)-9-(2-(2, 6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl) non-8-ynamide; 3-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)piperidin-1-yl)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)ethynyl)piperidin-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4- yl)methoxy)piperidin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)nicotinamide; 4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)but-3-yn-1-yl)oxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(1-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-1H-pyrazol-3-yl)- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(1-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-1H-pyrazol-4-yl)- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(1-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)pent-4-yn-1-yl)-1H-pyrazol-4-yl)- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 3-chloro-4-((3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(((2S)-4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)but-3-yn-2-yl)oxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(((2R)-4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)but-3-yn-2-yl)oxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 3-((9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)non-8-yn-1-yl)oxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 7-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]amino}-N-{2-[(2R)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c] pyridin-6-yl}heptanamide;7-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]amino}-N-{2-[(2S)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}heptanamide; 7-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}-N-{2-[(2R)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c] pyridin-6-yl}heptanamide; 9-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}-N-{2-[(2R)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}nonanamide; 12-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}-N-{2-[(2R)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}dodecanamide; 12-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}-N-{2-[(2S)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}dodecanamide; N-{3-chloro-2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}-7-{[2-(2,6- dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}heptanamide; ^4-[1-(3-{1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]piperidin-4- yl}propyl)pyrazol-4-yl]-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6- yl}benzamide; 4-[1-(3-{1-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]piperidin-4- yl}propyl)pyrazol-4-yl]-N-{2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6- yl}benzamide; 4-(3-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}propyl)-N-{2-[(2R)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}benzamide; 4-(3-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}propyl)-N-{2-[(2S)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}benzamide; 1-(3-{1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]piperidin-4-yl}propyl)-N-{2- [(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}pyrazole-4-carboxamide; 2-(((1r,4R)-4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)cyclohexyl)oxy)- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)acetamide; 2-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butoxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)acetamide; 4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)butanamide; 5-(1-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)pentanamide; 6-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)hexanamide; 4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-3-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)butanamide;3-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 3-(((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)methyl)amino)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 3-(1-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)propyl)-1H- pyrazol-4-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)azetidin-3-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)butanamide; 5-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)but-3-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)picolinamide; 5-[3-[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-4-yl]prop-2-ynoxy]-N-[2-(1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl]pyridine-2-carboxamide; 4-((3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)but-3-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4- yl)but-3-yn-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 4-(4-(2-(2, 6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl) but-3-yn-1-yl)-2-fluoro-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c] pyridin-6-yl) benzamide; 4-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-((5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)oxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-((3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)-2-fluoro-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 3-((3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(1-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-1H-pyrazol-4-yl)- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; N-((S)-2,6-dioxopiperidin-3-yl)-6-(4-(3-(4-(4-((2-((R)-1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl)carbamoyl)phenyl)-1H-pyrazol-1-yl)propyl)piperidin-1- yl)picolinamide;N-((S)-2,6-dioxopiperidin-3-yl)-6-(4-(2-(4-(4-((2-((R)-1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl)carbamoyl)phenyl)-1H-pyrazol-1-yl)ethoxy)piperidin-1- yl)picolinamide; N-((S)-2,6-dioxopiperidin-3-yl)-6-(5-(4-(4-((2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)carbamoyl)phenyl)-1H-pyrazol-1-yl)pent-1-yn-1-yl) picolinamide; (R)-4-(5-(6-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)pyridin-2-yl)pent-4-yn-1-yl)-N-(2-(1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazin-1-yl)piperidin-1-yl)- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 2-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)ethynyl)piperidin-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)pyrimidine-5-carboxamide; 4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4- yl)prop-2-yn-1-yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)phenyl)piperidin-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 7-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}-N-{2-[(2R)-1- methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl}heptanamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-(11-{[4-({2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2- c]pyridin-6-yl}carbamoyl)phenyl]formamido}undecanamido)butanoyl]-4-hydroxy-N-{[4-(4- methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-(11-{[4-({2-[(2S)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2- c]pyridin-6-yl}carbamoyl)phenyl]formamido}undecanamido)butanoyl]-4-hydroxy-N-{[4-(4- methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-6-(6-(2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)nicotinamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-6-(4-(3-(2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)piperazin-1-yl)nicotinamide; 6-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)piperidin-1-yl)-N- (2-((R)-1-ethylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-N-(2-((R)-1- ethylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(1'-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-[4,4'-bipiperidin]-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)propyl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide;4-(3-(1-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)propyl)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(3-(1-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)propyl)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(1-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(1-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) piperidin-4-yl) ethoxy)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c] pyridin-6-yl)benzamide; 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)ethoxy)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-3,5-difluoro-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl benzamide; 4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)benzyl)oxy)piperidin-1-yl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-N-(2-((rel-R)-5- methyl-5-azaspiro[2.4]heptan-6-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)but-3-yn-1-yl) (methyl)amino)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)acetyl) piperazin- 1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide ; 2-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)piperazin-1-yl)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)pyrimidine-5-carboxamide; 4-(5-(2-(2,6-dioxopiperidin-3-yl)-7-fluoro-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperazin-1-yl)methyl)piperidin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-3-fluoro-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-2-fluoro-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 3-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide;3-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; N-((S)-2,6-dioxopiperidin-3-yl)-6-(5-(4-((2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)carbamoyl)phenyl)pent-1-yn-1-yl)picolinamide; 4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)benzyl)piperazin-1-yl)-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-3-methylphenyl)piperidin-1-yl)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-4-(5-(2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)benzamide; 4-(5-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(5-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(5-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(6-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(6-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(5-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(1-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)acetyl)piperidin- 4-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)acetyl)piperazin- 1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)benzyl)oxy)piperidin-1-yl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-(5-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-N-(2-((R)-1-(methyl- d3)pyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-2-fluoro-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo [3, 2-c]pyridin-6-yl)benzamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-4-(6-(2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-2-fluorobenzamide;4-(6-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)hex-5-yn-1-yl)-2-fluoro-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-2-methoxy-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)piperazin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-((1-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4- yl)methyl)piperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 4-(4-((1-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4- yl)methyl)piperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 6-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)piperidin-4- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)piperazin-1- yl)-2-fluoro-6-methoxy-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 4-((1-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)piperidin- 4-yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-((1-((1-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4- yl)methyl)piperidin-4-yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin- 6-yl)benzamide; 4-((1-((1-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4- yl)methyl)piperidin-4-yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin- 6-yl)benzamide; 4-((1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4- yl)methyl)piperidin-4-yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin- 6-yl)benzamide; 6-((1-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)piperidin- 4-yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)piperazin-1- yl)-2-methoxy-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)nicotinamide; 6-((2S)-4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)-2- methylpiperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)nicotinamide;4-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)propyl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)benzyl)piperazin-1-yl)-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazin-1-yl)propyl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperazin-1-yl)propyl)-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-((2S)-4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)-2- methylpiperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 4-((2R)-4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)-2- methylpiperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 4-((R)-4-((1-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4- yl)methyl)-2-methylpiperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)benzamide; 4-((R)-4-((1-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)- 2-methylpiperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)oxy)piperidin- 1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)oxy)piperidin-1-yl)- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperazin-1-yl)ethyl)piperidin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-4-yl)oxy)piperidin-1-yl)- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(4-(((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4- yl)oxy)methyl)piperidin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin- 6-yl)nicotinamide; 4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-1-yl)ethoxy)-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperazin-1-yl)ethoxy)-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide;4-((1-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-4-yl)methyl)piperidin- 4-yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-((1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4- yl)methyl)piperidin-4-yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin- 6-yl)benzamide; 6-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)oxy)piperidin-1-yl)- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methoxy)piperidin- 1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methoxy)piperidin- 1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-[4-[[1-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]-4-piperidyl]oxy]-1-piperidyl]- N-[2-[(2R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl]pyridine-3-carboxamide; 6-(4-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)piperazin-1-yl)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-((5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)oxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4- yl)methoxy)piperidin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 6-(1'-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-[4,4'-bipiperidin]-1-yl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)piperidin-1-yl)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)pyridazine-3-carboxamide; 5-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)piperidin-1-yl)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)pyrazine-2-carboxamide; 4-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)piperazin-1-yl)-2- fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)-3,5-difluoro-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-((1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4- yl)methyl)azetidin-3-yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 6-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide;4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methoxy)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-4-(2-(1-(2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)benzamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-4-(2-(1-(2-((rel- S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)benzamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-4-(2-(1-(2-((rel- R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)benzamide; 6-((2R)-4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)-2- methylpiperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)nicotinamide; 4-(2-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-3,9-diazaspiro[5.5]undecan-3- yl)ethoxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-3,9-diazaspiro[5.5]undecan-3- yl)ethoxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-3,9-diazaspiro[5.5]undecan-3- yl)ethoxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)piperidin-4- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)piperazin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-(4-((1-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5- yl)piperidin-4-yl)methyl)piperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2- c]pyridin-6-yl)benzamide; 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-2-fluoro-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(1-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-2- fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(1-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-2- fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)propyl)-2-fluoro-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(3-(1-(2-((rel-S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)propyl)-2- fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(3-(1-(2-((rel-R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)propyl)-2- fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide;4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethyl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)phenyl)piperidin-1-yl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidin-4- yl)methyl)piperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; N-((S)-2,6-dioxopiperidin-3-yl)-5-(4-((4-(4-((2-((R)-1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl)carbamoyl)phenyl)piperazin-1-yl)methyl)piperidin-1- yl)picolinamide; N-((S)-2,6-dioxopiperidin-3-yl)-6-(4-((4-(4-((2-((R)-1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl)carbamoyl)phenyl)piperazin-1-yl)methyl)piperidin-1- yl)picolinamide; 4-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)methyl)azetidin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 4-((1-((1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidin-4- yl)methyl)piperidin-4-yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin- 6-yl)benzamide; 6-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)ethynyl)piperidin-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)pyridazine-3-carboxamide; 5-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)ethynyl)piperidin-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)pyrazine-2-carboxamide; 6-((3S)-3-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)pyrrolidin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(4-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)piperidin-1-yl)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-(4-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4- yl)propanoyl)piperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-4-(2-(1-(2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-2-fluorobenzamide;N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-6-(4-((1-(2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methoxy)piperidin-1- yl)nicotinamide; 3-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-4-yl)methyl)piperazin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethyl)piperazin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-((4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methyl)piperazin- 1-yl)methyl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-((3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)propa-1,2-dien-1-yl)oxy)piperidin- 1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-3-methylphenoxy)piperidin-1-yl)- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 5-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)picolinamide; 4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-1-yl)propyl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)phenyl)propyl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-((7-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-7-azaspiro[3.5]nonan-2-yl)oxy)-2- fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-((7-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-7-azaspiro[3.5]nonan-2- yl)methoxy)-2-fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 4-(9-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-3,9-diazaspiro[5.5]undecan-3-yl)-2- fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-3-methylphenoxy)piperidin-1-yl)- 2-fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-2-methyl-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 2-chloro-4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-3-fluoro-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)phenethoxy)-2-fluoro-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide;4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-3-methylphenethoxy)-2-fluoro-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)propoxy)-2-fluoro- N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(1-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)propyl)-1H- pyrazol-4-yl)-2-fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 5-(1-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)propyl)-1H- pyrazol-4-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)picolinamide; 4-(1-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)propyl)-1H- pyrazol-4-yl)-2-fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 4-((5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)oxy)-2-fluoro-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)methoxy)-2-fluoro-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; N-((S)-2,6-dioxopiperidin-3-yl)-2-fluoro-4-(4-(2-(3-fluoro-4-((2-((R)-1-methylpyrrolidin-2- yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)carbamoyl)phenoxy)ethyl)piperidin-1-yl)benzamide; 5-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-N-(2-((R)- 1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)picolinamide; 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-2- fluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)phenyl)piperidin-1-yl)-2-fluoro-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; N-((S)-2,6-dioxopiperidin-3-yl)-2-fluoro-3-(5-(4-((2-((R)-1-methylpyrrolidin-2-yl)-1H- pyrrolo[3,2-c]pyridin-6-yl)carbamoyl)phenyl)pent-1-yn-1-yl)benzamide; 3-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4- yl)methyl)piperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4- yl)methyl)piperazin-1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-4-yl)methyl)piperazin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide;4-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)hex-5-yn-1-yl)-2-fluoro-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 6-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)prop-2-yn-1-yl)piperidin-1-yl)-N- (2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-(5-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)pent-4-yn-1-yl)-N-(2-((R)-1- methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c] pyridin-6-yl)benzamide; 6-((3R)-3-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)pyrrolidin-1- yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; 4-((1-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4- yl)ethyl)azetidin-3-yl)oxy)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6- yl)benzamide; 6-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-4-yl)methoxy)piperidin- 1-yl)-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)nicotinamide; N-(3-chloro-2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-4-(2-(1-(2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-3-fluorobenzamide; 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-2,5- difluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)ethoxy)-2,3- difluoro-N-(2-((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; 4-(3-(1-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)propyl)-N-(2- ((R)-1-methylpyrrolidin-2-yl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzamide; and N-[3-chloro-2-[(R)-1-methylpyrrolidin-2-yl]-1H-pyrrolo[3,2-c]pyridin-6-yl]-4-[3-[1-[2-[(rel- S)-2,6-dioxo-3-piperidyl]-1-oxo-isoindolin-4-yl]-4-piperidyl]propyl]benzamide.

10. A compound according to any one of the preceding claims, wherein M is of formula (IV):wherein R8is (i) a bond to LINK or (ii) a group selected from a 6-membered aryl ring and a 5- to 6-membered heteroaryl ring, the group R8being unsubstituted or substituted by one, two or three substituents independently selected from halo, C1-4alkyl and R10;R10is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, oxadiazolyl, oxetanyl, phenyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, thiazinyl, thiazolyl and triazolyl, more preferably pyrazolyl and cyclopropyl; wherein either R8is (i) a bond to LINK, or R8is a group (ii) and M is bonded to LINK via a C or N atom within group R8such that a hydrogen atom on the C or N atom within group R8is replaced with a bond to LINK.

11. A pharmaceutical composition which comprises a compound as defined in any one of claims 1 to 10 and a pharmaceutically acceptable carrier or diluent.

12. A compound as defined in any one of claims 1 to 10 for use in the treatment of the human or animal body by therapy.

13. A compound as defined in any one of claims 1 to 10 for use in the treatment of cancer.

14. The compound for use according to claim 13, wherein the cancer is a transcriptionally addicted cancer, such as breast cancer, acute leukemia, chronic leukemia, prostate cancer, bladder cancer, cholangiocarcinoma, colon adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, kidney chromophobe, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, pheochromocytoma and paraganglioma, rectum adenocarcinoma, stomach adenocarcinoma, uterine corpus endometrial carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, lung squamous cell carcinoma, neuroblastoma, midline glioma or sarcoma, preferably neuroblastoma or midline glioma.

15. The compound for use according to claim 13, wherein the cancer is acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN) or acute lymphoblastic leukaemia (ALL), for instance wherein the cancer is mixed-lineage leukaemia (MLL) rearranged (also known as KMT2Ar) acute leukemia (AML and ALL), NPM1 mutant acute leukemia, RUNX1-fusion acute leukemia, E2A-fusion acute leukemia, PML-fusion acute leukemia or NUP98-fusion acute leukemia.

Images